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Diabetes during pregnancy is of serious concern as it causes spontaneous 
abortions, still births, fetal macrosomias, and congenital malformations.  Both 
structural and functional congenital malformations affecting various organ 
systems including the cardiovascular, genitourinary and nervous systems have 
been reported in diabetic pregnancy. Our understanding and management of 
diabetes over the years have reduced the risk of spontaneous abortion and still 
births in maternal diabetics. However, even in recent years diabetes during 
pregnancy has been considered to have a teratogenic effect causing fetal 
anomalies. Although all of the fetal tissues are susceptible to glucose-induced 
anomalies, birth defects of the developing heart and brain have been 
frequently reported in humans and mouse models of diabetic pregnancy 
indicating that these organs are more sensitive to glucose toxicity.  
In mammals, neurulation results in formation of the neural tube which 
gives rise to the brain and spinal cord. The neural tube is derived from neural 
stem cells (NSCs) that are self- renewing multipotent cells which give rise to 
the neuronal and glial cells of the brain. Neural tube development and closure 
require cell proliferation, migration, adhesion, differentiation and apoptosis of 
NSCs that are mediated by several genes. Disturbances or alterations in gene 
expression or cellular events that regulate neural tube closure results in neural 
tube defects (NTD) characterized by failure of closure of the neural tube. NTD 
are the second most common birth defects that result due to maternal diabetes.  
It has been shown that maternal diabetes alters the expression of several genes 
involved in neurulation, proliferation and cell fate specification of NSCs 
which may form the basis for NTD. In contrast to structural defects, infants of 
diabetic mothers are known to exhibit neuropsychological deficits including 
alterations in memory and intelligence, attention, psychomotor development, 
speech and language suggesting the importance of maintaining appropriate 
maternal and fetal glycemic levels during pregnancy.  
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Over the last two to three decades, several groups have focused on 
identifying the molecular cues and cellular changes resulting in altered gene 
expression and morphological defects in diabetic pregnancy. Numerous 
studies have shown that maternal diabetes alters the expression of several 
genes that are critical for neural tube development and closure. In addition, 
oxidative stress, hypoxia, and apoptosis that are triggered due to 
hyperglycemic conditions have been found to underlie NTD. However, the 
exact mechanism or the link between hyperglycemia and altered transcriptome 
remains unknown. Recently, maternal nutrition and metabolic disturbances 
during pregnancy have shown to alter epigenetic mechanisms in the fetus. 
Maternal diet has shown to be an important modulator of fetal outcome, since 
supplementation of maternal diet with methyl donor such as folate, prevented 
the occurrence of NTD. It was hypothesized that maternal diabetes activates 
epigenetic mechanisms (chromatin modification, DNA methylation and 
microRNA mediated) in NSC which alters their gene expression and cell fate 
during brain development resulting in NTD. In order to address this, the 
present author investigated the effect of maternal hyperglycemia on the  
epigenetic mechanisms of NSCs isolated from the forebrain of embryos of 
normal and diabetic mice and on the expression of several developmental 
control genes such as  Neuronal differentiation (Neurod1), Doublecortin 
(Dcx), Platelet activating factor acetyl hydrolase 1b1 (Pafah1b1), Glia 
maturation factor beta (Gmfb).  
In this study, NSCs were isolated from the forebrain of embryos of 
control and diabetic pregnancy and cultured in vitro in medium with 
physiological glucose concentration (PG, 5mmol/L). NSCs from normal 
pregnancy were cultured in medium with high glucose concentration (HG, 
40mmol/L) for 48 hours to mimic hyperglycemia in vitro. Chromatin 
reorganization was examined by transmission electron microscopy while 
global histone status at lysine 9 residue of histone H3 (acetylation and 
trimethylation) and global DNA methylation were examined by ELISA-based 
approach. The expression of several developmental control genes whose Gene 
Ontology biological processes indicated cell differentiation, neurogenesis, 
migration or gliogenesis were analysed by real time RT-PCR in NSCs from 
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embryos of control and diabetic pregnancy. HG altered the chromatin 
organization, histone H3 lysine 9 methylation/acetylation and DNA 
methylation status of NSCs (from diabetic pregnancy or that exposed to HG in 
vitro). Exposure to HG increased the expression of Dcx, Pafah1b1 and Gmfb 
proteins concomitant with the decreased expression of four microRNAs 
predicted to target them. Knockdown of specific microRNAs in NSCs from 
normal pregnancy resulted in increased expression of Dcx, Pafah1b1 and 
Gmfb proteins confirming target prediction and altered NSC fate by increasing 
the expression of neuronal and glial lineage markers. The present findings 
reveal novel insights on the mechanism of maternal diabetes induced NTD and 
suggest a link between maternal glucose and fetal epigenome. 
Further, the human and mouse brains have been shown to express more 
than 50% of the known miRNAs, whose expression patterns are reported to 
change dynamically during development.  Maternal diabetes induced NTD 
have long been attributed to be caused by deregulation of several metabolic 
pathways although the exact mechanism behind this remains unknown. Given 
that gene expression profiling in embryos of diabetic pregnancy have revealed 
altered gene expression in developing brains exposed to maternal diabetes and 
that miRNAs fine tune gene expression, it was hypothesized that maternal 
diabetes alters expression of miRNAs that regulate genes critical for neural 
tube closure. 
To address this, miRNA expression profiling was performed in 
embryonic NSCs. In this study, NSCs were isolated from the forebrain of 
embryos of control and diabetic pregnancy and cultured in vitro in medium 
with physiological glucose concentration (PG, 5mmol/L). Since maternal 
diabetes can cause fetal hyper/hypoglycemia or hypoxia, NSCs from normal 
pregnancy were cultured in medium with high glucose concentration (HG, 
40mmol/L) or low glucose concentration (LG, 2 mmol/L) for 48 hours. In 
addition, since hypoxia and oxidative stress have been attributed to maternal 
diabetes induced NTD, NSCs from normal pregnancy were cultured in 
reduced oxygen for 48 hours to mimic hypoxia in vitro. 
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Distinct miRNA expression patterns were observed in NSCs from 
different groups. Pathway analysis of differentially expressed miRNAs 
revealed top pathways that were deregulated by miRNAs in the different 
groups.  The pathways targeted by differentially expressed miRNAs identified 
in this study were already shown to be associated with or critical for neural 
tube development. This result suggested that maximum miRNAs deregulating 
that pathway were altered by glucose or glucose induced hypoxia. Finally, 
seven common pathways were identified (namely MAPK signalling, focal 
adhesion, actin cytoskeleton, wnt signalling, neurotrophin signalling, ErbB 
signalling and axon guidance) since they were predicted to be deregulated in 
NSCs from almost all groups. The present findings indicate that altered 
miRNA expression induced by maternal diabetes may form the basis for 
deregulation of several metabolic pathways resulting in NTD. Overall, these 
results provide novel insights into the mechanism of maternal diabetes induced 
NTD and altered brain function in infants of diabetic mothers.  
In conclusion, maternal diabetes activates epigenetic mechanisms in 
embryonic NSCs, resulting in chromatin reorganization, altered histone H3K9 
status, increased global DNA methylation. in vitro exposure of NSCs to high 
or low glucose resulted in altered CpG methylation of specific genes involved 
in neurogenesis and neuronal differentiation. In addition NSCs from diabetic 
pregnancy altered expression of miRNAs that regulate genes involved in NSC 
fate resulting in increased expression of neuronal and glial lineage markers. 
Further, maternal diabetes altered the expression of several microRNAs that 
regulate key metabolic pathways and signalling molecules that are critical for 
neural tube closure and brain development or function. Overall, the present 
findings provide novel insights into the mechanism of maternal diabetes-
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1.1. Diabetes Mellitus 
Diabetes mellitus (DM) is the most common chronic metabolic disease 
affecting humans worldwide.  DM occurs due to inherited and/ or acquired 
defects in secretion of insulin or its action or both.  Lack of insulin, a major 
hormone that controls glucose homeostasis, results in increased blood glucose, 
a condition termed as hyperglycemia which leads to progressive tissue damage 
and organ failure (Bloomgarden, 1996; Rayburn, 1997). The incidence of DM 
worldwide is 6.4% as of 2010 and estimated to increase to 7.7% by 2030 
(Shaw et al., 2010). According to the World Health Organization (WHO) 
statistics 2012 report, diabetes is prevalent in one in ten adults (Shaw et al., 
2010). Asians account for 60% of diabetic population in the world (Chan et 
al., 2009) and changes in diet, lifestyle, lack of physical activity and rapid 
urbanization are thought to fuel the increasing incidence of diabetes (Hu, 
2011). 
1.1.1. Types of diabetes mellitus 
According to the WHO classification, DM is categorised into two main types, 
namely type 1 and type 2, depending on the etiology. Type 1 diabetes (insulin 
dependent diabetes mellitus, IDDM) accounts for 5-10% of people with 
diabetes that occurs due to destruction of pancreatic beta cells resulting in lack 
of insulin secretion. Type 1 diabetes is classified clinically into two types 
based on presence (type 1a) or absence (type 1b) of autoimmune-mediated 
destruction of beta cells.  Type 1a diabetes accounts for 90% of diabetics in 
Europe, while type1b is more common in Africa and Asia (Betterle et al., 
1984; Zimmet et al., 1990; Atkinson and Maclaren, 1994). 
Type 2 diabetes (non-insulin dependent diabetes mellitus, NIDDM) is 
the most frequent type of diabetes (90-95%) that occurs as a result of 
resistance to action of insulin leading to insulin deficiency. The global 
prevalence of type 2 diabetes continues to increase and of late has decreased 
the age of onset affecting young children and adolescents (Cheng, 2005). 
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In addition to type 1 and type 2 diabetes, during pregnancy women 
develop gestational diabetes mellitus. 
1.1.1.1. Gestational diabetes mellitus (GDM) 
The American Diabetic Association (American Diabetes, 2010) has defined 
GDM as the “onset or initial recognition of any degree of glucose intolerance 
during pregnancy”. GDM exists only during pregnancy and vanishes after 
child birth (Buchanan and Xiang, 2005). The incidence of GDM varies 
between 1-14% with ethnicity and about 7% of pregnancies worldwide are 
reported to be complicated by GDM (American Diabetes, 2007, 2010). Several 
factors, including maternal age, family history of diabetes and obesity are 
attributed to the incidence of GDM (Jovanovic and Pettitt, 2001).Women with 
GDM and her offspring are at increased risk for type 2 diabetes (Boney et al., 
2005; Lee et al., 2007) contributing to the diabetes epidemic. 
1.2. Diabetes and pregnancy 
Diabetes is the most common medical complication of pregnancy and can be 
pre-gestational (type 1 or type 2 DM) or gestational (Reece and Homko, 1993; 
Sheffield et al., 2002). About 3-5% of pregnancies [of which 80%  is 
gestational diabetes (Nold and Georgieff, 2004)], are reported to be 
complicated by diabetes and is the leading cause for mortality and morbidity 
(Gabbe and Graves, 2003; Dheen et al., 2009). The incidence of diabetes in 
pregnancy however, varies with the geographical and ethnic background of 
women, with the highest incidence being in Asian women and lowest in 
African women (Kieffer et al., 1999; Ozumba et al., 2004). The increasing 
frequency of DM in adolescents and young adults (Hotu et al., 2004; Hsia et 
al., 2009) is alarming since the number of female adolescents and young 
women in this group who are growing up into child-bearing age is increasing 
and are at risk for maternal and fetal complications including congenital 
anomalies (Greene, 1999; Gabbe and Graves, 2003).  
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1.2.1. Maternal diabetes induced structural defects (congenital anomalies) 
Diabetes during pregnancy is of serious concern as it causes spontaneous 
abortions, still birth, fetal macrosomia, and congenital malformations (Combs 
and Kitzmiller, 1991; Kitzmiller et al., 1996; Greene, 1999; Langer, 2002).  
The risk for congenital anomalies in diabetic pregnancy is about three to five 
folds and type of anomalies found in pre-gestational or gestational diabetics 
are similar (Kucera, 1971; Aberg et al., 2001; Farrell et al., 2002). Indeed a 
linear relationship between the frequency of congenital anomalies and the 
presence of hyperglycemia early in pregnancy has been reported (Greene, 
1999; Schwartz and Teramo, 2000). Both structural and functional congenital 
malformations that affect a variety of organ systems including the 
cardiovascular, genitourinary and nervous systems have been reported in 
diabetic pregnancy (Gabbe, 1977; Cowett and Schwartz, 1982; Becerra et al., 
1990; Kumar et al., 2007). Our understanding and management of diabetes 
over the years have reduced the risk for spontaneous abortion and still birth in 
maternal diabetics. However, even in recent years diabetes during pregnancy 
has been considered to have a teratogenic effect causing fetal anomalies 
(Nelson, 1986; Greene, 1999; Aberg et al., 2001; Loffredo et al., 2001; Kumar 
et al., 2007). Although all of the fetal tissues are susceptible to glucose-
induced anomalies, the developing heart and brain have shown maximum 
defects (Becerra et al., 1990) and these defects are the most frequently 
reported birth defects in humans and mouse models of diabetic pregnancy 
(Langer and Conway, 2000; Loffredo et al., 2001; Sheffield et al., 2002; Wren 
et al., 2003), indicating that these organs are more sensitive to glucose 
toxicity.  
1.2.2. Maternal diabetes induced functional defects 
In addition to structural abnormalities, diabetes during pregnancy causes a 
range of functional abnormalities in the fetus including hypocalcaemia, 
hypomagnesaemia cardiomyopathy, macrosomia, hyperbilurubinemia and 
hypoxia (Hod et al., 1991). 
5 
 
Infants of diabetic mothers (IDM) have been shown to exhibit 
neuropsychological deficits (ter Braak et al., 2002) including alterations in 
memory and intelligence (Rizzo et al., 1997), attention (Wenman et al., 2004), 
psychomotor development (Rizzo et al., 1995; Ornoy et al., 1998; ter Braak et 
al., 2002), speech and language (Stenninger et al., 1998) suggesting the 
importance of maintaining appropriate maternal and fetal glycemic levels 
during pregnancy. The brain requires glucose for its normal functioning and 
deprivation of glucose negatively affects brain function (Deary and Frier, 
1996).  
1.3. Maternal glycemic levels and fetal outcomes 
Glucose is the main metabolic fuel that drives fetal growth and is transferred 
from the mother across the placenta to regulate fetal growth (Boden, 1996; 
Homko et al., 1999). Therefore, hyperglycemia or hypoglycemia in the 
pregnant mother affects fetal growth (Jovanovic-Peterson et al., 1991; Combs 
et al., 1992; Caruso et al., 1998).  Glycemic control in diabetic mothers is 
indeed a major challenge as tight glycemic control results in fetal 
hypoglycemia due to maternal hypoglycemia (Rosenn and Miodovnik, 2000). 
Maternal diabetes induced episodes of fetal hyperglycemia or hypoglycemia 
have been shown to increase mortality rate of fetuses (Lucas, 2001). 
During the period of organogenesis (first 12 weeks of pregnancy in 
humans), maternal glycemic control is important since hyperglycemia is 
teratogenic and induces damage to fetal tissues. Maternal glycosylated 
haemoglobin, HbA1c level is being used for monitoring maternal glycemic 
levels since an association between maternal HbA1c levels during the first 
trimester and congenital malformations has been reported (Greene et al., 1989; 
Kitzmiller et al., 1991a; Temple et al., 2002).  
Initial studies have shown that the type of malformations varied with 
the maternal glucose concentration (Langer, 2002) and achieving a particular 
glucose threshold may be beneficial in reducing or eliminating the risk for  
malformations. Further, the timing of hyperglycemia majorly determines the 
organ system that is affected since organ development occurs in a sequence 
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(Zabihi and Loeken, 2010).  While a tight glycemic control initiated before 
pregnancy has been shown to reduce the risk for congenital anomalies 
(Nelson, 1986; Kitzmiller et al., 1991b; Kitzmiller et al., 1996; Ryan, 1998), 
the same following the completion of organogenesis has been shown to be 
insufficient to reverse the damages already caused. As a majority of the 
pregnancies are diagnosed only after 7-8 weeks of conception, in a mother 
with undiagnosed and pre-existing diabetes, organogenesis in the fetus is 
likely to be impaired and the defect may be irreversible. 
In addition, brain abnormalities in neonates of diabetic mothers whose 
glucose concentration was less than 2.6mmol/L have been demonstrated 
(Evers et al., 2004). Fetal and neonatal hypoglycemia has been shown to be 
teratogenic, resulting in growth retardation and neuropsychological defects, 
brain dysfunction and deficits in attention, motor control, and perception 
(Buchanan et al., 1986; Stenninger et al., 1998; ter Braak et al., 2002).Given 
that both hyperglycemia and hypoglycemia in pregnant women have been 
shown to be teratogenic (Buchanan et al., 1986; Langer, 2002) it is therefore 
critical to maintain the glycemic index. 
1.4. Development of the Central Nervous System: Neurulation 
In mammals, neurulation which occurs during early embryogenesis results in 
formation of neural tube, that develops into the central nervous system (CNS) 
including the brain and spinal cord(Copp et al., 2003). During gastrulation, 
vertebrate embryos form three germ layers namely, the endoderm, mesoderm 
and the ectoderm and the neural tube is derived from the ectoderm that 
thickens to form the neuroectoderm (Colas and Schoenwolf, 2001). The initial 
step in neurulation is the formation of neural plate or neuroepithelium. The 
neural plate then forms the neural tube by the two stage processes namely 
primary and secondary neurulation (Copp et al., 2003; Bassuk and Kibar, 
2009). In primary neurulation, shaping and folding of the neural plate (np) 
occurs, resulting in formation of neural folds. Neural folds are formed  as a 
result of formation of 2 hinge points at two sites namely the median hinge 
point (MHP) that lies above the notochord (nc) and a pair of dorso-lateral 
hinge points (DLHP) on the lateral sides (Illustration 1)(Morriss-Kay, 1981; 
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Greene and Copp, 2009). The tips of the neural folds fuse along the midline 
when they come in contact and adhere to each other to form the neural tube. 
Following primary neurulation, secondary neurulation occurs to form the 
caudal neural tube (Copp et al., 2003; Bassuk and Kibar, 2009; Greene et al., 
2009b). In humans primary neurulation occurs between 3rd and 4th week, while 
secondary neurulation occurs during 5th and 6th week following conception and 
in mice, neurulation is initiated around embryonic day 8 (E8) and completed 
by E11 (Greene and Copp, 2009). 
 
Illustration 1: Schematic diagram showing the closure of neural tube (Adapted 
from Bassuk and Kibar 2009) 
Pe: primitive epidermis, nc: notochord; DLHP: dorsolateral hinge point; MHP: 
median hinge point. 
In mammals during primary neurulation, the closure of the neural tube 
is  initiated at distinct points along the rostro-caudal axis (Copp et al., 1990). 
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Three sites of closure (closure 1-3) have been identified in mouse while in 
humans upto 5 sites have been postulated among which only closure 1 and 
closure 3 are known to occur (Illustration2) (Greene and Copp, 2009). In mice, 
closure 1 occurs at E8 at the hindbrain/cervical boundary from where it 
proceeds to give rise to the brain rostrally and to spinal cord caudally. 
Subsequently, in the cranial region closure 2 occurs at E9 at the 
forebrain/midbrain boundary and closure 3 at the rostral region of the 
forebrain. The regions between the closure sites are called neuropores and as 
neural tube closure progresses bi-directionally from the sites of closure, the 
neuropores close resulting in formation of an intact neural tube by E9.5 (Copp 
et al., 1990; Copp, 2005). 
 
 
Illustration 2: Neural tube closure points in humans and mouse (Adapted from 
Copp and Greene 2009) 
1.4.1. Neural stem cells and neural tube development 
The CNS is composed of neurons and glial cells that are derived from neural 
stem cells (NSCs) (Lendahl et al., 1990; Gage, 2000; Gotz and Huttner, 2005; 
Merkle and Alvarez-Buylla, 2006). During development, the neural tube 
initially consists of a single layer of neuroepithelial cells that undergo 
symmetric division to amplify the NSC pool exponentially. Subsequently the 
NSCs undergo asymmetric division to produce two daughter cells; one NSC 
              Mouse                                                          Human 
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by self-renewal and one differentiated cell (neuron) that migrates outward 
(Merkle and Alvarez-Buylla, 2006). The asymmetric division generates 
intermediate lineage restricted progenitor populations which produce neurons 
or glial cells after one or many stages of cell division (transit amplifying cells) 
(Kriegstein and Alvarez-Buylla, 2009). In addition, the NSCs transform into 
radial glial cells which serve as the scaffold for neuronal migration (Noctor et 
al., 2001; Noctor et al., 2002). Immature neurons migrate from the place of 
origin in the neuroepithelium to their final destination in the cortex (Hatten, 
2002). Normal development and function of the brain depends on precise 
neuronal migration and numerous signalling molecules, adhesion molecules 
and cytoskeleton proteins. Impaired neuronal migration results in neuronal 
migration disorders characterized by cortical dysplasia that manifests as 
mental retardation and epilepsy (Gleeson, 2001). Following neurogenesis, 
glia-restricted progenitors are formed which give rise to the glial cells 
(astrocytes and oligodendrocytes) (Kriegstein and Alvarez-Buylla, 2009) and 
small populations of NSCs are retained and have been detected in the postnatal 
and adult brains (Weissman et al., 2001; Alvarez-Buylla et al., 2002). 
Therefore during development, NSCs transform from the neuroepithelium to 
radial glial cells which mature as astrocyte-like cells in neonatal and in adult 
brain (Noctor et al., 2001; Noctor et al., 2002). The distinct cell types of the 
brain are determined by spatial and temporal regulation of NSCs mediated by 
both extracellular signals and intracellular programmes such as epigenetic 
mechanisms and disturbances in NSC regulation therefore affect the 
architecture of the brain (size, shape and cellular composition)  (Temple, 
2001). In the embryonic brain, NSCs are localized in almost all regions, 
whereas in adult brains they are found only in the sub-ventricular zone and 
sub-granular zone in hippocampus (Temple, 2001). 
1.4.2. Signalling pathways involved in neural tube development and 
closure 
Neural tube development and closure require cell proliferation, migration, 
adhesion, differentiation and apoptosis of NSCs (Schoenwolf and Smith, 
1990) and these events are mediated by several genes (Copp et al., 2003). The 
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formation of neural plate that occurs foremost is mediated by antagonists of 
bone morphogenetic protein (BMPs), such as noggin, chordin which initiate 
formation of neuroectoderm (Bainter et al., 2001; Stern, 2006). Fibroblast 
growth factors, insulin-like growth factor and canonical Wnt signalling also 
aid in initiation of neurulation (Stern, 2006). The elongation of neural plate 
mediated by convergent extension (narrowing and lengthening) enables cells 
to move and intercalate with neighboring cells, and is mediated by non-
canonical Wnt/frizzled pathway (Wallingford et al., 2002). Following this, the 
neural plate undergoes bending at different levels mediated by sonic hedgehog 
signalling (Ybot-Gonzalez et al., 2002) along with the cells undergoing 
constriction mediated by actin binding proteins (Hildebrand and Soriano, 
1999; Brouns et al., 2000). Finally, adhesion of neural folds mediated by cell 
adhesion molecules such as Ephrins (Holmberg et al., 2000; Abdul-Aziz et al., 
2009) is required for neural tube closure. Disturbances or alterations in gene 
expression or cellular events that regulate neural tube closure results in failure 
of closure of the neural tube.  
1.5. Neural tube defects  
Neural tube defects (NTD) are complex and heterogeneous congenital 
malformations that occur due to failure of closure of the neural tube during the 
period of embryogenesis (Campbell et al., 1986; Padmanabhan, 2006). NTD 
are classified as open NTD or closed NTD depending on the presence or 
absence of skin layer covering the brain/ and or spinal cord (Lemire, 1988; 
Padmanabhan, 2006). The most commonly observed open NTD are 
anencephaly at the cranial neural tube and spina bifida (or myelomeningocele) 
at the spinal neural tube that is clinically apparent (Dias and Partington, 2004). 
While anencephaly is incompatible with survival, fetuses with spina bifida can 
survive with surgical correction post birth although they experience mild to 
severe motor and sensory dysfunction (Rintoul et al., 2002; Dias and 
Partington, 2004). Craniorachischisis is one of the very rare forms of open 
NTD in which the neural tube fails to close along the entire body axis. Closed 
NTD occur after neural tube closure and include encephalocele, meningocele, 
lipomeningocele, iniencephaly (Lemire, 1988; Mitchell, 2005). 
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1.5.1. NTD in diabetic pregnancy 
NTD are the second most common congenital abnormality observed in 
diabetic pregnancy and the risk for NTD is 3-5 fold higher in diabetic 
pregnancy when compared to non diabetic pregnancy (Aberg et al., 2001) in 
humans and mouse models. Animal studies have shown that altered glycemic 
levels during neurulation result in NTD (Langer and Conway, 2000; Loffredo 
et al., 2001) suggesting the importance of maintaining precise maternal 
glycemic levels. Maternal diabetes-induced NTD reported at the cranial region 
are anencephaly, holoprosencphaly and syntelencephaly (Eriksson, 1995; 
Robin et al., 1996). Syntelecephaly occurs as a result of fusion of the two 
cerebral hemispheres while in holoprosencephaly the forebrain fails to develop 
the two cephalic hemispheres, indicating defective brain patterning and 
shaping. 
1.5.2. Morphological and molecular characterisation of NTD 
Maternal diabetes has been shown to cause severe patterning defects in the 
brain of developing embryos. Maternal diabetes-induced malformations in 
various parts of the brain including the forebrain (telencephalon), spinal neural 
tube, choroid plexus (CP) and ventricles have been reported in mouse embryos 
(Liao et al., 2004; Jiang et al., 2008; Loh et al., 2011). The impaired 
development of CP by maternal diabetes results in decreased production of 
cerebro-spinal fluid (CSF) and has been proposed to cause defective shaping 
and patterning of the brain in embryos of diabetic pregnancy (Dziegielewska 
et al., 2001; Miyan et al., 2003; Gato et al., 2005; Parada et al., 2005). In 
addition, the neural tissue with defective patterning showed altered expression 
of several signalling molecules and transcription factors such as Shh, Nkx2.1, 
BF-1, TGF-β and Pax3 which are critical for closure of the neural tube and 
patterning of the forebrain (Liem et al., 1995; Furuta et al., 1997; Phelan et al., 
1997; Fine et al., 1999; Liao et al., 2004) 
Recently, high throughput gene expression profiling using cDNA 
microarray revealed the differential expression of several genes in the cranial 
neural tubes of embryos from diabetic pregnancy (Phelan et al., 1997; Chang 
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and Loeken, 1999; Jiang et al., 2008; Pavlinkova et al., 2009a). Higher 
numbers of genes involved in metabolic and cellular process were found to be 
altered by maternal diabetes (Jiang et al., 2008). Microarray analysis on whole 
embryos from diabetic pregnancy has also identified differential expression of 
several genes involved in critical developmental pathways (including genes 
known to cause NTD) that could contribute to maternal diabetes-induced birth 
defects (Pavlinkova et al., 2009a). These descriptive reports suggest that brain 
development is impaired due to the altered expression of developmental 
control genes caused by maternal diabetes-induced glucotoxicity. 
1.5.3. Characterisation of metabolic pathways in NTD 
In recent years, the research on maternal diabetes-induced congenital 
malformations in fetus has moved on from morphological characterisation to 
identifying the etiology of birth defects. It has been widely shown that 
maternal diabetes induces hypoxia, oxidative stress and other metabolic 
disturbances in the embryo (Li et al., 2005) Maternal hyperglycemia 
accelerates metabolic rates (glucose oxidation) resulting in hypoxia (Lai et al., 
2003; Li et al., 2005), which can in turn stimulate production of mitochondrial 
superoxide, thereby resulting in oxidative stress in the embryos (Chandel et 
al., 1998). These cellular changes alter several signalling pathways and 
molecules which have been proposed to be the major causative factors for the 
diabetes–induced malformations leading to embryopathy. For example, the 
oxidative stress caused by hyperglycemia has been shown to disrupt the 
expression of genes such as Pax3 involved in neural tube formation. This 
explains in part that hyperglycemia-induced oxidative stress alters gene 
expression leading to NTD (Loeken, 2006).  
Hyperglycemia-induced birth defects are attributed to the increased 
production of reactive oxygen species (ROS) which causes oxidative stress 
and subsequently increasing the risk for fetal malformations (Sakamaki et al., 
1999; Chang et al., 2003). Administration of antioxidants such as vitamin E 
and overexpression of ROS scavenging enzymes such as superoxide dismutase 
have been shown to prevent or reduce the risk for diabetic malformations in 
several animal studies although the exact mechanism is unknown (Eriksson 
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and Borg, 1991; Hagay et al., 1995; Sivan et al., 1996; Siman and Eriksson, 
1997; Sivan et al., 1997; Wentzel and Eriksson, 1998). In addition, several 
signalling pathways such as protein kinase C (Hiramatsu et al., 2002), 
prostaglandin synthesis (Wentzel et al., 1999), PPAR signalling (Capobianco 
et al., 2008), and JNK/MAPK (Li et al., 2012) have been implicated in 
hyperglycemia-induced birth defects. 
Development and patterning of normal brain depend on proliferation 
and differentiation of neural stem cells (NSCs) which are self-renewing 
multipotent cells that give rise to neuronal and glial cells (astrocytes and 
oligodendrocytes) in the central nervous system. NSCs are extremely sensitive 
to glucotoxicity, which alters the proliferation and lineage specification of 
NSCs (Fu et al., 2006). Apoptosis in the neuroepithelium is the hallmark of 
maternal diabetes-induced NTD.  In addition, the balance between cell 
proliferation and cell death that is altered by hyperglycemia may contribute to 
the malformations seen in the developing neural tube (Copp and Greene, 
2010). Also, high glucose induces ROS production and intracellular oxidative 
stress in NSCs by increasing glucose reduction via the polyol pathway (Fu et 
al., 2007). Overall, these studies indicate that the development of strategy to 
prevent oxidative stress during fetal development may alleviate the risk of 
congenital anomalies in embryos. 
1.5.4. Unravelling epigenetic mechanisms contributing to neural tube 
defects 
The exact mechanism behind maternal diabetes-induced NTD still remains 
unknown. However, maternal diet has been shown to be an important 
modulator of fetal outcome, since supplementation of maternal diet with 
methyl donor such as folate, has prevented the occurrence of NTD (Wentzel et 
al., 2005) in animal models of diabetic pregnancy. 
It has been reported that maternal nutrition and metabolic disturbances 
during fetal development can alter epigenetic mechanisms such as histone 
modifications, DNA methylation and chromosomal changes in fetus, and such 
epigenetic changes may have long lasting effects on the offspring postnatally 
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(Jaenisch and Bird, 2003; Wu et al., 2004; Gallou-Kabani and Junien, 2005; 
Junien, 2006). Study on pregnant mice fed with diets low in choline/ 
methionine have resulted in decreased methylation in genes that control brain 
development (Niculescu et al., 2006; Zeisel, 2009), and altered memory and 
long-term potentiation (Meck and Williams, 1997; Pyapali et al., 1998) 
indicating that the developing embryo is influenced by maternal diet.  
It has been widely shown that diabetic complications are associated 
with epigenetic modifications. In recent years, several reports have shown that 
the onset of diabetes in adults is caused by DNA methylation at specific gene 
promoters or chromosomal regions (Temple and Shield, 2002; Ling et al., 
2008; Park et al., 2008; Ronn et al., 2008), signifying epigenetic basis for 
onset of diabetes in adults. In addition, studies have shown that the effect of 
nutrition or diet on epigenetic mechanisms is not reflected in the next 
generation alone but may also be trans-generational (Kaati et al., 2007) and is 
alarming due to the increasing incidence of diabetes worldwide. 
High glucose has also been shown to cause persistent change in gene 
expression by modifying histones (acetylation or methylation of lysine 
residues) during transient exposure of human aortic endothelial cells (El-Osta 
et al., 2008) and chronic exposure of human monocytic cell line (Miao et al., 
2007) to high glucose. Further, excess glucose has been shown to increase 
histone acetylation in mammalian cells (Wellen et al., 2009), while excess 
dietary methyl donors increase DNA/ histone methylation in offspring 
(Waterland, 2006) providing evidence for the relationship between maternal 
hyperglycemia (or diet) and fetal epigenome. Recently, glucose responsive 
microRNAs such as miR-26a, miR107 and miR-16 that show increased 
expression in high glucose conditions have been identified (Tang et al., 2009), 
suggesting that epigenetic mechanisms could be activated by hyperglycemia. 
Further, epigenetic factors have been shown to regulate gene expression of 
developmental control genes and fate specification of NSCs (Hsieh and Gage, 
2004; Kondo, 2006). It is possible that high glucose modifies epigenetic 
mechanisms which subsequently alter expression of genes that control fate 
specification of NSCs, resulting in NTD. 
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         In mouse models of diabetic pregnancy, it is observed that not all 
embryos exhibit NTD phenotype although they are exposed to the same 
maternal glycemic environment. Transcriptome profiling of embryos from 
diabetic pregnancy with NTD and those without NTD appear to be similar 
(Salbaum and Kappen, 2010), supporting the notion that the developmental 
program is accompanied by fine tuning of gene expression possibly by specific 
epigenetic marks (Salbaum and Kappen, 2011). Further investigation of 
epigenetics will be useful to understand the relationship between maternal diet 
and the fetal epigenome. It will be intriguing to know how high glucose/ 
hyperglycemia activates epigenetic mechanisms that alter gene expression in 
the fetus resulting in NTD.  
1.6. Epigenetics 
The term ‘Epigenetics’ was first coined by Conrad Waddington in 1942 
(Goldberg et al., 2007) refers to heritable and reversible changes in gene 
expression without alterations of underlying DNA sequences. Epigenetic 
mechanisms are of three types a) Histone modifications (that control 
accessibility of chromatin for transcription), b) DNA methylation (which is 
responsible for maintaining normal expression pattern of genes in mammals) 
and c) microRNA (miRNA, which regulate target gene expression) mediated 
process. DNA methylation was discovered in 1970s and has been the most 
extensively studied mechanism while histone modifications and microRNAs 
were identified later in 1990s and early 2000s (Chuang and Jones, 2007; 
Kouzarides, 2007; Urdinguio et al., 2009). Gene expression can be controlled 
by one or more epigenetic mechanisms which require detailed evaluation. 
1.6.1. DNA methylation 
DNA methylation involves the addition of methyl group at the 5th position of 
cytosine residue of DNA. DNA methylation regulates the normal gene 
expression and most of the methylated DNA is found in non-coding regions of 
the genome in mammalian cells. Methylation occurs on cytosine residues of 
CpG dinucelotides wherein a cytosine residue is followed by a guanine 
residue.  The distribution of CpG dinucleotides is irregular across the genome 
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which consists of CpG rich and CpG poor regions (Takai and Jones, 2002). 
The promoter regions of about 70% of the genes are known to contain 1000 bp 
long CpG rich sites referred to as CpG islands that are normally unmethylated 
(Bird, 1986; Deaton and Bird, 2011). CpG islands are methylated for 
transcriptional repression associated with imprinted genes, X-chromosome 
inactivation in females and tissue specific genes (Jones and Takai, 2001; 
Edwards and Ferguson-Smith, 2007). Therefore, hypomethylation of CpG 
islands facilitate gene expression while hypermethylation of CpG islands 
inhibit gene expression. 
CpG sites apart from those in promoter are normally methylated and 
are found in repetitive or centromere regions of the chromosomes (Bird, 
2002). A methylated cytosine can undergo deamination spontaneously 
resulting in guanine due to which  majority of the genome is poor in CpG sites 
(Egger et al., 2004). DNA methyltransferases (DNMTs) mediate DNA 
methylation by transferring methyl groups to cytosine residues. In mammals, 
three major types of DNMTs have been identified, namely DNMT1, 
DNMT3A and DNMT3B (Bestor, 2000). DNMT1 is a maintenance 
methyltransferase that copies DNA methylation pattern from the parent strand 
to the daughter strand after replication of DNA.  DNMT3A and DNMT3B are 
structurally similar and serve as de novo methyltransferases that introduce 
methylation patterns in unmethylated (or naked) DNA (Turek-Plewa and 
Jagodzinski, 2005). Knockout of Dnmt1 results in embryonic lethality due to 
impaired cell division and differentiation in mice (Li et al., 1992). Dnmt3b is 
also critical for early embryonic development as knockout results in 
embryonic lethality, whereas loss of Dnmt3a impairs cell differentiation 
(Okano et al., 1999) and affects the survival of postnatal mice pups.  
DNA methylation can repress gene expression by blocking the binding 
of transcription factor to target genes either directly or indirectly. The methyl-
CpG binding protein family (MBDs), which consists of MDB1-4, MECP2 and 
Keiso (Klose and Bird, 2006) mediate indirect repression of gene expression. 
DNA methylation is reversible since DNA demethylation can occur by 
chemical reactions and DNA repair mechanisms although the exact 
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mechanism is not fully understood (Zhang et al., 2007). DNA methylation in 
vitro can be inhibited using nucleoside analogues such as 5-aza2’-
deoxycytidine and Zebularine which have been extensively used to examine 
dynamic functions of DNA methylation. 
 
1.6.1.1. DNA methylation in brain development and function 
The brain contains highest levels of DNA methylation compared to other 
tissues and exhibits high expression of MBDs which suggest functional roles 
for DNA methylation in brain development (Amir et al., 1999). Loss of 
DNMTs results in various birth defects including NTD (Okano et al., 1999) 
suggesting its role in diverse cellular functions including cell fate specification 
and regulation of cell differentiation. DNA methylation has been shown to 
regulate differentiation of NSCs into neurons or astrocytes by methylation or 
hypomethylation of Gfap (astrocyte marker) promoters (Takizawa et al., 
2001).  In mice, the Gfap promoter is methylated at E11.5 when astrogenesis 
does not occur and becomes demethylated at E14.5 when neural progenitor 
cells differentiate into astrocytes (astrogenesis) (Teter et al., 1996). In 
postnatal brains (3 weeks post birth), Gfap promoter is remethylated which 
corresponds to decline in Gfap expression (Fan et al., 2005). Further, loss of 
Dnmt1 enzyme during development results in increased generation of glial 
cells (Fan et al., 2005) by altering methylation levels of differentiating neurons 
(hypomethylation) and neuronal precursors (demethylation). Hypomethylation 
of neurons result in defective neuronal maturation indicating that DNA 
methylation and DNMTs are essential for differentiation and maturation of 
neurons (Fan et al., 2001; Golshani et al., 2005; Hutnick et al., 2009). MDBs 
have also been shown to play critical roles in brain development. Loss of 
Mbd1 results in decreased neurogenesis and deficits in learning in adult mice 
(Zhao et al., 2003).  In addition, loss of MECP2 results in neurodevelopmental 
disorders in both humans and rodent models (Zhao et al., 2003; Moretti and 
Zoghbi, 2006). Although the expression of Dnmts is decreased in 
differentiated cells, post mitotic neurons in the adult brain are known to 
express Dnmt1 and Dnmt3a, suggesting significant regulatory roles in adult 
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brain (Fan et al., 2005). Overall, DNA methylation regulates brain functions 
including learning and memory (Levenson et al., 2006; Miller and Sweatt, 
2007; Nelson et al., 2008) and altered DNA methylation underlies various 
brain disorders (Poulter et al., 2008). 
 
1.6.2. Histone modifications 
In eukaryotes, the chromatin consists of DNA that is wrapped with histone 
proteins to facilitate packaging of DNA into the nucleus. The nucleosomes are 
fundamental units of chromatin that consists of 147bp of DNA enfolding 
around an octamer of histone proteins. Two molecules each of the core histone 
proteins (H2A, H2B, H3 and H4) form the octamer while linker histones (H5) 
link the adjacent nucleosomes (Lachner et al., 2003). The N-terminus of the 
core histones undergoes post-translational modifications, thereby regulating 
gene expression. At least a dozen post-translational modifications have been 
identified including methylation, acetylation, phosphorylation, ubiquitination, 
sumoylation that occur over 60 different residues on the histone (Lachner et 
al., 2003; Kouzarides, 2007). These post-translational modifications regulate 
gene expression by shifting the charge on histone proteins or by recruiting 
proteins that bind to these modifications, thereby altering chromatin packaging 
and accessibility of DNA to transcription factors (Kouzarides, 2007). Histone 
modifications are extremely important as it determines chromatin packaging 
and gene transcription and depending on the level of condensation, chromatin 
exists in two different states, namely the euchromatin or heterochromatin. 
Euchromatin is less condensed and consists of actively transcribed genes while 
heterochromatin is highly condensed and present in centromere and telomere 
regions of chromosomes (Grewal and Elgin, 2007). 
Among the different modifications identified, the acetylation and 
methylation of histone residues have been extensively studied. While 
acetylation of lysine (K) residue is generally identified in active genes, the 
level of methylation at lysine residues (monomethyl or dimethyl or trimethyl) 
and the position of lysine residue vary in active and inactive genes, generating 
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high level of complexity. In general, specific histone marks are associated with 
active and inactive genes. For example, acetylation of histone H3 lysine 9 
residue (H3K9ac), or lysine 14 residue (H3K14ac) or trimethylation of H3K4 
(H3K4me3) are found in promoters of transcriptionally active genes while 
trimethylation of histone H3 lysine9 (H3K9me3) and/or lysine 27 residues 
(H3K27me3) are found in transcriptionally repressed genes (Vakoc et al., 
2005; Kouzarides, 2007).  
Histone acetylation is mediated by two enzymes with opposing actions 
namely histone acetyltransferases (HATs) that add acetyl groups (e.g., p300, 
GCN5, PCAF5,CREB-binding protein) and histone deacetylases (HDACs) 
that remove acetyl groups (e.g., Class I [HDAC 1, 2, 3, 8] class II [HDAC 4, 
5, 6, 7, 9,10] class III [Sirtuin 1-7] and class IV HDAC[11]). Acetylation by 
HATs results in alteration of net charge on the histone, thereby decreasing its 
interaction with negatively charged DNA resulting in relaxation of chromatin 
thereby allowing DNA transcription. HDACs on the other hand catalyze the 
condensation of chromatin making the DNA inaccessible for transcription 
(Kouzarides, 2007). HDACs can be inhibited by chemical substances such as 
valproic acid (VPA), sodium butyrate or trichostatin A (TSA) and have been 
extensively used to study importance of histone acetylation in various 
cells/tissues (Kouzarides, 2007).  
Histone methylation is catalyzed by histone methyltransferases 
(HMTs) that add methyl groups (e.g., G9a, SUV39h), resulting in 
transcriptional activation or repression and can be reversed by histone 
demethylases (HDMs, e.g., lysine-specific demethylase 1[LSD1]). 
1.6.2.1. Histone modifications (lysine acetylation and methylation) in 
brain development and functions 
HATs and HDACs play important roles in embryonic NSCs, since loss of 
specific HATs or HDACs has been shown to result in NTD signifying that 
increased or decreased acetylation is implicated in NTD (Yao et al., 1998; 
Tanaka et al., 2000; Cheng et al., 2003; Vega et al., 2004; Bu et al., 2007).  
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NSC fate has been shown to be regulated by specific HATs, which 
acetylate and thereby induce the expression of genes involved in 
differentiation (Nakashima et al., 1999; Sun et al., 2001). In addition, 
inhibition of HDACs in embryonic mouse brain results in increased 
neurogenesis in cortex while in rat brain, it causes delays in oligodendrocyte 
differentiation, indicating that acetylation of histones mediated by HATs and 
HDACs is critical for regulating the expression of cell lineage markers during 
brain development (Shen et al., 2005; Shaked et al., 2008). Similarly, HDAC1 
and HDAC2 have been shown to be critical for differentiation of neurons and 
oligodendrocytes in the CNS since loss of Hdac1 and Hdac2 in the CNS 
results in abnormalities in the hippocampus, decreased differentiation and 
disruption of cortical neuronal organization. In oligodendrocyte progenitors, 
loss of Hdac1 and Hdac2 eliminates the differentiation of oligodendrocytes 
(Montgomery et al., 2009; Ye et al., 2009).  
The histone methyltransferases (HMTs) and histone demethylases 
(HDMs) are essential for neurogenesis and for switching NSC fate from 
neurogenesis to astrogenesis during brain development since the loss of 
specific HMTs in NSCs impair neuronal differentiation (Song and Ghosh, 
2004). During astrogenesis, the levels of H3K4me3 were increased while 
H3K9me3 decreased in the promoter of Gfap (astrocytes marker). Moreover, 
decreased histone acetylation levels and increased H3K27me3 were detected 
in Neurog1 (Neurogenin 1- marker for neurons) promoter in NSCs (Lim et al., 
2009). In addition,  Ezh2 (Enhancer of Zeste homologue 2) a member of the 
polycomb group of proteins that mediate H3K27me3 are highly expressed by 
undifferentiated NSCs and their levels decrease during differentiation into 
neurons and astrocytes. However, the levels of Ezh2 remain high during 
differentiation of NSCs into oligodendrocytes, suggesting the importance of 
histone modifications in NSC fate determination (Sher et al., 2008). Although 
recently discovered, HDMs are proven to be critical in regulating survival of 
neurons and NSC proliferation (Iwase et al., 2007; Sun et al., 2010). 
Overall, it is evident that histone acetylation and methylation mediated 
by HATs, HDACs, HMTs and HDMs regulate development of the nervous 
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system and loss/deficiency of these enzymes has been linked to developmental 




MicroRNAs (miRNAs) are small, single stranded, non-coding RNA molecules 
that are 18-25 nucleotides in length (Ambros, 2001, 2004) and function 
predominantly as translational repressors although of late, they have been 
identified to increase translation (Vasudevan et al., 2007; Bartel, 2009).  
miRNAs were first discovered in Caenorhabditis elegans and since then, 
found to be expressed ubiquitously in all species (Ambros, 2004). About one 
third of the genes in mammals are predicted to be regulated by miRNAs 
(Filipowicz et al., 2008) and miRNAs have diverse functions in cells ranging 
from regulation of neuronal development and differentiation, synapse 
formation (Presutti et al., 2006; Fiore and Schratt, 2007b, a), angiogenesis 
(Kloosterman and Plasterk, 2006), stem cell pluripotence and differentiation 
(Ivey et al., 2008), apoptosis, and cell cycle (Ambros, 2004). In addition, 
miRNAs have been shown to be involved in pathogenesis of 
neurodegenerative diseases (Hebert and De Strooper, 2009) and neurological 
disorders (Haramati et al., 2010). 
1.6.3.1. miRNA biosynthesis 
In mammals, primary precursors of microRNAs (pri-miRNAs) are generated 
via transcription by RNA polymerase II or III from their own promoters 
(intergenic miRNAs) or from host genes (intragenic miRNAs) (Kim et al., 
2009). It has been reported that about half of the mammalian miRNAs are 
transcribed from introns of functional genes (Saini et al., 2008). These pri-
miRNAs undergo cropping and dicing to generate mature and functional 
miRNAs. They are first cropped by Drosha and DGRC8 (DiGeorge syndrome 
cirtical region gene 8), a nuclear RNase III endonuclease to generate precursor 
miRNAs (pre-miRNAs). Pre-miRNAs are about 70-100 nucleotides long 
stem-loop structures and are exported via Exportin 5 for dicing in the 
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cytoplasm. An RNase III enzyme (dicer) cleaves the pre-miRNAs to generate 
mature miRNAs duplex that is around 18-25 nucleotides long (Bartel, 2009). 
This duplex contains the mature miRNA that acts as the guide and miRNA* 
that acts as the passenger strand. The RNA-induced silencing complex (RISC) 
is loaded with miRNA forming the miRNA-loaded RISC (miRISC) while the 
miRNA* is degraded (Bernstein et al., 2001; Schwarz et al., 2003). The 
nucleotides 2-8 at the 5’ end of the mature miRNA is referred to as the “seed 
region” and is critical for determining the mRNA target. Hybridization 
between seed region and complementary mRNA is required for miRNA 
function such as mRNA degradation, inhibition of translation or deadenylation 
(Eulalio et al., 2008). Complete complementarity between the miRNA seed 
region and the mRNA target results in degradation of mRNA (in plants), while 
partial complementarity results in inhibition of translation or mRNA 
deadenylation (in mammals) (Bartel, 2009). The cytoplasm contains P-bodies 
(processing bodies) which contain miRISC complex, decapping enzymes and 
deadenylation complex and is the site wherein translational inhibition, mRNA 
degradation or deadenylation occurs (Liu et al., 2005; Giraldez et al., 2006). 
Based on the seed complementarity, a miRNA can target hundreds of mRNAs 
and in turn, a mRNA can be targeted by numerous miRNAs (Miranda et al., 
2006). 
1.6.3.2. miRNAs in brain development and function 
The human and mouse brains are known to express more than 50% of the 
known miRNAs, and their expression patterns change dynamically during 
development (Miska et al., 2004; Delaloy and Gao, 2008), indicating 
significant regulatory roles during brain development. miRNAs are essential 
for neurogenesis and gliogenesis during neurodevelopment since they regulate 
genes involved in neuronal and glial differentiation in the brain (Krichevsky et 
al., 2006; Zhao et al., 2009; Shi et al., 2010). Loss of dicer in NSCs results in 
lethality and defective brain development in embryos due to impaired 
neurogenesis (De Pietri Tonelli et al., 2008). In addition, deficiency in 
microRNA processing enzyme component, DGRC8 results in altered synaptic 
plasticity and impaired cognition (Davis et al., 2008; Schofield et al., 2011), 
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signifying the importance of miRNAs in the brain functions. The levels of 
miRNA expression is also critical in regulating neuronal development (Shi et 
al., 2004), signifying the importance of precise miRNA expression for normal 
brain development. miRNAs are shown to be critical for neural tube formation 
and closure in mouse (Hosako et al., 2009; Hoesel et al., 2010) and altered 
expression of miRNAs identified in human fetuses with anencephaly (Zhang 
et al., 2010) support these findings. In the brain, the expression of miRNAs 
has been found to be specific to cell-type, tissue, region and developmental 
stage indicating their dynamic roles in brain development and function.  
1.6.3.3. Cell-type specific miRNA expression 
Several miRNAs have been found to be specific to neurons and glial cells. 
miR-9, miR-124 and miR-128 are expressed by neurons, miR-219 and miR-
338 are specific to oligodendrocytes and miR-26a and miR-26b are highly 
expressed in astrocytes (Smirnova et al., 2005; Lau et al., 2008; Zhao et al., 
2010; Feng and Feng, 2011). The expression of these miRNAs appears to be 
critical, since they regulate differentiation of NSCs into neuronal or glial 
lineages. 
1.6.3.4. Region specific miRNA expression 
miRNA expression varies spatially. The hippocampus is enriched with miR-
218, miR-26a, miR-138, miR-221 while miR-195, miR-30b and miR-497 are 
enriched in the cerebellum (Bak et al., 2008) and miR-200 family (miR-200a, 
miR-200b, miR-200c) is highly expressed in the frontal cortex (Juhila et al., 
2011), indicating that miRNA expression in different regions vary with the 
cellular composition and function of the different regions of the brain. 
1.6.3.5. Developmental stage specific expression of miRNAs 
miRNA expression patterns are dynamic during brain development. MiRNA 
expression is regulated spatially and temporally, indicating functional roles for 
miRNAs during different developmental stages (Krichevsky et al., 2003; Ason 
et al., 2006; Kapsimali et al., 2007). 
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1.6.3.6. miRNAs in neurogenesis 
The role of miRNAs in neurogenesis has been extensively studied. miR-124 
and miR-9 are brain-specific miRNAs that regulate neuronal differentiation in 
rodents and humans (Conaco et al., 2006). The expression of miR-9 which is 
identified in neuronal precursors and differentiated neurons (Kapsimali et al., 
2007), and has diverse functions in neural progenitor cells from various 
species (Gao, 2010). MiR-124 is the most abundant miRNA identified in the 
mammalian brain that accounts for about 25-50% of all miRNAs (Lagos-
Quintana et al., 2002). MiR-124 is specifically expressed by neurons and its 
expression level increased during CNS development (Krichevsky et al., 2003; 
Smirnova et al., 2005), indicating its role in regulating neuronal 
differentiation. 
miR-124 promotes neuronal differentiation, while miR-9* and miR-
124 were found to decrease proliferation and induce differentiation of neural 
progenitors (Makeyev et al., 2007; Yoo et al., 2009). Recently, exogenous 
expression of miR-9/9* and miR-124 in human fibroblasts generated neurons 
(Ambasudhan et al., 2011; Yoo et al., 2011), while the exogenous expression 
of miR-124 in HeLa cells shifted the transcriptome profile of HeLa cells to 
that of the brain, indicating the instructive roles of miRNAs in neurogenesis. 
Further, miR-124 inhibition in differentiated neurons increased the expression 
of non-neural mRNAs supporting the regulation of neurogenesis by miRNAs. 
In addition to neurogenesis, miRNAs are also critical for the maintenance and 
survival of differentiated neurons (Schaefer et al., 2007; Davis et al., 2008). 
1.6.3.7. miRNAs in oligodendrocyte differentiation 
miR-219, miR-138 and miR-338 have been implicated in promoting 
differentiation of oligodendrocytes by inhibiting transcription factors that 
repress differentiation of oligodendrocytes (Lau et al., 2008; Dugas et al., 
2010). In addition, loss of dicer in oligodendrocytes results in dysmyelination 
and deficits in motor function revealing novel roles of miRNAs in regulating 
myelination (Zhao et al., 2010). 
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1.6.3.8. miRNAs in brain function 
Proper brain function depends on neuronal circuitry (formation of synapses 
and synaptic plasticity). miRNAs and components of miRNA biogenesis such 
as enzymes and pre-miRNA have been identified in dendrite and synapses 
(Lugli et al., 2005; Kye et al., 2007; Siegel et al., 2009). In addition, miRNAs 
mediate dendritic spine formation and plasticity of synapses (Simons and 
Mlodzik, 2008; Williams et al., 2009) and the localisation of miRNAs in 
dendrites implicates regulation of brain function by miRNAs. 
1.7. Crosstalk between epigenetic mechanisms in regulating gene 
expression 
It has been shown that DNA methylation and histone modifications jointly 
regulate gene expression. For example, CpG islands are known to contain 
increased levels of H3K4me3 (active mark) which prevents binding of Dnmts, 
thereby preventing DNA methylation (Mikkelsen et al., 2007; Zhang et al., 
2010). The MBDs such as MeCP2 repress gene expression by recruiting 
HDACs and HMTs to remove active marks and add repressive marks (Fuks et 
al., 2003). Therefore one epigenetic factor can influence the other to activate 
or inhibit gene expression. Similarly, DNA methylation regulates miRNA 
expression (Han et al., 2007) and miRNAs regulate DNA methylation by 
regulating histone modifications and Dnmts (Benetti et al., 2008). The 
crosstalk between epigenetic mechanisms offers major challenge in terms of 
understanding the epigenetic regulation of gene expression. 
1.8. Epigenetic therapy or “Epidrugs” 
The current focus of treatment is to target epigenetic mechanisms since they 
underlie various diseases and disorders. Epigenetic drugs or Epidrugs are those 
that alter the activity of enzymes that cause epigenetic modifications. HDAC 
inhibitors (e.g., butyrate, valproic acid) have been used widely as anti-cancer 
drugs (Karagiannis and Maulik, 2012) and also in treatment of 
neurodegenerative disorders, mood and anxiety disorders (Abel and Zukin, 
2008; Xu et al., 2011), muscular dystrophies (Consalvi et al., 2011) and as 
anti-inflammatory and immunomodulatory agents (Akimova et al., 2012; 
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Cantley et al., 2012). 5-azacytidine, a hypomethylating (FDA approved) drug 
is used in treatment of myelodysplastic syndrome (Egger et al., 2004) and 
under trial for treatment of various diseases. Currently, three FDA approved 
drugs (DNMT inhibitors and HDAC inhibitors) are used for treatment of 
myelodysplastic syndrome and urea cycle disorder and as anti-seizure drug 
(Mack, 2006). In addition, phase 2 clinical trials are currently ongoing for 
targeting miRNA (miR-122) in the treatment of Hepatitis C infection. At 
present, there are no epidrugs developed for metabolic syndrome such as 
diabetes, and extensive studies are required to establish and identify epigenetic 
signatures. The fact that epigenetic mechanisms are reversible offers great 
promise in reversing disease status to that of a healthy one. 
1.9. Isolation and culture of NSCs 
Isolation and culture of NSCs in vitro is valuable for understanding CNS 
development and function. NSCs can be isolated from both embryonic and 
adult brains and cultured in vitro. NSCs can be cultured in suspension as 
“neurospheres” in the absence of serum and in the presence of mitogens such 
as epidermal growth factor (EGF) (Reynolds and Weiss, 1992; Bez et al., 
2003). Neurospheres are small cluster of cells that expand in size (due to cell 
proliferation) and grow in suspension. The intermediate filamentous protein, 
Nestin has been widely used as a marker to identify NSCs (Lendahl et al., 
1990). NSCs can be maintained as neurospheres for up to ten weeks and 
expanded in culture by passaging and re-plating them as smaller neurospheres. 
Passaging also prevents necrosis at the centre of large neurospheres that occurs 
due to lack of nutrients and oxygen at the centre. NSCs can be induced to 
differentiate by plating them in medium containing serum and extracellular 
matrix for cell attachment and by seven days, NSCs differentiate into the three 
cell types namely neurons, astrocytes and oligodendrocytes (Galli et al., 2003; 
Moyse et al., 2008). 
The major limitation in culture of NSCs is the heterogeneous 
population of cells. The neurospheres consist of both neural stem cells and 
progenitor cells (Doetsch et al., 2002) and this is because only 10-50 % of the 
progeny cells in neurosphere retain stemness while the others undergo 
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differentiation spontaneously (Galli et al., 2003; Bergstrom and Forsberg-
Nilsson, 2012). In addition, culture of NSCs in vitro compromises its 
characteristics such as self renewal and differentiation since the culture 
conditions do not reflect an in vivo scenario entirely. In spite of the limitations, 
NSCs prove valuable in understanding CNS development.  The NSCs exposed 
to high glucose have distinct transcriptional profiles compared to the control 
(Fu et al., 2006) and understanding the molecular mechanisms behind altered 
gene expression is critical to prevent neural tube defects and altered brain 
function in embryos/infants of diabetic pregnancy.  
1.10. Animal models of diabetic pregnancy 
Animal models reproduce several important characteristics of human diabetic 
pregnancy such as spontaneous abortion, congenital anomalies and diseases in 
offspring that manifest later and are therefore extensively used to gain 
valuable insights into fetal consequences of diabetic pregnancy.  Indeed 
studies in animal models have shown that diabetes during pregnancy 
predisposes the pups to diabetes during later stages and the risk also continues 
into the following generations (Van Assche et al., 1991; Reusens and 
Remacle, 2001). In addition, the importance of intra uterine environment is 
understood from experiments in which transfer of embryos of Wistar rats that 
genetically display low risk for diabetes into the uterus of diabetic mother 
(Goto Kakizaki) resulted in increased risk for development of hyperglycemia 
in the adult stage (Van Assche et al., 1991). 
Diabetic animal models can be obtained by surgical procedures 
involving partial removal of the pancreas (Foglia et al., 1967), or by non-
surgical procedures as in the administration of chemicals such as 
Streptozotocin or Alloxan (Tsai et al., 1982; Lopez-Soldado and Herrera, 
2003) or by using genetically derived animals (Formby et al., 1987). 
Surgical models in rodents involve partial removal of pancreas 
(pancreatectomy) which results in mild type1 diabetes and does not affect the 
pregnancy rates. However, this model requires expertise and has a high 
mortality rate in animals post-surgery and was therefore replaced by other 
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available models to induce diabetes (Foglia et al., 1967; Jawerbaum et al., 
1993). 
The genetic models of diabetic pregnancy are available for both type 1 
and type 2 diabetes. The non-obese diabetic mice (NOD) and bio-breeding 
(BB) mice spontaneously develop type 1 diabetes and are most commonly 
used (Kay et al., 2000). The NOD mouse is a model for mild diabetes while 
the BB rat is a model for severe diabetes and requires exogenous 
administration of insulin which may otherwise result in mortality. The db/db 
mice is a model for gestational diabetes (Lambin et al., 2007), while Cohen 
diabetic rats and Goto Kakizaki rats are widely used as type 2 diabetic 
models(Goto et al., 1976).  
Compared to surgical methods, non-surgical methods are preferred to 
induce diabetes in animals. Chemicals/diabetogens such as Alloxan, 
Streptozotocin and Dithizone have been administered to animals to induce 
diabetes.  Among these chemicals, Streptozotocin (STZ), a N-nitroso 
derivative of glucosamine isolated from Streptomyces achromogenes is 
predominantly used to induce diabetes in various animal species (Reynolds et 
al., 1974; Ezekwe et al., 1984; Wilson et al., 1984; Kolb, 1987). STZ causes 
selective destruction of pancreatic beta cells resulting in hyperglycemia due to 
insulin deficiency (Junod et al., 1967) and is an excellent model to study the 
fetal consequences of diabetic pregnancy (Sivan et al., 1997; Kumar et al., 
2007; Sugimura et al., 2009). STZ induced diabetes is considered as a model 
for type 1 diabetes since it causes insulin deficiency. Depending on the dose 
and route of administration, STZ can cause mild (120-300mg/dl) to severe 
diabetes (>300mg/dl) in rodents (Junod et al., 1967; Brosky and 
Logothetopoulos, 1969). However, administration of STZ to new born pups 
(Tsuji et al., 1988; Wang et al., 1994) or to adult rats before mating (Eriksson 
et al., 1982; Kinney et al., 2003) or during pregnancy causes type 2 diabetes 
(Oh et al., 1988; Merzouk et al., 2000).  
In mice, diabetes can be induced by high or low doses of STZ via 
different administration routes. A single high dose of STZ (200-240 mg/kg) or 
three consecutive low doses (75-90mg/kg) injected intra-peritoneally or intra-
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venously prior to mating induces mild to severe diabetes. Following 
administration, changes in blood glucose and insulin levels are observed that 
reflect impairment of beta cell function. Initially, hyperglycemia and 
hypoinsulinemia are detected 2 hours after STZ administration, following 
which hypoglycemia and hyperinsulinemia can be identified at 6 hours. 
Finally decreased insulin secretion results in hyperglycemia (West et al., 
1996). 
STZ causes decrease in biosynthesis and secretion of insulin and 
impairs the oxidation of glucose (Bolaffi et al., 1987; Bedoya et al., 1996). 
The destruction of pancreatic beta cells by STZ occurs due to DNA damage 
that is attributed to the nitrosourea moiety in STZ which induces alkylation of 
DNA in beta cells (Elsner et al., 2000). In addition, STZ inhibits Krebs cycle 
and decreases mitochondrial oxygen consumption generating reactive oxygen 
species that aids in DNA damage (Nukatsuka et al., 1990; Turk et al., 1993). 
Finally, the induction of DNA damage by STZ activates poly-ADP-
ribosylation which depletes cellular NAD+ resulting in reduced ATP, thereby 
inhibiting synthesis and secretion of insulin (Sandler and Swenne, 1983; 
Nukatsuka et al., 1990; Heller et al., 1994). The activation of poly-ADP-
ribosylation appears to be critical for the diabetogenic potential of STZ, since 
its inhibition offers protection against STZ-induced beta cell damage (Pieper 
et al., 1999). 
1.11. Scope of the study 
The present study aimed at identifying the epigenetic mechanisms by which 
maternal diabetes altered gene expression in the developing neural tube. It has 
been shown that maternal diabetes alters the expression of several genes 
involved in neurulation, proliferation and cell fate specification of neural stem 
cells (NSCs) which may form the basis for NTD. Since neural tube 
development and closure require proliferation, migration, adhesion, 
differentiation and apoptosis of NSCs (Schoenwolf and Smith, 1990), NSCs 
isolated from the forebrain of embryos of control and diabetic pregnancy were 
cultured in vitro in physiological glucose concentration in the present study. In 
addition, NSCs isolated from control pregnancy were exposed in vitro to high 
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glucose to mimic maternal diabetes induced hyperglycemia. It is 
hypothesized that exposure of NSCs to hyperglycemia results in activation 
of epigenetic mechanisms (chromatin modification, DNA methylation and 
microRNA mediated), which alter the expression of genes during brain 
development resulting in NTD. 
 First, the author will examine whether epigenetic mechanisms 
are altered by hyperglycemia. The global histone H3lysine 9 status 
(trimethylation and acetylation) and global DNA methylation status of NSCs 
will be analysed. Next, specific genes that control NSC proliferation, 
differentiation and neuronal migration will be examined if they are 
epigenetically regulated.  Finally, the role of specific microRNAs (miRNAs) 
in regulating NSC fate will be investigated. 
 Secondly, the author will examine miRNA signatures in the 
developing neural tube during normal and diabetic pregnancy. Maternal 
diabetes-induced NTD have long been attributed to be caused by deregulation 
of several metabolic pathways, although the exact mechanism behind this 
remains unknown. Given that gene expression profiling in embryos of diabetic 
pregnancy has revealed altered gene expression in developing brains exposed 
to maternal diabetes (Jiang et al., 2008), and that miRNAs regulate gene 
expression, it is hypothesized that maternal diabetes alters expression of 
miRNAs that regulate genes/biological pathways  critical for neural tube 
development and closure. To address this, the author will perform miRNA 
expression profiling in NSCs isolated from the forebrain of embryos of control 
and diabetic pregnancy. Since maternal diabetes induces fetal 
hypoglycemia/hyperglycemia or hypoxia (induced by hyperglycemia), the 
author will expose NSCs in vitro to low glucose, high glucose or low oxygen 
conditions and compared their miRNA profiles.  These findings would provide 
novel insights into the mechanism of maternal diabetes-induced NTD and 
altered brain function in infants of diabetic mothers. Modulation of miRNA 


























In this study, adult Swiss albino mice and pregnant mice (gestational day 13.5-
15) were purchased from Centre for Animal Resources, (CARE), National 
University of Singapore, Singapore. The mice were housed in clean cages in a 
temperature-controlled room with light (14h) and dark (10h) cycles. Water, ad 
libitum was provided to all animals. For diabetic pregnancy, female adult mice 
were purchased and induced with diabetes, following which diabetic females 
were mated with adult male mice to obtain embryos. The numbers of adult 
animals used in this study are listed in table 1. All procedures used in this 
study were approved by the Institutional Animal Care and Use Committee 
(IACUC), NUS and its guidelines were followed (protocol number 122\09). 
Table 1: Adult Swiss albino mice used in this study 
Age Sex Number Experiments 
8-10 weeks Pregnant females N= 70 Normal pregnancy 
8-10 weeks Female N= 50 
Diabetic 
pregnancy 
Adult Male N= 20 Used for mating 
 
2.2. Induction of diabetes mellitus in mice 
2.2.1. Materials 
Streptozotocin (STZ) (Cat. No. S0130, Sigma-Aldrich, USA)  
0.01M sodium citrate buffer: 
Deionised water  100ml 
Sodium citrate   2.94g 
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Sodium citrate was dissolved in deionised water and 0.01mol/l 
citric acid was used to adjust the pH to 4.5 
2.2.2. Procedure 
STZ was freshly dissolved in 0.01M sodium citrate buffer at a final 
concentration of 24mg/ml. 8-10 week old female Swiss albino mice were 
induced with type 1 diabetes mellitus by a single intraperitoneal injection of 
STZ (75mg/kg body weight) under sterile conditions. 
2.3. Measurement of blood glucose 
2.3.1. Procedure 
A week after STZ injection, blood glucose level of the mice injected with STZ 
was measured. The mouse was trapped using a restrainer and the tip of the 
protruding tail was punctured with a sharp-sterile blade to obtain a drop of 
blood. A drop of blood was placed on the blood glucose strip which was 
inserted into the glucose meter (Abbott’s laboratories, Illinois, USA) in order 
to measure the blood glucose levels. Only mice with non-fasting blood sugar 
levels greater than 300mg/dL were used as diabetic group while the mice in 
the control group had a blood glucose level of about 90-140 mg/dL. 
2.4. Collection of embryos 
2.4.1. Materials 
0.1M phosphate buffered saline (PBS) 
Di-sodium hydrogen phosphate heptahydrate
 13.3g 
Sodium chloride    
 8.5g 
The above salts were added to 700 ml of deionized water. The 





 One week after mice were confirmed to be diabetic, timed mating was done 
by placing 3-4 diabetic females with one age-matched healthy male mice in 
cages overnight. The day when the copulation plug was seen was counted as 
embryonic day 0.5 (E 0.5). Time mated E13.5 pregnant age-matched control 
mice were purchased from CARE, NUS. On E13.5, the embryos were 
collected by Caesarean section of diabetic and control mice that were 
anesthetized with intraperitoneal injection of pentobarbital (150mg/kg body 
weight). Images of whole embryos from control and diabetic pregnancy 
were captured using a stereomicroscope fitted with a camera (Nikon 
SMZ1500, Nikon, Japan). E13.5 day non –malformed embryos (or embryos 
without apparent neural tube defects) from diabetic pregnancy (experimental 
group) and control pregnancy (control group) were used in this study. E13.5 
day embryos were used since they contain sufficient forebrain tissue for 
isolation of NSCs. 
2.5. Primary culture of mouse embryonic neural stem cells 
2.5.1. Materials 
Dulbecco’s Modified Eagle Medium (DMEM) without D-
glucose (Cat. No. 11966025, Invitrogen, USA) 
F-12 Nutrient Mixture (F12) (Cat. No. 31765035, Invitrogen, 
USA) 
Insulin-Transferrin-Selenium (ITS) supplement (Cat. No. 
51500056, Invitrogen, USA) 
Epidermal Growth Factor (EGF)(Cat. No. E4127, Sigma-
Aldrich, USA) 
Antibiotic antimycotic solution(Cat. No. A5955, Sigma-
Aldrich, USA) 
TryPLE TM Select (Cat. No. 12563-011, Gibco, USA) 
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70µm nylon mesh (BD Biosciences, USA) 
75cm2 tissue culture flasks (Corning Life sciences, USA) 
2.5.2. Procedure 
On E13.5, the embryos were collected by Caesarean section of diabetic and 
control mice that were anesthetized with pentobarbital (150mg/kg body 
weight). Primary culture of NSCs was obtained from the telencephalon region 
of embryonic brains as described previously (Fu et al., 2006, 2007). Briefly, 
the tissue sections were subjected to mechanical dissociation in DMEM/F12 
(1:1, Invitrogen Life technologies, USA) and the cell suspension was filtered 
through a nylon mesh (70µm, BD biosciences, USA). The cells were plated at 
a concentration of 10-15 cells/µl (Tropepe et al., 1999; Morshead et al., 
2003)in DMEM/F12 medium with 5mM/L D-Glucose (PG) concentration and 
supplemented with insulin-transferrin-selenium supplements (Invitrogen), 
20ng/ml EGF (Sigma-Aldrich, USA)  and an antibiotic antimycotic solution 
(Sigma- Aldrich) in T-75 flasks (Corning Life sciences, USA). The cultures 
were incubated at 37oC/5% CO2 for 5 days after which the supernatant 
containing freely floating neurospheres was collected in 50ml tubes (Greiner 
Bio-One, Germany) and centrifuged at 800rpm/5min.  Harvested neurospheres 
were dissociated with TryPLETM Select (Gibco, Life Technologies, USA) and 
re-plated (50-70 cells/ µl) for 3-4 days, during which new neurospheres 
formed. Subsequently, a second passage was done (as previously) and cells 
were grown for 4-5 days. NSCs were grown for 12-14 days in total and 
passaged at least twice before they were used for experiments. The cells 
isolated were confirmed to be NSCs by staining with NSC marker, Nestin. 
2.6. Treatment of NSCs 
2.6.1. Materials 
50mM D-glucose solution: 
D-glucose (Amresco, USA) 360mg 
DMEM/F12 (1:1)  40ml 
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Syringe   10ml (BD Biosciences, USA) 
Filter    0.22 µm (Millipore, USA) 
D-glucose was dissolved in DMEM/F12 mixture and the 
solution was filtered through 0.22 µm filter under aseptic 
conditions 
2.6.2. Procedure 
To study the effects of hyperglycemia, hypoglycemia and hypoxia on the 
epigenetic mechanisms of NSCs, the NSCs from embryos of control 
pregnancy were cultured in medium containing physiological glucose 
concentration (PG, 5mmol/L), or cultured in medium with high glucose 
concentration (HG, 40mmol/L), or low glucose concentration (LG, 2 mmol/L) 
for 48h. 
 In order to mimic hypoxia, NSCs from control pregnancy (in medium 
with PG concentration) were cultured in the presence of low oxygen 






2.7. Differentiation of NSCs 
2.7.1. Materials 
Dulbecco’s Modified Eagle Medium (DMEM) without D-
glucose (Cat. No. 11966025, Invitrogen, USA) 
F-12 Nutrient Mixture (F12) (Cat. No. 31765035, Invitrogen, 
USA) 
Insulin-Transferrin-Selenium (ITS) supplement (Cat. No. 
51500056, Invitrogen, USA) 
Antibiotic antimycotic solution (Cat. No. A5955, Sigma-
Aldrich, USA) 
Fetal bovine serum (FBS) (Cat. No. 10099, Invitrogen, USA) 
TryPLE TM Select (Cat. No. 12563-011, Gibco, USA) 
0.01% poly-L-ornithine solution (Cat. No. P4957, Sigma-
Aldrich, USA) 
24 well plates (Corning Life Sciences, USA) 
Glass coverslips (Round, 13mm in diameter) 
2.7.2. Procedure 
Preparation of poly-L-ornithine coated coverslips: 
The coverslips were cleaned by immersing them in absolute alcohol overnight, 
followed by washing with deionized water. The washed coverslips were air-
dried individually on filter papers, after which they were autoclaved and 
stored. Using a forceps, a sterile coverslip was placed in to each of the desired 
number of wells of a 24 well plate. Next, 0.4ml of Poly-L-ornithine solution 
was added to each well to coat the coverslips and the plates were incubated at 
370C for 2-3h. Following incubation, the poly-L-ornithine solution was 
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removed and the wells were washed twice with sterile PBS, after which NSCs 
were added. 
The neurospheres were harvested by centrifugation, trypsinised gently 
with TryPLE TM Select (Gibco, Life Technologies, USA) and resuspended in 
DMEM/F12 mixture, supplemented with physiological glucose, ITS and 
antibiotic antimycotic solution, without EGF and with 2% fetal bovine serum. 
EGF was replaced by 2% fetal bovine serum in order to induce differentiation. 
The cells in suspension were added on to poly-L-Ornithine coated coverslips 
and incubated at 37oC and 5% CO2 for 24h. 
2.8. Immunocytochemical analysis 
2.8.1. Principle 
Immunocytochemistry (ICC) is a highly sensitive and specific technique that 
involves identification of specific proteins in cells providing spatial 
localization. The protein (antigen) is identified or detected using labeled 
antibodies raised against the antigen. The antibody used for detection can be 
labeled with enzymes (light microscope), or particles that are electron dense 
(electron microscope) or with fluorescent dyes (Fluorescence or confocal 
microscope) (Johnson et al., 1982). Mostly, indirect methods of detection, 
using a primary (unlabeled) antibody and secondary (labeled) antibody are 
employed for signal amplification and greater sensitivity. 
 The typical steps involved in ICC analysis are fixation and 
permeabilisation, blocking, and detection using primary and secondary 
antibodies (Oliver and Jamur, 2010). Fixation and permeabilisation results in 
immobilization of the antigen while retaining the cellular and organelle 
structures. In addition, it also provides accessibility of antibody to the antigens 
(intracellular and cytosolic epitopes). Blocking is essential as it reduces non 
specific binding of primary/ secondary antibodies which otherwise results in 
high background. Subsequently addition of primary antibody results in binding 
with the specific antigen to be detected. The primary antibody is then detected 
using a labeled secondary antibody (against the primary antibody), thereby 
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revealing the cellular localization of the specific protein under study 
(Happonen and Heikinheimo, 1989). 
2.8.2. Materials 
Mouse anti-Nestin monoclonal antibody (Cat.No. MAB353, 
Chemicon, USA) 
Rabbit anti-trimethylated histone H3 lysine 9 (H3K9me3) 
monoclonal antibody (Cat.No.17-625, Millipore, USA) 
Rabbit anti-acetylated histone H3 lysine 9 (H3K9ac) 
monoclonal antibody (Cat.No.17-615, Millipore, USA) 
Rabbit anti-microtubule associated protein (MAP2) polyclonal 
antibody (Cat.No.AB5622, Chemicon, USA) 
Rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal 
antibody (Cat.No.AB5804,Chemicon, USA) 
Rabbit anti-chondroitin sulfate proteoglycan (NG2) polyclonal 
antibody (Cat.No.AB5320,Chemicon, USA) 
Cy3-conjugated goat anti-mouse IgG (Chemicon, USA) 
Cy3-conjugated goat anti-rabbit IgG (Chemicon, USA) 
Normal goat serum (Chemicon, USA) 
4’,6-diamidino-2-phenylindole dihyrochloride (DAPI) 
(Molecular Probes) 
Fluorescent mounting medium (Dako) 
0.1M phosphate –buffered saline (PBS) 
0.1M PBS with 0.1% Triton-X 100 (PBS-TX) 
4% paraformaldehyde (PF)  
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Paraformaldehyde    4g 
0.1M Phosphate buffer (pH 7.4) 100ml 
Paraformaldehyde powder was added to 0.1M phosphate buffer 
and dissolved by heating. The solution was cooled and then 
stored at 40 C. 
Poly-L-lysine or Poly-L-ornithine coated coverslips 
2.8.3. Procedure 
Preparation of poly-L-lysine coated coverslips: 
The coverslips were cleaned by immersing them in absolute alcohol overnight, 
followed by washing with deionized water. The washed coverslips were air-
dried individually on filter papers, after which they were autoclaved and 
stored. Using a forceps, a sterile coverslip was placed in to each of the desired 
number of wells of a 24 well plate. Next, 0.4ml of Poly-L-lysine solution was 
added to each well to immerse the coverslips and the plates were incubated at 
370C for 2-3h. Following incubation, the poly-L-lysine solution was removed 
and the wells were washed twice with sterile PBS after which NSCs were 
added. 
Neurospheres were harvested by centrifugation and transferred to the 
poly-L-lysine coated coverslips (whole neurospheres) or poly-L-ornithine 
coated coverslips (following dissociation) and cultured in 24 well plates for 
appropriate time points. The cells were first fixed with freshly prepared, ice 
cold 4% PF for 30min at room temperature, and then permeabilised with PBS-
TX for 20min. Following permeabilisation, the wells were washed atleast 
thrice with PBS to remove PBS-TX completely. The cells were then blocked 
with 3% blocking serum and incubated with appropriate primary antibodies 
overnight at 40C. The cells were incubated with mouse monoclonal anti-Nestin 
antibody (1:500, Chemicon, USA) an intermediate filament marker for NSCs 
or rabbit polyclonal anti- H3K9me3 antibody (1:500, Millipore,USA) or anti-
H3K9ac antibody (1:500 Chemicon) to detect histone H3 lysine 9 methylation 
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or acetylation. The following day, the wells were washed and appropriate Cy3 
conjugated secondary antibodies (1:100, Chemicon, USA) were added and 
incubated for 1h at room temperature. Following removal of secondary 
antibody, the nucleus was counterstained with DAPI (1µg/ml) and the 
coverslips were mounted on glass slides using mounting medium. The slides 
were protected from light, stored at 40C overnight before viewing and 
photographed using a confocal microscope (Olympus FV1000, Japan). 
2.9. Transmission electron microscopy 
2.9.1 Materials 
0.1M Phosphate buffer (pH 7.4) 
NaH2PO4.H20   2.76g 
Na2HPO4.2H20  14.24g  
The above salts were added to 700 ml of deionized water and 
the pH was adjusted to 7.4 using 1N hydrochloric acid. The 
solution was then made up to 1L using deionized water. 
2% paraformaldehyde and 3% glutaraldehyde  
Paraformaldehyde    2g 
0.1M Phosphate buffer (pH 7.4) 100ml 
Paraformaldehyde powder was added to 0.1M phosphate buffer 
and dissolved by heating. The solution was cooled to room 
temperature and mixed with 3% glutaraldehyde. 
2.9.2. Procedure 
NSCs from control and experimental groups were harvested by centrifugation. 
The cells were washed twice with PBS, after which they were fixed (2% 
paraformaldehyde, 3% glutaraldehyde in PBS) for 1h at room temperature. 
The fixed cells were harvested by centrifugation, washed thrice with PBS and 
incubated in PBS solution overnight at 4oC. The cells were then post-fixed in 
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1% osmium tetroxide, (OsO4, pH 7.4) for 2h at room temperature after which 
they were washed with 0.1M phosphate buffer pH 7.4). The cells were then 
dehydrated through an ascending ethanol series at room temperature and 
infiltrated with 100%acetone: resin (1:6) overnight at room temperature. After 
three changes in resin, the cells were embedded in fresh resin and polymerised 
at 550C for 1h. Sections cut were supported on grids (150nm) and stained with 
uranyl acetate (10min) and lead citrate (8min). Images were captured using 
Bio Twin CM 120 (Philips, USA) electron microscope. 
2.10. Histone protein extraction 
The histone extraction kit used in this study uses a simple and fast method for 
isolation of histone proteins. The kit includes pre-lysis, lysis and balance 
buffers and provides high yield of total histones, while it does not affect the 
status or levels of histone modifications.  
2.10.1. Materials 
EpiQuikTM Histone protein extraction kit (Cat. No. OP-0006-
100, Epigentek, USA)  
0.1M phosphate buffered saline (PBS) 
2.10.2. Procedure 
Total histone proteins were isolated from control and experimental groups 
using EpiQuik TM total histone extraction kit (Epigentek, USA), following the 
manufacturers’ instruction. Briefly, the NSCs were harvested by 
centrifugation, resupsended in 1X pre-lysis buffer and incubated at 40C in 
order to lyse the cells. Subsequently, the lysate was centrifuged at 10,000 rpm 
and the pellet obtained was resuspended in 3 volumes of lysis buffer. The tube 
was incubated for 30min on ice and centrifuged at 12,000rpm. The supernatant 
containing acid soluble proteins were transferred to a new tube and neutralized 
with 0.3 volumes of balanced buffer containing DTT (dithiothreitol) solution. 
The concentration of the extracted histone proteins was estimated using 
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Bradford’s reagent. Histone protein extracts were used for quantification of the 
histone modifications by ELISA-based approach and Western blot. 
2.11. Quantification of histone H3 lysine9 acetylation and methylation 
2.11.1. Principle 
The quantification of histone H3 lysine modification was done using a kit that 
uses an ELISA-based approach. The enzyme linked immunosorbent assay 
(ELISA) is a powerful technique for identification and quantification of 
specific protein from complex mixture (Engvall and Perlmann, 1971; Van 
Weemen and Schuurs, 1971). ELISA is of many types namely, direct ELISA, 
indirect ELISA and sandwich ELISA. In the direct and indirect ELISA, the 
antigen is immobilized on to the well of a microplate and is detected with 
labeled primary antibody (direct) or with an unlabelled primary antibody and 
labeled secondary antibody (indirect). 
In a conventional sandwich ELISA, the antigen is sandwiched between 
two antibodies. First, the antibody against the specific protein to be detected is 
adsorbed on to the wells of a microplate.  Upon incubation with protein 
mixture, the adsorbed antibody binds to the specific protein in the mixture. 
Subsequently, a labeled secondary antibody is added and the protein is 
detected using an appropriate substrate. The secondary antibody can be labeled 
with enzyme or fluorescent dye and detected using appropriate substrates. As a 
result of enzyme substrate reaction, a signal (colorimetric or fluorimetric) is 
detected. The signal is detected using a spectrophotometer and is proportional 
to the amount of protein in the mixture (Lequin, 2005). 
2.11.2. Materials 
EpiQuik TM Global trimethyl histone H3K9 quantification kit 
(Cat. No. P3034-48, Epigentek, USA)  
EpiQuik TM Global acetyl histone H3K9 quantification kit (Cat. 




The histone protein extracts from the control and experimental groups were 
used to quantify Histone H3K9 trimethylation (H3K9me3) or acetylation 
(H3K9ac) using quantification kits and following the manufacturer’s protocol. 
The microplate in the kit contained adsorbed antibodies for detecting 
H3K9me3 (EpiQuik TM Global trimethyl histone H3K9 quantification kit) or 
H3K9ac (EpiQuik TM Global acetyl histone H3K9 quantification kit). 2 µg of 
histone protein extract was added to the wells of the microplate and incubated 
for 2h at room temperature. Subsequently, the captured histone H3K9me3 or 
H3K9ac was detected using enzyme labeled secondary antibodies and 
appropriate substrate supplied in the kit. Upon colour development as a result 
of enzyme-substrate reaction, the absorbance was read at 450nm in a 
spectrophotometer (Tecan GENios, USA) and the percentage of histone 
H3K9me3 or H3K9ac was calculated using the formula given below. 
Acetylation or methylation % =   OD [Treated sample]      X   100% 
     OD [Untreated sample]  
Treated sample = Test- blank 
Untreated sample = Control – blank 
All samples were analysed in duplicates and the standard control supplied with 
the kit was used as the internal control. 
2.12. DNA isolation 
2.12.1. Principle 
In this study, the DNeasy technology (Qiagen Germany) was used to isolate 
DNA from the NSCs. This technology consists of silica-based purification of 
DNA and microspin technology that substitutes the conventional DNA 
isolation using organic solvents and ethanol precipitation. This kit is used for 
quick and convenient isolation and purification of total DNA from variety of 
samples including cultured animal cells. The cells are lysed using proteinase K 
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in the presence of chaotropic salt containing buffers. Proteinase K reduces 
handling time since it substitutes mechanical disruption, while the buffer 
provides optimal DNA binding to the silica column. The chaotropic salt 
removes water from the hydrated molecules in solution, thereby providing 
specific adsorption of DNA. The contaminants are eliminated as they pass 
through the column and the subsequent washing steps using ethanol containing 
buffers remove the residual contaminants. Finally the pure DNA is eluted in 
water or buffer. This DNeasy technology generates high yields and high 
quality of DNA in shorter time period and the DNA obtained is compatible 
with a variety of downstream applications. 
2.12.2. Materials 
DNeasy Blood and tissue kit (Cat.No. 69504, Qiagen, 
Germany) 
0.1M phosphate buffered saline (PBS) 
2.12.3. Procedure 
Genomic DNA was extracted from NSCs (control and experimental groups) 
using DNeasy blood and tissue kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions. Briefly, the NSCs were harvested by 
centrifugation and the cells were resuspended in lysis buffer to enable cell 
lysis. Subsequently, equal volume of absolute ethanol was added and vortexed 
to obtain homogenous solution. The lysate was transferred to DNAeasy mini 
spin column (placed in a collection tube) and the column was centrifuged at 
8000rpm, after which the flow-through was discarded. The DNA bound to the 
column was washed with wash buffers provided in the kit and the pure DNA 
was eluted in elution buffer supplied in the kit. The quality and concentration 
of DNA obtained was examined using the Nanodrop spectrophotometer 
(Thermo Scientific, USA). 
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2.13. Global DNA methylation quantification 
2.13.1. Principle 
MethylampTM global DNA methylation quantification kit used in this study is 
a fast, highly sensitive and convenient ELISA-based approach to measure the 
global DNA methylation levels. In this technique, the genomic DNA is 
immobilized on to the wells using a DNA affinity substance. The bound DNA 
is then detected using 5-methyl cytosine antibody (capture antibody) that 
recognizes methylated DNA. Subsequently, a labeled detection antibody and 
appropriate substrate are added, giving rise to colored product as a 
consequence of enzyme-substrate reaction. The absorbance is then read at 450 
nm where the intensity is proportional to the amount of methylated DNA. 
2.13.2. Materials 
MethylampTM global DNA methylation quantification kit 
(Cat.No.P1014-48, Epigentek, USA) 
2.13.3. Procedure 
Genomic DNA from control and experimental groups were used to quantify 
the global DNA methylation levels using MethylampTM global DNA 
methylation quantification kit (Epigentek, Farmingdale, NY) following the 
manufacturer’s instructions. 200ng of DNA from control and experimental 
groups were immobilized using GM2 solution on to the wells. In addition, the 
methylated DNA provided in the kit was diluted from 20-100ng/well in order 
to generate a standard curve. Following incubation, the bound DNA was 
detected using capture antibody and detection antibody. Finally the substrate 
was added and the absorbance was read at 450nm in a spectrophotometer 
(Tecan GENios, USA) after development of color. A standard curve was 
plotted using the methylated DNA control supplied in the kit and the DNA 





Methyl DNA (ng) = OD (sample-blank) /slope 
Methylation % =     Methyl DNA amount                X 100%  
                          Sample DNA amount added 
2.14. RNA isolation and real time RT-PCR 
2.14.1. RNA isolation 
2.14.1.1. Principle 
The miRNeasy mini kit (Qiagen, Germany) was used to isolate total RNA 
including small RNA (and miRNAs) in this study. The technique involves of 
lysis of samples and purification of RNA by using silica membrane based 
columns. The lysis reagent, QIAzol supplied in the kit is a monophasic 
solution of phenol and guanidine thiocyanate (GITC) that serves to lyse cells 
and inhibit RNases. In addition, it eliminates genomic DNA and other protein 
contaminants from the lysate during organic extraction. Following lysis, 
chloroform is added to the lysate and centrifuged to obtain aqueous and 
organic phases, separating RNA from the other contaminants. The upper 
aqueous phase contains RNA, while DNA and proteins are retained in the 
interphase and organic phase respectively. The upper aqueous phase is 
transferred to a new tube wherein RNA is precipitated using ethanol. The 
mixture is transferred into the RNeasy mini spin column in which total RNA 
binds to the silica based membrane, while residual contaminants are washed 
away using ethanol. Finally, the RNA is eluted in RNAase-free water and 
contains RNA molecules that are 18 nucleotides and more in size.  
2.14.1.2. Materials 
miRNeasy mini kit (Cat. No 217004, Qiagen, Germany) 
2.14.1.3. Procedure 
Total RNA was extracted from NSCs (control and experimental groups) using 
miRNeasy mini kit (Qiagen, Germany) following the manufacturer’s 
instructions. Briefly, the NSCs were harvested by centrifugation and the cells 
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were resuspended in 700µl of QIAzol lysis reagent. Following lysis, 140 µl of 
chloroform was added and mixed well to ensure that a homogenous solution 
was obtained. The tube was then centrifuged at 10,000 rpm to separate the 
sample into three phases. The upper aqueous phase (colorless) was transferred 
to a fresh tube and RNA was precipitated with 1.5 volumes of absolute 
ethanol. Finally, the mixture was transferred into RNeasy mini spin colunm 
and centrifuged, after which the flow through was discarded. The column was 
washed twice with 500µl of RPE buffer containing ethanol and finally the 
RNA was eluted in 40µl of RNase-free water. The concentration and quality of 
extracted RNA was examined using the Nanodrop spectrophotometer (Thermo 
Scientific, USA). 
2.14.2. cDNA synthesis and mRNA analysis 
2.14.2.1. Principle 
Polymerase chain reaction (PCR) generates high copies of a region of DNA 
from single or low copies of original template. It was first discovered by Kary 
Mullis in 1983 and is routinely used in molecular biology to amplify DNA 
sequences (Saiki et al., 1985; Bartlett and Stirling, 2003). A conventional PCR 
reaction consists of 30-40 cycles of repetitive changes in temperatures that can 
be divided into three distinct steps, namely denaturation, annealing and 
extension. Denaturation is the first step in which the PCR mixture is heated to 
950C causing DNA melting or dissociation of the two DNA strands producing 
single stranded DNA. This facilitates binding of set of 5’ and 3’ primers (or 
short sequences of DNA) that are complementary to the region to be amplified 
during the annealing step in which the temperature is lowered to about 50-
650C. The final step in a PCR reaction is extension (DNA synthesis) at 720C, 
in which deoxyribonucelotides (dNTPs) are added by a DNA polymerase 
resulting in synthesis of a new DNA strand that is complementary to the DNA 
template Since forward and reverse primers are complementary to both strands 
of the DNA, the PCR products serve as template for subsequent reactions 
resulting in exponential amplification of DNA (Bartlett and Stirling, 2003). 
The reverse transcription PCR (RT-PCR) is a variant of PCR reaction that is 
used to detect expression levels of RNA (Freeman et al., 1999). 
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Real time RT-PCR was first discovered in 1992 by Higuchi and co-
workers and has extensive applications including in gene expression analysis 
(Gibson et al., 1996). Real time RT-PCR enables direct visualization and 
monitoring of PCR amplification and is an extremely sensitive technique since 
it can detect even low concentration of input cDNA. In a real-time RT-PCR, 
SYBR green (a double stranded DNA binding dye)is added to the PCR 
mixture (Vandesompele et al., 2002), and the dye binds to double stranded 
DNA (ds DNA) resulting in increased fluorescent signal (upto 100 folds) 
which is detected by the real time PCR instrument (Giglio et al., 2003).  
Therefore, fluorescent signals increase with the increase in dsDNA which 
enables quantification of PCR products “real-time” at each cycle. After few 
cycles, the cycle threshold (Ct) value is recorded by the instrument. The Ct is 
the number of cycles required to generate a fluorescent signal that is above the 
background signal. The ct values are therefore inversely proportional to the 
amount of DNA template present in the sample. In addition, since SYBR 
green binds to any dsDNA, a dissociation curve or melting curve is run to 
ensure specific amplification as indicated by the presence of a single peak 
(Arya et al., 2005).  
For gene expression analysis, a house keeping gene which serves as an 
internal control, is amplified simultaneously, and the expression of target gene 
is normalized to that of the housekeeping gene to minimize variations in input 
template (Arya et al., 2005). The fold change in gene expression is calculated 
by relative quantification of a gene in control and treatment group by the delta-
delta Ct method (Livak and Schmittgen, 2001). 
2.14.2.2. Materials 
Oligo(dT) primer (Cat. No. C1101, Promega, USA) 
dNTP mix (Cat. No. U1240, Promega, USA) 
Molony murine leukemia virus reverse transcriptase (M-MLV, 
Cat.No. M1701, Promega, USA) 
RNase inhibitor (Cat. No.N2111, Promega, USA) 
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Quantitect SYBR green (Cat. No 204143, Qiagen, Germany) 
2.14.2.3. Procedure 
2.14.2.3.1. cDNA synthesis 
Reverse transcription was carried out using  2µg RNA and 2 µl oligo dT, 
200U of molony murine leukemia virus (M-MLV) reverse transcriptase, 5U of 
RNasin, 2mmol/L of each dNTPs,  in a 25 µl reaction volume along with 
RNase free water. 2 µg of RNA was first incubated with OligodT at 700C for 
5min. After incubation, the tube was cooled on ice and the other reagents were 
added, mixed and incubated for 1h at 420C. Subsequently, the tubes were 
incubated at 950C in order to stop the reaction and the cDNA synthesized was 
stored at 40C. 
2.14.2.3.2. Real time RT-PCR 
Real time RT-PCR analysis was carried out in using a high throughput 
instrument (7900HT, Applied Biosystems, USA). 10 µl master mix containing 
5 µl SYBR green (Qiagen, Germany), 1 µM/L of each primer, 1 µl cDNA and 
nuclease free water was added to the wells of 96 well FAST optical plates. The 
PCR program was selected as recommended by the instrument manufacturer. 
Table2 below contains the sequences of the primer and their annealing 
temperatures used in this study. The fold change of mRNA expression was 
calculated by 2- ∆∆Ct method.  
2.14.2.3.3. Imaging of PCR products 
The PCR amplicons were electrophoresed on 2% agarose gel containing 
ethidium bromide. The PCR products were visualized as bands using a 
transilluminator and images were captured using gel documentation 




Table 2: List of primers used for qRT-PCR 
Gene 
name 
Forward Primer(5’ - 3’) Reverse primer(5’- 3’) Product 
size 
Dcx TCCAGTCAGCAAAGGTAAGGA CCAAGAGAGAACAGCAAACCA 146 bp 
Pafah1b1 GATGACAAGACCCTCCGTGT GAGCTCAAATGGGGTAACCA 240 bp 
Map2 CTGGACATCAGCCTCACTCA AATAGGTGCCCTGTGACCTG 164 bp 
Gfap AGAAAACCGCATCACCATTC TCACATCACCACGTCCTTGT 184 bp 
Ng2 GCACGATGACTCTGAGACCA AGCATCGCTGAAGGCTACAT 223 bp 
Beta 
actin 
GAAGAGCTATGAGCTGCCTGA GGATTCCATACCCAAGAAGGA 103 bp 
 
2.15. In situ hybridization 
2.15.1. Principle 
In situ hybridization (ISH) is routinely used for detection of specific sequences 
of nucleic acids in cells. RNA/DNA sequence that is complementary to 
sequence to be detected is referred to as the probe and can be labeled with 
fluorescent molecules, radioisotopes or antigens in order to allow visualization 
and quantification (Looi and Cheah, 1992). Compared to the other labels, 
fluorescent ISH is widely used for detection of specific sequence since it 
allows easy visualization. The first step in ISH using cells/tissues is to fix and 
permeabilise the cells in order to form pores in the cell membrane that allows 
permeabilisation of the labeled probe. Following this, the fluorescent probe is 
allowed to hybridize to the complementary sequence and subsequently 
identified using a fluorescent or confocal microscope (Jin and Lloyd, 1997). 
Recently, ISH has been used for identification of microRNA (miRNA) 
expression in variety of samples(Thompson et al., 2007). In this study, 
miRCURY LNATM (locked nucleic acid) microRNA detection probes that 
have high affinity and specificity for detection of miRNAs that are expressed 
even in low levels (Wienholds et al., 2005) were used. LNA refers to RNA 
nucleotide in which the 4’carbon of the ribose moiety is connected to the 
2’oxygen with a bridge making the RNA inaccessible by locking the ribose in 
3’endo conformation (Vester and Wengel, 2004). This technology increases 
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the melting temperature of oligonucleotides thereby increasing the sensitivity 
and specificity (Jepsen et al., 2004). 
2.15.2. Materials 
5’ Fluorescein labeled miRCURY LNA TM probes (Exiqon, 
Denmark) 
4% paraformaldehyde solution 
0.1%PBS-Tx  
4’,6-diamidino-2-phenylindole dihyrochloride (DAPI) 
(Molecular probes) 
Fluorescent mounting medium (Dako) 
Acetylation solution 
Acetic anhydride   50µl 
0.1M Triethanolamine 20ml 
The acetylation solution was prepared by adding 50µl acetic 
anhydride to 20 ml of 0.1M triethanolamine. 
DEPC treated water 
DEPC    100 µl 
Water     1L 
DEPC was added to water and mixed well overnight after 
which it was sterilised by autoclaving. 
20X saline sodium citrate buffer (SSC) 
NaCl    87.6g 
Sodium citrate   44.1g 
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DEPC-treated water was added to make upto 500ml and the pH 
was adjusted with 2N HCl to 4.5  
10X Denhardt’s solution 
Bovine serum albumin (BSA) 200mg 
Polyvinlypyrrolidone    200mg 
Ficoll 400    200mg 
The reagents were dissolved and made upto 100 ml with DEPC 
water. 
Hybridization buffer 
Formamide     50ml 
20X SSC    25ml 
Yeast tRNA    50mg 
Heparin    10mg 
10X Denhardt’s solution  10ml 
Tween 20    0.1ml 
0.5M EDTA    1ml 
The above reagents were added and made up to 100ml with 
DEPC treated water. 
Solution A 
Solution A consists of 50 % formamide, 1X SSC and 





NSCs from normal pregnancy were cultured on poly-L-lysine coated cover 
slips for 48 h.  5’ Fluorescein labeled miRCURY LNA TM probes were 
purchased for mouse U6, mmu-miR-200b and mmu-miR-466d-3p from 
Exiqon (Vedbaek, Denmark). The sequences of the probe are listed in table 3. 
ISH of microRNA was carried out following a previously published protocol 
(Obernosterer et al., 2007; Silahtaroglu et al., 2007). Briefly, the cells were 
fixed with 4% PF for 20minand permeabilised with 0.1% PBS-Tx for 20min. 
Subsequently, the cells were washed with PBS and acetylated with freshly 
prepared acetylation solution for 5min, The cells were further washed with 5X 
SSC buffer for 5min and pre- warmed (at a temperature that was 22oC less 
than the melting temperature (Tm - 22
oC)) hybridization solution for 10min. 
The probes were then denatured by heating to 650C for 5min and then allowed 
to hybridize to cells overnight (temperature = Tm - 22
oC). Post hybridization 
washes were done using 5X SSC (15 mins) that was warmed to a temperature 
which was 20oC greater than hybridization temperature. Finally, the cells were 
washed in solution A twice for 30min and in 0.2X SSC for 15 min. The NSCs 
were counterstained with DAPI (1 µg/ml, Molecular Probes) and coverslips 
were mounted on glass slides with fluorescent mounting medium (DAKO). 
Images were captured with a confocal microscope (Olympus FV1000). 




99002-04 U6(hsa/rno/mmu) CACGAATTTGCGTGTCATCCTT 
88080-04 mmu-miR-200b TCATCATTACCAGGCAGTATTA 




2.16. Western blotting 
2.16.1. Principle 
Western blotting is routinely used for identification and quantitation of a 
specific protein from a homogenous mixture such as tissue/cell lysate. It was 
first identified by Towbin and his co-workers (Towbin et al., 1979) and a 
conventional Western blot consists of the following steps. First, the protein 
samples are separated on the basis of their size by electrophoresis, following 
which they are transferred to a Polyvinylidene fluoride (PVDF) membrane. 
The PVDF membrane is then blocked with blocking agent and followed by 
addition of primary antibody that is raised against the protein to be detected 
and an enzyme-labeled secondary antibody that is reactive to the primary 
antibody. Subsequently the specific protein is detected with chemiluminescent 
substrate. The light produced as a result of enzyme-substrate reaction is 
captured by X-ray film resulting in permanent documentation of protein 
expression (Kurien and Scofield, 2006). 
2.16.2. Materials 
Protease inhibitor cocktail (Cat.No. 0078425, Pierce, USA) 
Mammalian protein extraction reagent (M-PER, Cat. No. 
78503, Pierce, USA) 
Protein assay kit (Cat. No. 5000002, Bio-Rad, USA) 
SDS-PAGE (Sodium Dodecyl Sulfate-Poly Acrylamide Gel 
Electrophoresis) 
10% resolving gel 
Water 7.9ml 
30% acrylamide mixture   6.7ml 
1.5Mtris (pH 8.8)   5ml 
10% SDS     0.2ml 
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10% ammonium persulfate (APS) 0.2ml 
TEMED       0.008 ml 
5% stacking gel 
Water     5.5ml 
30% acrylamide mixture 1.3ml 
1.0M Tris (pH 6.8)  1.0ml 
10% SDS    0.08ml 
10% APS   0.08ml 
TEMED      0.008 ml 
3 X protein loading dye (Bio-Rad, USA) 









Tris base   2.42g 
NaCl    0.8g 
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The above salts were added to 700ml of water after which the 
pH was adjusted 7.6 with 4NHCl and made upto to 1L. 
1X TBST 
1xTBS   1L 
0.1% Tween-20  0.1 ml 
Mouse anti -beta actin monoclonal antibody (Cat.No.8227, 
Abcam, UK) 
Rabbit anti-doublecortin polyclonal antibody (Cat. No. 
Ab18723, Abcam, UK) 
Rabbit anti-Pafah1b1 polyclonal antibody (Cat. No. Ab2607, 
Abcam, UK) 
Rabbit anti-Hif1a polyclonal antibody (Cat. No. Ab2185, 
Abcam, UK) 
Rabbit anti-Ezh2 polyclonal antibody (Cat. No. Ab3748, 
Abcam, UK) 
Rabbit anti-MKP-1 polyclonal antibody (Cat. No. Sc1102, 
Santa-Cruz biotechnology, USA) 
Goat anti-mouse IgG conjugated with horseradish peroxidase 
(Chemicon, USA) 
Goat anti-rabbit IgG conjugated with horseradish peroxidase 
(Chemicon, USA) 
SuperSignal West Pico Chemiluminescent substrate (Cat. No 
34080, Pierce, USA) 





2.16.3.1. Isolation of mammalian protein 
Total mammalian protein was extracted from NSCs from control and 
experimental groups using the mammalian protein extraction reagent (M-PER, 
Thermo scientific, USA) following the manufacturer’s protocol. Briefly, NSCs 
were harvested by centrifugation and the pellet was resuspended in 150µl of 
M-PER reagent with protease inhibitor. The cells were allowed to lyse on ice 
for 30min with shaking. Following lysis, the lysate was centrifuged at 12,000 
rpm for 15 min at 40C and the supernatant containing protein fraction was 
transferred to a fresh tube and the concentration of protein was estimated 
2.16.3.2. Estimation of protein concentration 
The extracted protein was quantitated using the Bradford method (Bio-Rad, 
Hercules, CA, USA). A standard curve was plotted by diluting BSA protein 
(0.06, 0.12, 0.24 and 0.48mg/ml concentration) provided in the kit. 200µl of 
Bradford’s reagent was mixed with 10µl of extracted protein (histone proteins 
or mammalian total protein) or the standard in duplicates in a 96 well plate. 
The plate was incubated at room temperature for 20min after which the 
absorbance was read at 595 using a plate reader (Tecan GENios, Switzerland). 
A standard curve was plotted using the OD values of BSA standard and the 
protein concentration of the sample was estimated from the standard curve. 
2.16.3.3. Gel electrophoresis and protein detection 
20µg of mammalian protein from control and experimental groups were mixed 
with 3X protein loading dye and denatured at 950C for 5min after which they 
were separated on a 10% SDS-PAGE. The proteins were transferred to PVDF 
membranes using a semi-dry electrophoretic transfer cell (Trans-Blot, Bio-
Rad, USA) and subsequently the membranes were blocked with 5% non-fat 
milk for 1h at room temperature. The blots were incubated in primary 
antibody, rabbit anti-Dcx antibody (1:1000, Abcam, UK) or rabbit anti-
Pafah1b1 antibody (1:1000, Abcam, UK) or mouse anti- beta actin antibody 
(1:5000, Sigma- Aldrich, USA) overnight at 4 0C. The blots were then 
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incubated with secondary anti-mouse or anti-rabbit HRP antibody (Pierce, 
USA) for 1h at room temperature. Finally, the blots were developed with 
enhanced chemiluminescence reagent (Pierce, USA) and the protein 
expression was quantitated on a densitometer (Bio-rad, USA) using Quantity 
One software (Bio-rad, USA). Equal protein loading was confirmed by 
stripping and re-probing the blots with beta actin antibody. 
2.17. miRNA-mRNA target prediction 
2.17.1. miRWalk database 
The miRWalk database (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/) was used in this study to predict 
microRNAs that target the specific genes under study (Dweep et al., 2011). 
Using this database, gene symbols can be input to identify miRNAs predicted 
(or already validated) to target a gene. The miRWalk algorithm identifies the 
miRNAs that bind to the specific region selected (eg., 3’UTR) based on the 
seed length. Subsequently, miRWalk compares the binding sites of the 
miRNA with 8 other databases and provides a comparison. This algorithm has 
been developed to predict miRNA-mRNA target interactions of humans and 
rodents and presents information on the miRNA-mRNA interaction from eight 
different miRNA-target prediction databases (Diana-microT, miRanda, 
miRDB, PICTAR, PITA, RNA22, RNA hybrid, Targetscan). The eight 
databases are well established and widely used for miRNA-mRNA target 
prediction and their prediction is based on different methods such as 
complementarity, seed complementarity and thermodynamics. Therefore a 
predicted interaction is highly reliable if more than one database predicts the 
same interaction as miRWalk and miRWalk provides an easy comparison.  
Gene symbols were input to obtain the miRNAs that bind to the 3’UTR 
of the specific genes. The results of miRNA-mRNA target predictions 











mmu-miR-200a, mmu-miR-200b, mmu-miR-466a-3p, mmu-
miR-466d-3p 













Reln mmu-miR-200b,mmu-miR-466a-3p, mmu-miR-466d-3p 
Neurod4 mmu-miR-200a,mmu-miR-466a-3p, mmu-miR-466d-3p 
Dclk2 None from miR-200 and miR-466 family 









2.18. Analysis of miRNA expression by qRT-PCR 
2.18.1. Principle 
2.18.1.1. Taqman probe chemistry 
MicroRNA expression was analysed in NSCs from control and experimental 
groups by QRT-PCR using specific miRNA primers. The miRNA qRT-PCR 
assay consists of two steps. In the first step, reverse transcription with a 
miRNA specific stem loop primer is performed. Following this, a Taqman 
probe-based real time amplification is performed to detect miRNA expression. 
Taqman probe based miRNA primers are the gold standard for miRNA 
expression analysis. The 5’-3’ exonuclease activity of Taq polymerase 
underlies taqman probe chemistry. The probe consists of fluorophore (F) at the 
5’ end and quencher (Q) at 3’ end. The Quencher quenches the fluorescence 
signal from the fluorophore as long as they are in proximity.  During PCR 
reaction, the taqman probes bind to a sequence within the region to be 
amplified by specific primers. During the extension step, the 5’-3’ exonuclease 
degrades the annealed probe, which releases the fluorophore and separates it 
from the quencher resulting in fluorescence signal. The fluorescence signal is 
detected by the real time RT- PCR instrument, and the amount of fluorescence 
is directly proportional to the amounts of fluorophore and template generated 
(Holland et al., 1991). 
2.18.1.2. Universal cDNA synthesis 
MicroRNA expression was also analysed by qRT-PCR using primers and 
reagents from Exiqon, Denmark. This system generates universal cDNA from 
RNA that allows quantification of numerous miRNAs from the same cDNA. 
In this method, a polyA tail is added to the mature microRNA template and 
cDNA is synthesized using poly T primer that has a 5’universal tag and 3’ 
degenerate anchor. The resulting cDNA can be used for quantification of 
numerous miRNAs using miRNA specific forward and reverse primers. This 
procedure is enhanced by LNA (Locked nucleic acid) technology, thus 




miRVANATM kit (Cat. No AM1560, Ambion, USA) for qRT-
PCR using miRNA primers purchased from Applied 
Biosystems (USA) 
miRNA primers  
Taqman universal PCR master mix, no UNG (Cat. No. 
4324018, Applied Biosystems, USA) 
Taqman microRNA RT kit (Cat. No. 4366596, Applied 
Biosystems, USA) 
miRNeasy mini kit (Cat. No 217004, Qiagen, Germany) for 
qRT-PCR using miRNA primers purchased from Exiqon 
(Denmark) 
Universal cDNA synthesis kit (Cat. No. 203300, Exiqon, 
Denmark) 




Mouse miRNA primers were purchased from two different sources. Mouse 
miRNA primers for mmu-miR-200a, mmu-miR-200b, mmu-miR-466a-3p 
mmu-miR- 466d-3p and control primer set snoRNA234 (used as internal 
control to normalize the samples) were purchased from Applied Biosystems, 
USA (Taqman TM microRNA Real time assay). Mouse miRNA primers for 
mmu-miR-124, mmu-miR-101a, mmu-miR-26a, mmu-miR-320, mmu-miR-
210, mmu-miR-744, and control U6 primers were purchased from Exiqon 
(Vedbaek, Denmark). The microRNA primer sequences are summarized in 
table 5. Total RNA was converted to cDNA using specific RT primers 
(Applied Biosystems, USA) or universal cDNA was synthesized (Exiqon, 
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Denmark). The cDNA was then used for quantification of miRNA expression 
by qRT-PCR and the manufacturer’s protocol was followed. The miRNA 
expression was detected using a real time RT-PCR instrument (7900 HT, 
Applied Biosystems, USA) and the fold change in miRNA expression was 
calculated by 2- ∆∆Ct method. 
Table 5: List of microRNA primers used in this study 




4395716 002586 mmu-miR-466a-3p 
4395665 002535 mmu-miR-466d-3p 
4378069 000502 mmu-miR-200a 
4395362 002251 mmu-miR-200b 
 
Exiqon, Denmark 
Cat. No  miRNA name 
203907  U6 
20486  mmu-miR-101a 
204333  mmu-miR-210 
204663  mmu-miR-744 
204724  mmu-miR-26a 
204154  mmu-miR-320 




2.18.1.3. Visualization of PCR products 
2.18.4. Materials 
1x Tris boric acid EDTA buffer (TBE): 
 89mM Tris base 
 89mM boric acid 
 2mM EDTA 
20% PAGE (Poly Acrylamide Gel) 
Quick load low molecular weight DNA ladder (Cat. 
No.N0474S, New England Biolabs, USA) 
6X DNA loading dye (Cat. No. G1881, Promega, USA) 
2.18.5. Procedure 
The PCR amplicons were electrophoresed on 20% PAGE and subsequently, 
the gel was immersed in running buffer containing ethidium bromide. The 
PCR products were visualized as bands using an ultraviolet transilluminator 
and images were captured using gel documentation instrument (Syngene, UK). 
2.19. miRNA loss of function studies 
2.19.1. Principle 
miRNA inhibitors are single stranded chemically modified oligonucleotides 
that are capable of binding and inhibiting the function of endogenous 
miRNAs(Stenvang et al., 2012). Loss-of-function analysis using miRNA 
inhibitors enables analysis of miRNA function. Owing to the small size, these 
inhibitors can be easily transfected into cells in culture, where in they bind to 
specific endogenous miRNA and inhibit its function. The mRNA and protein 
expression of miRNA target can be validated by qRT-PCR and Western 
blotting.  miRNA inhibition results in increased expression of target protein 
although predominantly the mRNA expression is not upregulated since 
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miRNAs regulate gene expression post-transcriptionally(Valastyan and 
Weinberg, 2009). 
2.19.2. Materials 
X-tremeGENE siRNA transfection reagent (Cat. No 
04476093001, Roche Applied Science, USA) 
miRCURY LNA TM microRNA inhibitors  
OptiMEM medium (Invitrogen, USA) 
2.19.3. Procedure 
2.19.3.1. miRNA knockdown 
NSCs from normal pregnancy were harvested by centrifugation and 
trypsinised gently to yield single cells/ smaller neurospheres. About 2x105 
cells were seeded per well of a 24 well plate in DMEM/F12 medium 
containing PG concentration. Transfection was done using X-tremeGENE 
siRNA transfection reagent (Roche Applied Sciences, USA) following the 
manufacturer’s instruction. 5’flourescently labeled miRCURY LNA TM 
microRNA inhibitors for mmu-miR-200b, mmu-miR-466d-3p, and non 
labeled miRCURY LNA TM mmu-miR-200a, mmu-miR-466a-3p were 
purchased from Exiqon (Vedbaek, Denmark). The sequences of the inhibitors 
are summarized in table 6. Transfection complexes were prepared in opti-
MEM medium (Invitrogen, Life Technologies, USA) and added to the cells at 
final concentration of 20 nM/L. 5’ fluorescently labeled scrambled miR probe 
was used as the negative control. The cells were harvested 48h post 
transfection and protein expressions of the predicted mRNA targets were 


































CTATGTGTGCGTGTATGT 5’ fluorescein 
 
2.19.3.2. MicroRNA knockdown and lineage specification of NSCs 
For lineage specification, the NSCs were harvested by centrifugation 48h after 
knockdown with microRNA inhibitors, trypsinised to yield single cells and 
divided into three fractions (one each for staining with Gfap, Map2 and Ng2 
antibodies). The cells were re-plated in 24 well plates containing poly-
ornithine (Sigma-Aldrich, USA) coated coverslips. In order to induce 
differentiation, EGF was withdrawn from the culture medium and 2% FBS 
was added to the medium and then cells were cultured for 24 h before 
proceeding with ICC analysis using glial and neuronal cell lineage markers. 
The cells were fixed and incubated with anti-Gfap antibody (1:500, Chemicon, 
USA) or anti- Map2 antibody (1:500, Chemicon, USA) or anti-Ng2 antibody 
(1:200 Chemicon, USA) overnight at 40C and with appropriate secondary 
antibodies. Confocal images from at least five random fields were captured for 
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each sample. The percentage of Gfap, Ng2 and Map2 positive cells were 
calculated and normalized to scrambled transfected cells.  
2.20. Bisulphite sequencing and cloning 
2.20.1. Principle 
The bisulphite sequencing technique is the ‘gold standard’ for identification of 
DNA methylation and provides single base pair resolution. This technique 
exploits the differences in amination of cytosine and 5-methylcytosine 
residues. In this technique, genomic DNA is treated with sodium bisulfite 
which results in conversion of cytosine residues to uracil, while 5-methylated 
cytosine residues remain unaffected (Frommer et al., 1992). Following this, 
PCR amplification of genomic DNA is performed in which uracil is 
recognized as thymine thereby distinguishing methylated and non methylated 
cytosine residues. Subsequently, the PCR amplicons are sub-cloned and 
sequenced to identify methylation pattern of each CpG site in the amplified 
region (Li and Tollefsbol, 2011). 
2.20.2. Materials 
EpiTect Bisulfite kit (Cat. No. 59104, Qiagen, Germany) 
TOPO TA R cloning kit (Cat. No K4575-40, Invitrogen, Life 
technologies, USA). 
2.20.3. Procedure 
DNA (1µg) from NSCs from control and experimental group was treated with 
bisulfite and purified using Epitect bisulfite kit (Qiagen, Germany), following 
the manufacturer’s protocol. Bisulfite specific primers were designed using 
Methylprimer Express softwareV1.0 (Applied Biosystems, USA) spanning 
350-400bp of CpG islands in the promoters of selected genes. The bisulfite-
treated DNA was amplified by PCR and the PCR amplicons were purified and 
subcloned into the TOPO TA R cloning kit (Invitrogen, Life technologies, 
USA). Subsequently, the plasmid DNA was isolated from 10-12 positive 
colonies and sequenced. The eletropherograms obtained by sequencing were 
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analysed using the BiQ analyzer software (Max-Planck Institut fur Informatik, 
Germany) and the methylation pattern was represented as lollipop grids. Open 
circles represent unmethylated CpG sites and closed (shaded) circles represent 
methylated CpG sites.  The primer sequences used for PCR and sequencing 
are listed in table7. 
Table 7: Sequences of primers used for DNA methylation analysis 
Pafah 1b1  
DNA 
(399bp) 
Forward primer Reverse primer 





2.21. miRNA profiling 
Total RNA was isolated from NSCs from control and experimental groups 
using miRNeasy RNA isolation kit (Qiagen, Germany) and the quality of total 
RNA was analysed (Agilent 2100 Bioanalyser) before the samples were used 
for profiling. Microarray profiling was conducted at Exiqon Services, 
Denmark. Total RNA (750ng) was labeled with Hy3™ (sample RNA) or 
Hy5™ (reference RNA) fluorescent label (miRCURY LNA™ microRNA Hi-
Power Labeling Kit, Hy3™/Hy5™ Exiqon, Denmark) following the 
manufacturer’s instructions. The labeled samples (Hy3™-sample RNA and 
Hy5™-reference RNA) were mixed pair-wise and were allowed hybridize to 
the miRCURY LNA™ microRNA Array (6th gen - hsa, mmu & rno) (Exiqon, 
Denmark).  This 6th gen array contains capture probes that target all human, 
mouse and rat miRNAs registered in the miRBASE 16.0. Hybridization was 
done using the Tecan HS 4800™ hybridization station (Tecan, Austria) 
following the instructions in the miRCURY LNA™ microRNA Array 
instruction manual. Following hybridization, the microarray slides were 
scanned using Agilent G2565BA Microarray Scanner System (Agilent 
Technologies, Inc., USA). The slides were stored in an ozone free 
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environment (ozone level below 2.0 ppb) to prevent possible bleaching of the 
fluorescent dyes. Images were analysed using the ImaGene 9.0 software 
(BioDiscovery, Inc., USA) and the quantified signals were background 
corrected (Normexp with offset value 10,(Ritchie et al., 2007)) and normalized 
using the Quantile normalization algorithm. 
2.22. miRNA pathway analysis 
In the present study, the DIANA (DNA-Intelligent analysis) miRPath V2.0 
(http://www.microrna.gr/miRPathv2) was used to predict and identify 
molecular pathways altered by single or multiple microRNAs (Papadopoulos 
et al., 2009; Vlachos et al., 2012). This web server is highly efficient and easy 
to use to predict pathways with high accuracy. Upon input of list of 
microRNAs, this web-based application identifies the pathways targeted by 
these miRNAs and, calculates the p-value, and finally lists the pathways that 
are significant targets. A significant pathway identified by this server indicates 
the probability that the gene targets of these miRNAs (input) are enriched in 
that pathway(Vlachos et al., 2012).  Top 10 pathways with lowest p-value and 
targeted by highest number of microRNAs were obtained for the differentially 
expressed miRNAs.  
In order to obtain gene and miRNA interaction networks, the 
differentially expressed miRNAs were used for input to Ingenuity Pathway 
Analysis (IPA) (http://www.ingenuity.com). IPA analysis offers a robust 
platform (microRNA target filter) to identify gene targets/ molecular pathways 
targeted by miRNAs. Upon input of differentially expressed miRNAs, the list 
of gene targets were obtained using microRNA target filter with default 
parameters (but restricted to TargetScan database with high confidence levels). 
The top biological pathways that were predicted to be altered by DIANA 






2.23. Statistical Analysis 
Data were represented as mean ± SD from at least three independent 
experiments. Student’s t test was performed by using Microsoft excel 
































3.1. Diabetic pregnancy induces neural tube defects in embryos 
In this study, about 10% of the mouse embryos derived from diabetic 
pregnancy showed neural tube defects (NTD) when compared to normal 
pregnancy. The embryos (Embryonic day 13.5) of diabetic pregnancy 
displayed NTD in the cranial region (Fig 1b,c) while no NTD were found in 
the embryos from normal pregnant mice (Fig 1a). In this study, only non-
malformed embryos of diabetic pregnancy with no apparent NTD (Fig 1d) 
were used for isolation of neural stem cells (NSCs). 
NSCs isolated from embryos of control and diabetic pregnancy were 
maintained in physiological glucose concentrations (PG, 5mmol/L). The NSCs 
were cultured in serum free conditions and formed free-floating clusters called 
neurospheres in 2-3 days (Figs 2a,b). The NSC characteristics such as self 
renewal and multipotent nature were examined by immunostaining. 
Immunostaining with Nestin, an intermediate filament protein marker for 
NSCs revealed that all the neurospheres express Nestin (Fig 3a,b). Further, all 
cells within a neurosphere expressed Nestin immunoreactivity (Fig 3c,d). In 
addition, multipotent nature of NSCs was examined by inducing 
differentiation in the presence of serum and absence of EGF (Fig 4a,b). 
Following differentiation, immunostaining revealed that NSCs generate 
neuronal and non-neuronal cells as indicated by the presence of Map2 
(Microtubule associated protein 2) or Gfap (Glial fibrillary acidic protein) or 
Ng2 (neuron-glial antigen 2) positive cells (Figs 4c-e). 
3.2. High glucose causes chromatin reorganization in NSCs 
Maternal diabetes causes NTD in embryos and neuropsychological deficits in 
infants. Maternal diabetes-induced NTD have been attributed to altered 
biochemical pathways and signalling molecules although the exact mechanism 
behind deregulation of gene expression remains unknown. It was hypothesized 
that exposure of NSCs to hyperglycemia results in activation of epigenetic 
mechanisms (chromatin modification, DNA methylation and microRNA 




The effect of glucose on the chromatin organization in nucleus of 
NSCs was examined by transmission electron microscopy as it was 
hypothesized that HG could trigger chromatin modifications in NSCs. To 
mimic hyperglycemia in vitro, NSCs from normal pregnancy were incubated 
in medium with high glucose concentration (HG, 40mmol/L) for 48h. 
Chromatin reorganization such as increased heterochromatin regions 
(indicated as dark, dense regions) was observed at the nuclear periphery of 
NSCs exposed to HG (Fig. 5b) and that from diabetic pregnancy (Fig. 5c) 
when compared to the control (5mmol/L) (Fig.5a). This experiment suggested 
that hyperglycemia triggers the reorganization of chromatin in embryonic 
NSCs. This also provides evidence that the chromatin reorganization observed 
in NSCs from embryos of diabetic pregnancy was indeed the effect of 
hyperglycemia as similar results were obtained when NSCs (derived from 
normal pregnancy) were cultured in HG in vitro. 
3.2.1. Global DNA methylation and histone H3 lysine 9 status are altered 
by High glucose 
The chromatin consists of DNA that can be methylated and histone proteins 
that undergo modifications which control chromatin packaging and 
organization (Jones and Wolffe, 1999). Hence, the present author postulated 
that the chromatin reorganization observed in NSCs exposed to hyperglycemia 
is associated with histone modifications or DNA modifications. To address 
this, the status of histone modifications and DNA methylation was examined 
by an ELISA-based approach. The percentage of DNA methylation was found 
to be increased significantly in NSCs exposed to HG in vitro and that from 
diabetic pregnancy when compared to control (Fig 6). Next, two histone 
antibodies were selected namely: anti trimethyl histone H3 lysine 9 
(H3K9me3) and anti acetyl histone H3 lysine 9 (H3K9ac). The reason for 
selection of these two antibodies was because H3K9me3 is generally 
associated with transcriptional silencing whereas H3K9ac is associated with 
transcriptional activation (Villeneuve et al., 2008). Interestingly, NSCs 
exposed to HG in vitro and that from diabetic pregnancy showed increased 
transcriptional silencing (Fig 7a) as indicated by increased percentage of 
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H3K9me3, when compared to the control. Further, immunostaining using anti-
H3K9me3 antibodies (Fig 7b-d) confirmed the increased level of H3K9me3. 
In addition, NSCs exposed to HG in vitro and that from diabetic pregnancy 
showed decreased transcriptional activation (Fig 8a) as indicated by decreased 
percentage of H3K9ac. Immunostaining using anti-H3K9ac antibody (Fig 8b-
d) confirmed decreased transcriptional silencing.  
Overall, high glucose altered the DNA methylation levels and histone 
H3 lysine 9 status in NSCs, suggesting glucose concentration-induced 
epigenetic regulation of gene expression in NSCs. 
3.3. Maternal diabetes alters gene expression in NSCs 
Transcriptome profiling of cranial neural tube of malformed embryos of 
diabetic pregnancy done previously by our group identified differential gene 
expression of numerous genes (Jiang et al., 2008). Several genes that regulate 
NSC proliferation, differentiation and migration were altered in neural tube of 
embryos of diabetic pregnancy.  It was found that maternal diabetes impaired 
neurogenesis and neuronal migration in the embryos of diabetic pregnancy 
that forms the basis for defective neural tube development. 
To confirm the microarray findings, ten genes (Igf1, Neurog1, 
Neurod1, Dcx, Pafah1b1, Neurod4, Clk2, Sema6a, Gmfb, Reln) that were 
differentially expressed in NSCs from embryos of diabetic pregnancy and 
whose Gene Ontology (GO) biological processes indicated cell differentiation, 
neurogenesis, migration or gliogenesis were therefore selected for further 
analysis. Real time RT-PCR analysis was performed to analyse the expression 
of selected genes in NSCs. The results revealed significantly increased 
expression of nine genes (Igf1, Neurog1, Neurod1, Dcx, Pafah1b1, Neurod4, 
Clk2, Sema6a, Gmfb) except Reln that was significantly decreased in NSCs of 
diabetic pregnancy (Fig 9a,b) signifying that maternal diabetes altered NSC 
fate and migration.  
Next, the expression of neuronal and glial cell markers was evaluated 
since the expression of genes involved in NSC fate was found to be altered. 
The neurospheres of control and diabetic pregnancy were allowed to 
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differentiate in medium with PG and 2% FBS, without EGF for 3 days or 6 
days in vitro and the neuronal and glial populations were identified by 
immunostaining with Map2 or Gfap or Ng2 or Nestin (Fig 10 A-) and 
quantified. The percentages of neuronal and glial positive cells were estimated 
after 3 and 6 days of differentiation in order to check if prolonged 
differentiation would alter the neurogenesis: gliogenesis ratio. All the 
differentiated cells from NSCs of control and diabetic pregnancy showed 
Nestin immunoreactivity (Fig 10 G,H and O,P). The percentage of Map2 
positive cells increased significantly at 3 days and 6 days post differentiation. 
However, the percentages of Gfap positive cells at 3 days and 6 days and Ng2 
positive cells at 3 days and 6 days decreased significantly in differentiated 
cells from NSCs of diabetic pregnancy when compared to the control 
signifying that hyperglycemia increased neurogenesis and decreased 
gliogenesis (Fig 11Q). 
3.4. Effect of high glucose concentration on promoter CpG methylation 
and gene expression 
To understand the effect of HG on DNA methylation at specific gene 
promoters, two genes namely Pafah1b1 and Neurod1 whose expression was 
increased in NSCs from diabetic pregnancy were selected for the analysis. The 
promoter of these genes contains CpG islands and hence DNA methylation 
status of each CpG site across a selected region was evaluated. The mRNA 
expression was analysed by real time RT-PCR and DNA methylation status of 
gene promoter was analysed by bisulphite conversion and sequencing. The 
promoter sequence of each gene was obtained from TRED database. The CpG 
islands were identified from the sequence obtained and primers were designed 
using MethPrimer software. For each promoter, a pair of primers to identify 
genomic DNA or bisulphite modified DNA regions were designed. 
3.4.1. DNA methylation at Pafah1b1 
Exposure of NSCs to HG in vitro increased the mRNA expression of Pafah1b1 
(Fig 11a). In order to examine if altered mRNA expression was due to altered 
DNA methylation levels, the promoter of Pafah1b1 was evaluated. Pafah1b1 
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promoter contained ~ 620bp long CpG island across the transcription start site 
(TSS) (Fig 11b). To evaluate DNA methylation at Pafah1b1 promoter, primers 
were designed for 399bp region upstream of the transcription start site (TSS) 
of the promoter for analysis of DNA methylation. The analysis revealed that 
the DNA methylation levels were unaltered in NSCs exposed to HG in vitro or 
that from diabetic pregnancy when compared to the controls (Fig 11c-e).  
3.4.2. DNA methylation at Neurod1 
Expression of Neurod1 mRNA was increased in NSCs exposed to HG in vitro 
(Fig 13a) when compared to the control. To evaluate the status of DNA 
methylation at Neurod1 promoter, the promoter sequence was obtained. The 
Neurod1 promoter contained ~ 439bp long CpG island that was located 
upstream of the transcription start site (TSS) (Fig 13b). Next, primers were 
designed for 394bp region upstream of the transcription start site (TSS) of the 
promoter for analysis of DNA methylation. The analysis revealed that the 
DNA methylation levels were altered in NSCs exposed to HG in vitro when 
compared to the controls (Fig 13c-f). It was found that distinct CpG sites were 
preferentially methylated in NSCs exposed to HG in vitro. Further, the DNA 
methylation levels could not be evaluated across all CpG sites in NSCs from 
diabetic pregnancy. However, only one CpG site (-383) was found to be 
methylated in all clones when compared to the control. 
3.5. Expression of microRNAs in NSCs 
3.5.1. High glucose alters expression of mmu-miR-200a, mmu-miR-200b, 
mmu-miR-466a-3p and mmu-miR-466d-3p in NSCs 
MicroRNAs (miRNAs) have been shown to be critical for brain development 
and their expression is regulated both spatially and temporally during brain 
development. Gene expression can be regulated by miRNAs by binding to 
3’UTR of target genes, resulting in inhibition of translation.  
In order to identify if the selected genes could be possible targets of 
miRNAs, bioinformatic analysis was performed. miRNAs predicted to target 
the 3’ UTR of the selected genes were identified from online databases (such 
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as miRDB, TargetScan and miRWalk database). Among several miRNAs 
predicted to target the ten genes, four miRNAs from two families (Table 4) 
namely mmu-miR-200a, mmu-miR-200b and mmu-miR-466a-3p and mmu-
miR-466d-3p were commonly found to target the selected genes.  Since these 
miRNAs were not shown to be expressed by NSCs previously, the present 
author first selected two miRNAs (one from each family of microRNAs in this 
study, i.e., mmu-miR-200b and mmu-miR-466d-3p) and performed in situ 
hybridization to check their expression. Both mmu-miR-200b and mmu-miR-
466d-3p were found to be expressed by NSCs (Fig 13 a,b).  Having confirmed 
that these miRNAs were expressed in NSCs, the expression levels of these 
miRNAs were quantitated by real time RT-PCR. The expression levels of 
miRNAs mmu-miR-200a, mmu-miR-200b, mmu-miR-466a-3p and mmu-
miR-466d-3p were significantly decreased in NSCs from diabetic pregnancy 
when compared to the control (Fig 14a,b).  
3.5.2. High glucose increases the expression of miRNA, miR-124 
Since hyperglycemia increased the expression of neuronal marker Map2 
indicating increased neurogenesis, the expression of miRNA miR-124, which 
is highly abundant in mammalian brain and widely shown to promote 
neurogenesis (Maiorano and Mallamaci, 2009) was analysed. The expression 
of mmu-miR-124 was increased significantly in NSCs from diabetic 
pregnancy when compared to the control (Fig 15). The increased expression of 
miR-124 correlated with increased neurogenesis in NSCs from diabetic 
pregnancy (Figs 15 and 10q). 
3.6. Regulation of gene expression by miRNAs 
In order to examine the role of specific miRNAs in regulating gene expression, 
three genes from the top ten differentially expressed genes were selected. 
Recently, miR-200b family was shown to regulate olfactory neurogenesis 
(Choi et al., 2008) in mammals and it was hypothesized that miR-200 and 
miR-466 families may have critical roles in regulating cell differentiation, 
neurogenesis and neuronal migration during development. Therefore, three 
genes namely Dcx, Pafah1b1 and Gmfb were selected, on the basis that they 
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were involved in neurogenesis, neuronal migration and cell differentiation and 
that our group has previously shown that maternal diabetes impaired 
neurogenesis and neuronal migration in the developing embryos.  
Firstly, the expression of Dcx, Pafah1b1 and Gmfb proteins were 
analysed in NSCs from control and diabetic pregnancy. The quantities of Dcx 
(Fig 16a,b), Pafah1b1 (Fig 17a,b)  and Gmfb (Fig18a,b) proteins were 
significantly increased in NSCs from embryos of diabetic pregnancy compared 
to that of control. The increased expression of Dcx, Pafah1b1 and Gmfb 
correlate with the decreased expression of predicted miRNAs (mmu-miR-
200a, mmu-miR-200b, mmu-miR-466a-3p and mmu-miR-466d-3p), 
suggesting that these genes could be direct targets of the miRNAs selected. 
3.6.1. MiRNA-mRNA target validation confirms target prediction 
In order to determine the functional roles for specific miRNAs identified, the 
miRNA-mRNA target interactions predicted were first validated. Since the 
miRNA expression was down regulated in NSCs from diabetic pregnancy, 
miRNA loss of function studies were carried out.  Individual miRNAs were 
knocked down in NSCs isolated from normal pregnancy using miRCURY 
LNA TM miR inhibitors. Following knockdown of miRNAs, the expression of 
the target proteins (Dcx , Pafah1b1 and Gmfb) were analysed by Western blot. 
 To determine effective transfection of miRNA inhibitors, a small 
proportion of NSCs were transferred to poly-lysine coated coverslips and 
allowed to adhere overnight. Subsequently, the NSCs were fixed and their 
nuclei were counterstained with DAPI. Since the inhibitors contained 
5’fluorescein, effective transfection was identified by confocal microscopy 
(Fig19a, b). Further, the knockdown efficiency was calculated and found to be 
approximately 70 % (Fig19c) in miR-466d-3p transfected NSCs. 
 Knockdown of miRNAs, mmu-miR-200a, or mmu-miR-200b, or 
mmu-miR-466a-3p or mmu-miR-466d-3p resulted in increased expression of 
Dcx protein (Fig20a,b) when compared to scrambled transfected cells. 
Knockdown of miRs, mmu-miR-200a, or mmu-miR-200b, or mmu-miR-466a-
3p or mmu-miR-466d-3p also resulted in increased expression of Pafah1b1 
79 
 
(Fig 21 a,b) proteins when compared to scrambled transfected cells. These two 
results indicated that Dcx and Pafah1b1 may be direct targets of these 
miRNAs. In addition, knockdown of miRNA mmu-miR-200a resulted in 
significantly decreased expression of Gmfb protein, while knockdown of 
mmu-miR-466d-3p significantly increased expression of Gmfb protein when 
compared to the scrambled transfected cells (Fig 22a,b). This result indicated 
that Gmfb may be an indirect target of miR-200b and a direct target of miR-
466d. In miRNA mmu-miR-200b or mmu-miR-466d-3p transfected NSCs, 
there was no significant alterations in Gmfb protein expression. 
3.7. MicroRNAs regulate NSC fate 
Given that increased expression of proteins involved in neurogenesis, neuronal 
migration and cell differentiation following knockdown of miRNAs was 
observed, the role of these miRNAs in NSC fate determination was examined. 
miRNAs, mmu-miR-200a, mmu-miR-200b, mmu-miR-466a-3p and mmu-
miR-466d-3p were knocked down individually in NSCs from normal 
pregnancy. Following knockdown of miRNAs, differentiation was induced 
and the expression of neuronal and glial lineage populations was estimated by 
immunocytochemical analysis.  
 There was significantly increased astrogenesis as indicated by 
increased Gfap (glial fibrillary acidic protein) positive cells following 
knockdown of miRNAs, mmu-miR-200a or mmu-miR-200b or mmu-miR-
466a-3p compared to scrambled transfected cells (fig 23 a-f). Similarly, the 
knockdown of microRNA mmu-miR-200b or mmu-miR-466d increased the 
number of Ng2 positive cells when compared to scrambled transfected cells 
(Fig 24a-f). Knockdown of only mmu-miR-200a or mmu-miR-466a-3p 
significantly increased the number of Map2 (microtubule- associated protein 
2) positive cells compared to scrambled transfected cells (Fig25a-f), signifying 
increased neurogenesis. Overall, knockdown of specific miRNAs altered NSC 




3.8. Global miRNA expression profiling of NSCs 
Given that specific miRNAs were altered in diabetic pregnancy, it will be 
intriguing to identify miRNA signatures during brain development. It was 
hypothesized that expression profiling would reveal functional roles of 
miRNA during brain development and function under normal conditions as 
well as in diabetic pregnancy. For this, global miRNA expression profiling 
was performed in NSCs. Since maternal diabetes can cause fetal 
hyper/hypoglycemia or hypoxia, NSCs derived from normal pregnancy 
(control) were exposed to HG (to mimic hyperglycemia) or LG (to mimic 
hypoglycemia) or 1%oxygen (to mimic hypoxia).  
miRNA expression profiling was performed in NSCs from various 
groups using miRCURY LNA™ microRNA Array (6th gen – human, mouse 
and rat) (Exiqon, Denmark) that contains ~2383 capture probes (human, 
mouse and rat). The Heat map in Fig 26 shows the results of hierarchical 
clustering performed on all samples, on the top 50 miRNAs with highest 
standard deviation (Sheet1). Only those miRNAs with values from all 15 
samples (Con, HG, LG, hypoxia, dia in triplicate) were included. A one-way 
ANOVA analysis revealed that 45 miRNAs were significantly different (p-
value <0.001) between the various groups (Sheet 2). 
3.8.1. NSCs from diabetic pregnancy show distinct miRNA expression 
pattern 
Since this study involved many groups, Principal Component Analysis (PCA) 
was performed in order to identify differences and similarities between the 
samples. PCA analysis was carried out on all samples, including the top 50 
miRNAs with highest standard deviation. This method was used to trim down 
large data sets and cluster samples based on their expression profile which 
results in separation of samples in different regions of the plot. The analysis 
revealed that the NSCs from diabetic pregnancy were biologically different 
from the other group of samples (Fig 29). Compared to the other groups, the 
differences between the NSCs from control and diabetic pregnancy were 
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larger than the differences within their biological replicates, indicating results 
with increased reproducibility and decreased variation.  
3.8.2. Validation of miRNA expression 
The miRNA expression was validated in NSCs from control and diabetic 
pregnancy since PCA plot revealed that they were the most distinct. From the 
top ten differentially expressed miRNAs, four miRNAs that were upregulated 
(mmu-miR-101a, mmu-miR-26a, mmu-miR-320, mmu-miR-744) and one 
miRNAs that was downregulated (mmu-miR-210) in NSCs from diabetic 
pregnancy were chosen for validation.  The expression of miRNA was 
validated by real time RT-PCR and was found to be consistent with the array 
results (Fig28).   
3.8.3. mRNA target validation shows negative correlation with miRNA 
expression 
The gene targets of a few miRNAs were already identified in the cells of the 
nervous system and some of these targets were selected for validation. Since 
hyperglycemia induces oxidative stress and hypoxia (Li et al., 2005), and also 
increases neural cell differentiation (Horie et al., 2008), three genes (Ezh2, 
Hif1a, Mkp-1) that were involved in these processes were chosen. These genes 
have been shown to be the targets of a few miRNAs (miR101a, miR-26a and 
miR-130b) that were differentially expressed in the present study.  
Enhancer of zeste homologue 2 (Ezh2), a member of the polycomb 
group of proteins, are highly expressed by undifferentiated NSCs and are 
downregulated during differentiation of NSCs into neurons and astrocytes 
(Sher et al., 2008). Hypoxia inducible factor 1alpha (Hif1a), a transcription 
factor that is known to be activated under hypoxia (Lendahl et al., 2009) has 
been shown to promote cell differentiation (neurogenesis in particular) (Studer 
et al., 2000; Horie et al., 2008; Santilli et al., 2010). MAPK-phospatase-1 
(MKP-1) negatively regulates the MAPK pathway (Zhou et al., 2007) which 
controls cell growth, proliferation, differentiation and cell death (Pearson et 
al., 2001) . Western blot analysis showed the downregulation of expression of 
Ezh2 and MKP-1 and upregulation of Hif-1a in NSCs from diabetic pregnancy 
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(Fig 29a, b). In addition, the altered expression shows negative correlation to 
the expression of miRNAs (miR101a, miR-26a and miR-130b) targeting those 
genes. 
3.9. Identification of differentially expressed miRNAs in NSCs and 
prediction of biological pathways regulated by them 
The miRNA expression profiles between groups (by student’s t-test) were 
compared in order to obtain the list of miRNAs that were differentially 
expressed. The numbers of differentially expressed miRNAs identified by t-
test between the different groups are summarized in Fig 30.  
Owing to the fact that a single miRNA can target multiple genes, the 
author identified several differentially expressed miRNAs for each group and 
predicted biological pathways that may be regulated by the miRNAs. The top 
pathway in each group would signify that maximum miRNAs deregulating 
that pathway were altered by glucose or glucose-induced hypoxia.   
First, Diana miRpath V2.0, a free online database was used to predict 
biological pathways regulated by differentially expressed miRNAs. The top 10 
pathways targeted by maximum number of differentially expressed miRNAs 
(both upregulated and downregulated) were obtained for each group. A 
detailed description of all the pathways targeted and the p-values has been 
shown in the appendix section. Next, the top pathways identified using Diana 
miRpath were verified using the Ingenuity Pathway Analysis (IPA) and 
miRNA- gene interaction networks were obtained.  
3.9.1. Low glucose modifies expression of miRNAs that regulate GnRH 
signalling and ErbB signalling in NSCs 
In NSCs exposed to LG, seven miRNAs (6 up regulated and 1 down 
regulated) were differentially expressed with p<0.01 (Fig 31a and sheet 3a). 
Fig 31b shows the list of pathways targeted by upregulated miRNA and 
maximum numbers of miRNA were found to target Gonadotropin- Releasing 
Hormone (GnRH) signalling and ErbB signalling pathways (Sheet3b). The 
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miRNA-gene network interaction of GnRH signalling was obtained by IPA 
analysis (Fig 31c). 
3.9.2. High glucose alters the expression of miRNAs that regulate actin 
cytoskeleton and MAPK in NSCs 
Fourteen miRNAs were differentially expressed (8 were up regulated and 6 
were down regulated) in NSCs exposed to HG in vitro with p<0.005 (Fig 32a 
and sheet 4a). Maximum number miRNAs were predicted to target the 
regulation of actin cytoskeleton and Mitogen Activated Protein Kinase 
(MAPK) pathways (Fig 32b and Sheet 4b). The miRNA-gene network 
interaction of actin cytoskeleton pathway was obtained using IPA analysis (fig 
32c). 
3.9.3. Hypoxia modifies expression of miRNAs that regulate MAPK and 
calcium signalling in NSCs 
In NSCs exposed to hypoxia, 40 miRNAs (27miRNAs were up regulated and 
13 miRNAs were down regulated) showed differential expression with 
p<0.005 when compared to the control (Fig 33a and sheet 5a). Of these, 11 
miRNAs had a p<0.001. Maximum number of miRNAs was predicted to 
target the MAPK and calcium signalling pathways (Figs 33b and Sheet 5b). 
The miRNA-gene network interaction of calcium signalling pathway was 
obtained using IPA analysis (fig 33c). 
3.9.4. Maternal diabetes alters the expression of miRNAs that regulate 
MAPK pathway and actin cytoskeleton 
In NSCs from diabetic pregnancy, 42 miRNAs were differentially expressed 
with p< 0.001 when compared to the control. Of these 24 miRNAs were 
upregulated and 18 miRNAs were downregulated (Fig 34a and sheet 6a). 
Highest numbers of miRNAs were found to target MAPK signalling and actin 
cytoskeleton pathways (Fig 34b and Sheet 6b). The miRNA-gene network 
interaction of MAPK signalling pathway was obtained using IPA analysis 
(figure 34c). In addition, the expressions of neuronal and glial specific 
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miRNAs such as miR-124, miR-219 and miR-26a were upregulated in NSCs 
from diabetic pregnancy.  
3.9.5. Comparisons between LG vs Dia, HG vs Dia and Hypoxia vs Dia 
Owing to the fact that maternal diabetes causes hypo-, or hyperglycemia or 
hypoxia to fetus, the miRNA expression profile between LG vs Dia and HG vs 
Dia and Hypoxia vs Dia were compared.  
LG vs Dia 
In LG vs Dia group, 10 miRNAs were upregulated while 8 miRNAs were 
downregulated with p<0.001 (Fig35a and Sheet 7a). The top pathways 
targeted by differentially expressed miRNAs in LG vs Dia were MAPK 
signalling, Insulin signalling, TGF-beta signalling (Fig 35b,c and sheet 7b). 
The miRNA-gene network interaction of insulin signalling obtained by IPA 
analysis is represented in Fig 35c. 
HG vs Dia 
In HG vs Dia group, 24 miRNAs were upregulated while 21 miRNAs were 
downregulated with p< 0.001 (Fig36a and Sheet 8a). The top pathways 
targeted by differentially expressed miRNAs in HG vs Dia were regulation of 
actin cytoskeleton, axon guidance and Wnt signalling (Fig 36b, c and sheet 
8b).). The miRNA-gene network interaction of Wnt signalling obtained by 
IPA analysis is represented in Fig 36c. 
Hypoxia vs Dia 
In Hypoxia vs Dia group, 17 miRNAs were upregulated while 26 miRNAs 
were downregulated with p< 0.001 (Fig37a and Sheet 9a). The top pathways 
targeted by differentially expressed miRNAs in Hypoxia vs Dia were MAPK 
signalling (Fig 37b, c and sheet 9b).). The miRNA-gene network interaction of 





LG/HG/Hypoxia vs Dia 
From the comparison between LG vs Dia, HG vs Dia and Hypoxia vs 
Dia, 6 miRNAs were identified to be common to all three groups. Among 
these, 5 miRNAs were significantly upregulated and while one miRNA was 
significantly downregulated in Dia compared to LG/HG/Hypoxia (Sheet 10a). 
The top pathway targeted by these miRNAs was found to be 
phosphatidylinositol signalling (Fig38a,b and Sheet 10b). 
3.9.6. miRNAs deregulate signalling pathways critical for neural tube 
development in NSCs 
The top pathways predicted to be targets of differentially expressed miRNAs 
in all groups (Con vs LG, Con vs HG, Con vs hypoxia, Con vs dia, LG vs dia, 
HG vs Dia and hypoxia vs Dia) were compared (Sheet 11). It is hypothesized 
that common pathways between these groups, are mainly responsible for the 
etiology behind maternal diabetes-induced alterations in neural tube closure 
and brain function. The comparison revealed seven common pathways (ErbB 
signalling, MAPK signalling pathway, axon guidance, focal adhesion, 
regulation of actin cytoskeleton, Wnt signalling, and neurotrophin signalling) 
that were deregulated in almost all groups (with the exception of Con vs LG 
that is consistent with Wnt and ErbB signalling only, and Con vs Hypoxia 
consistent with all pathways except actin cytoskeleton)(sheet11). Based on 
literature, it was evident that these pathways were known to be critical for 
neural tube morphogenesis and these findings suggested that deregulation of 
























The fact that the developing brain is sensitive to glucotoxicity is evident from 
the high incidence of NTD in diabetic pregnancy (Becerra et al., 1990; 
Sheffield et al., 2002). Although the management of diabetes during 
pregnancy has reduced the occurrence of congenital malformations greatly, 
infants of diabetic mothers have been shown to develop neuropsychological 
deficits later in life (ter Braak et al., 2002). Analysing phenotypically normal 
embryos may therefore be essential in understanding the molecular details 
behind the occurrence of altered brain functions in offspring of diabetic 
mothers. Hence in this study, NSCs were isolated from non-malformed 
embryos of diabetic and control pregnancies. 
 Over the last two to three decades, several groups around the world 
have focused on identifying the molecular cues and cellular as well as gene 
expression changes resulting in morphological defects in diabetic pregnancy. 
Several theories such as oxidative stress, hypoxia, and apoptosis triggered due 
to hyperglycemic conditions have been proposed and proven for being the 
cause for these defects, although the exact mechanism or the link between 
hyperglycemia and gene expression/ transcriptome profiles remains unknown 
(Liao et al., 2004; Fu et al., 2006; Jiang et al., 2008; Pavlinkova et al., 2009b).  
High glucose has been shown to alter histone modifications, DNA 
methylation and expression of miRNAs suggesting that epigenetic 
mechanisms can be activated by high glucose (Waterland et al., 2006; El-Osta 
et al., 2008; Tang et al., 2009). Further, epigenetic mechanisms have been 
shown to regulate expression of developmental control genes and fate 
specification of NSCs (Hsieh and Gage, 2004; Kondo, 2006). The present 
study was aimed to understand the epigenetic mechanisms by which maternal 
diabetes induced NTD. In this study, effect of impaired maternal glucose 
levels (hyperglycemia) on the epigenome of the NSCs in developing embryo 
was explored. Further, the impaired gene expression in NSCs due to altered 
epigenetic mechanisms was investigated since it was hypothesized that 
maternal diabetes activates epigenetic mechanisms resulting in altered gene 
expression, thereby causing defects in neural tube development.  
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4.1. High glucose alters the expression of genes that regulate NSC fate and 
neuronal migration 
Neurogenesis and neuronal migration are key events that determine proper 
development of the brain. During development of the cortex in mammals, the 
NSCs switch from symmetric cell division to asymmetric cell division (around 
E11) producing two neurons eventually. Newly formed neurons migrate from 
the ventricular zone to their final destination and this process occurs as distinct 
waves of neuronal migration that places neurons in distinct cellular layers of 
the cortex (Ayala et al., 2007). Defective neurogenesis or neuronal migration 
results in brain abnormalities that affect brain size, shape and cellular 
organization (Guerrini et al., 2008; Pramparo et al., 2010).  
In order to understand the effect of hyperglycemia on fate specification 
of NSCs and neuronal migration, ten genes that were involved in 
neurogenesis, gliogenesis, or neuronal migration whose expression was 
significantly altered in the microarray studies done previously were selected 
(Jiang et al., 2008). The differential expression of genes indicated that 
maternal diabetes-induced hyperglycemia in the fetus altered the NSC fate. 
The expression of Reln, a gene involved in neuronal migration was decreased 
further substantiating the fact that hyperglycemia perturbed neuronal 
migration. 
In this study, the NSCs from diabetic pregnancy gave rise to increased 
Map2 positive neurons, indicating increased neurogenesis. It appears that 
hyperglycemia promotes neurogenesis at the cost of gliogenesis since the 
expression levels of Gfap and Ng2, markers of astrocytes and 
oligodendrocytes respectively, were found to be decreased in NSCs from 
diabetic mice. The decreased expression of glial markers in NSCs exposed to 
hyperglycemia could also be due to the fact that gliogenesis has been shown to 
be preceded by neurogenesis in the developing cortex (Qian et al., 2000). 
Although there was no change in the differentiation pattern in NSCs from 
embryos of control and diabetic pregnancy at different time points (3 days and 
6 days of differentiation), the possibility of delayed gliogenesis cannot be 
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excluded since NSCs were isolated from only one embryonic stage (E13.5) in 
the present study.  
Neural tube development and closure require proliferation, migration, 
adhesion, differentiation and apoptosis of NSCs (Schoenwolf and Smith, 
1990) and these events are mediated by several genes, matrix proteins and 
morphogens (Copp et al., 2003). Several cellular mechanisms such as altered 
actin cytoskeleton and increased neuroepithelial apoptosis have been attributed 
to NTD (Greene and Copp, 2009). Another important mechanism that is 
implicated in the occurrence of NTD is the balance of cell proliferation and 
differentiation during neurulation (Copp and Greene 2010).  During 
neurulation, NSCs undergo symmetric cell division and expand the stem cell 
pool. Once neurulation is complete, the NSCs exit cell cycle and undergo 
differentiation. In animal mutants, precocious differentiation of NSCs has 
shown to result in cranial NTD (Ishibashi et al., 1995; Zhong et al., 2000) 
suggesting the importance of balanced cell proliferation: differentiation ratio. 
It has been suggested that precocious differentiation of NSCs during 
neurulation can alter the flexibility of the neural plate, and affects the bending 
of neuroepithelium, resulting in NTD (Copp et al., 2003; Greene et al., 2009a). 
Overall, it is suggested that hyperglycemia perturbed the cell fate choice 
between neurons and glia. It is not clear what drives the hyperglycemia-
induced glia–neuron switch, since several signalling molecules appear to be 
involved. 
4.1.1. High glucose alters chromatin organization in NSCs by modifying 
histone status and DNA methylation 
Chromatin packaging in a cell is controlled by reversible histone 
modifications and DNA methylation patterns which determine accessibility 
and availability of DNA for transcription.  Heterochromatin regions that 
regulate gene expression by adding or removing silencing marks to genes 
(Dimitri et al., 2005), are known to be present at the nuclear periphery 
(Shaklai et al., 2007) as revealed in TEM analysis. Among the histone lysine 
methylation, trimethylation of histone H3 lysine 9 (H3K9 me3) residue has 
been the most extensively studied chromatin modification that has been shown 
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to be associated with gene promoters which are transcriptionally repressed. 
H3K9me3 is most abundant in heterochromatin regions (Kouzarides, 2007) 
and is thus referred to as the ‘hallmark of silenced chromatin’ (Dillon and 
Festenstein, 2002). On the other hand, histone lysine9 acetylation (H3K9 ac) 
has been found near the transcription start sites of active gene promoters 
indicating its role in transcription initiation (Nishida et al., 2006). 
 In mammalian cells, high glucose has been reported to alter gene 
expression by acetylation or methylation of lysine residues on histone H3 
(Miao et al., 2007; El-Osta et al., 2008). Taken together, the increased global 
H3K9me3 and decreased H3K9ac observed in NSCs exposed to high glucose 
indicate that histone modifying enzymes are possibly activated by high 
glucose, resulting in altered gene expression due to altered histone status.  
DNA methylation is the most stable epigenetic mechanism identified 
and its role in regulation of gene expression has been extensively studied. The 
promoters of 60-70% of mammalian genes contain CpG sites that are enriched 
as CpG islands. In normal conditions, the CpG islands are unmethylated and 
hypermethylation of promoters usually results in transcriptional silencing of 
genes (Bird, 2002; Jaenisch and Bird, 2003). In the present study, global 
methylation assay revealed increased DNA methylation in NSCs exposed to 
HG. The increased DNA methylation may be responsible for aberrant gene 
expression (possibly due to DNA hypermethylation at gene promoters) in 
NSCs exposed to HG. Recently, vascular endothelial cells exposed to high 
glucose resulted in increased methylation near the transcription start site (TSS) 
of genes (Pirola et al., 2011) and hence changes in CpG methylation near the 
TSS of selected genes (Pafah1b1 and Neurod1) were evaluated. The lack of 
CpG methylation changes at Pafah1b1 promoter concomitant with increased 
Pafah1b1 mRNA in NSCs exposed to HG, suggest that more than one 
epigenetic mechanism may be implicated in regulating gene expression. Also, 
although Neurod1 promoter exhibited changes in CpG methylation at few sites 
in NSCs exposed to HG, the lack of substantial CpG methylation data across 
all sites on the promoters makes interpretation difficult. In addition, all the 
CpG sites within the Neurod1 promoter were not evaluated and it is not clear 
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whether methylation of one/ few CpG sites is sufficient to inhibit transcription. 
A detailed evaluation of DNA methylation at specific gene promoters is 
required to thoroughly understand the mechanisms of high glucose-induced 
altered gene expression. 
4.1.2. HG alters expression of miRNAs that regulate genes involved in 
NSC fate 
It has been shown that miRNAs are essential for neurogenesis and 
neurodevelopment (Krichevsky et al., 2006; Singh, 2007; Maller Schulman et 
al., 2008; Zhao et al., 2008). In NSCs, loss of dicer results in increased 
apoptosis, abnormal neuronal differentiation and migration (De Pietri Tonelli 
et al., 2008; Kawase-Koga et al., 2009), that suggests the importance of 
miRNAs in brain development and maturation. miR-200 family has been 
reported to regulate olfactory neurogenesis in mouse and zebrafish models 
previously (Choi et al., 2008). In addition, the expression of few members of 
miR-466 family has been localized in mouse ocular tissue (Karali et al., 2010). 
The present study is the first to report the expression of miRNAs mmu-miR-
200a, mmu-miR-200b, mmu-miR-466a-3p and mmu-miR-466 d-3p in NSCs 
obtained from mouse embryonic forebrain. Recently, the miR-200 family was 
shown to be highly expressed in frontal cortex of adult mice suggesting that 
region specific expression of miRNAs may be associated with specific 
biological functions (Juhila et al., 2011). 
Expression of Dcx, Pafah1b1 and Gmfb was increased in NSCs from 
neural tube of diabetic pregnancy and inversely correlated with expression of 
miRNAs that target these genes. Dcx is expressed by migrating neuronal 
precursors (Gleeson et al., 1999) and functions upstream to Pafah1b1 gene 
during neuronal migration (Caspi et al., 2000). Further, Pafah1b1 is required 
for accurate orientation of spindle in neuroepithelial stem cells (and therefore 
proliferation) and radial glial progenitor cells (Yingling et al., 2008). Increased 
or decreased expression of Pafah1b1 and/ or Dcx have been shown to affect 
brain development (Filipovic et al., 2012). Decreased expression of Dcx and 
or Pafah1b1 contributes to Lissencephaly that is characterized by “smooth 
brain appearance” (Kato and Dobyns, 2003). In addition, our group has 
92 
 
already shown decreased number of Dcx positive cells in the brain of 
malformed embryos (cranial malformations) from diabetic pregnancy (Jiang et 
al., 2008). On the other hand, increased expression of  Dcx inhibits 
proliferation and promotes migration of human neural progenitors (Filipovic et 
al., 2012). Increased expression of Pafah1b1 has also been shown to affect 
brain development including size and cellular organization in humans and 
mice (Bi et al., 2009). Gmfb which is highly conserved among many animal 
species (Zaheer et al., 1993) has been found to be expressed mainly in the 
brain (Lim and Huang, 1989; Wang et al., 1992) and promotes cell 
differentiation (Kaplan et al., 1991). In the rat brain, the expression of Gmfb 
mRNA can be found right from E10 (Zaheer et al., 1993) that coincides with 
the period of initiation of neurogenesis. In the present study, an increased 
expression of Dcx, Pafah1b1and Gmfb proteins in the NSCs from diabetic 
pregnancy appear to be associated with increased neurogenesis in particular.  
Further, Dcx and Pafah1b1 were confirmed to be targets of miRNAs mmu-
miR-200a, mmu-miR-200b, and mmu-miR-466a-3p and mmu-miR-466 d-3p 
by using knockdown approach. Gmfb was shown to be a direct target of mmu-
miR-466d-3p (since knockdown of miR-466d-3p increased Gmfb protein 
expression) and indirect target of mmu-miR-200a (since knockdown of miR-
200a decreased Gmfb protein expression). These results indicate that several 
miRNAs contribute to neurogenesis during neurodevelopment. 
MiR-124 is expressed abundantly in the mouse brain (Deo et al., 
2006), specifically in the neurons and its expression is increased during 
development  (Krichevsky et al., 2006; Cao et al., 2007; Visvanathan et al., 
2007). Several studies have demonstrated the role of miR-124 in promoting 
neurogenesis and neuronal differentiation (Lim et al., 2005; Visvanathan et al., 
2007; Yu et al., 2008; Cheng et al., 2009). In the present study, increased 
neurogenesis from the NSCs derived from diabetic mice correlated with 
increased expression of neuron specific miR-124. 
Recently microRNAs have been shown to promote and regulate cell 
lineage specification in mouse and human cells (Ivey et al., 2008).  Since 
knockdown of specific miRNAs increased the expression of proteins involved 
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in neurogenesis, differentiation and neuronal migration, the role of specific 
miRNAs in NSC fate determination was examined.  The present study 
revealed the novel role of miRNAs mu-miR-200a, mmu-miR-200b, mmu-
miR-466a-3p and mmu-miR-466d-3p in regulating neurogenesis and 
gliogenesis in vitro by targeting and up regulating Gfap, Map2 and Ng2 
proteins either through direct target or through an indirect regulation. Since 
each of the miRNAs are predicted to target hundreds of mRNAs, it is possible 
that many targets are involved in this complex process of NSC fate 
determination.  
The present findings reveal novel insights into the mechanism by 
which maternal diabetes-induced NTD occur and suggest a link between 
maternal glucose and fetal epigenome. Overall, this study demonstrates that 
epigenetic mechanisms are activated in NSCs by HG, resulting in chromatin 
reorganization, altered histone H3K9 status, increased global DNA 
methylation, and altered miRNA expression, thereby promoting altered 
expression of neuronal and glial lineage gene markers resulting in NTD. The 
present study further confirms that epigenetic changes are persistent even 
when NSCs from diabetic pregnancy were cultured in normoglycemia and 
NSCs from non-malformed embryos are sensitive to glucotoxicity suggesting 
that phenotypically normal embryos are genotypically distinct. 
4.2. Maternal diabetes alters the miRNA transcriptome in NSCs. 
Neural tube closure requires the complex orchestration of cellular and 
molecular events while normal brain function depends on appropriate neuronal 
wiring (Ayala et al., 2007).  In the brain, neuronal differentiation and 
migration are critical for neuronal wiring. Several signalling molecules, 
microtubule and cytoskeletal proteins facilitate migration of neuronal cells to 
their final destination. Defects in neuronal migration lead to neuronal 
migration disorders which disrupt cortical organization resulting in altered 
brain shape and size. In addition, disruption in the balance of proliferation-
differentiation cycle affects size of the cortex (Caviness and Takahashi, 1995) 
resulting in altered brain function.   
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miRNAs have been shown to regulate development of the neural tube 
(Cao et al., 2007; Hoesel et al., 2010; Mukhopadhyay et al., 2011) by targeting 
genes that are critical for neural tube development and closure. In the brain, 
the expression of miRNAs has been found to be cell-type and tissue specific, 
region specific and developmental stage specific indicating their dynamic roles 
in brain development and function (Babak et al., 2004; Miska et al., 2004; Bak 
et al., 2008; Lau et al., 2008; Lugli et al., 2008; Dugas et al., 2010; Zhao et al., 
2010). The fact that miRNAs are temporally expressed and spatially regulated 
has been attributed to the robustness of neural networks (Lau and Hudson, 
2010) and exploring their roles in brain development and function are 
therefore critical. Hence, miRNA profiling was carried out to identify miRNA 
signatures of maternal diabetes-induced NTD. miRNA profiling is a robust 
technique that has recently been extensively used to study miRNA expression 
patterns in various samples (Mukhopadhyay et al., 2011; Yao et al., 2012).  
Validation of microarray results confirmed a high degree of accuracy 
and reproducibility of results obtained. Further validation of a few known 
mRNA targets (Hif1a, Mkp-1 and Ezh2) of the miRNAs showed negative 
correlation to miRNA expression, indicating the possibility of gene regulation 
by miRNAs.  
4.2.1. Maternal diabetes alters the expression of neuronal- and glial -
specific miRNAs in NSCs 
Neuronal and glial cells exhibit specific miRNA expression patterns. miR-9, 
miR-124 and miR-128 are expressed by neurons, miR-219 and miR-338 are 
specific to oligodendrocytes and miR-26a and miR-26b are highly expressed 
in astrocytes (Smirnova et al., 2005; Zhao et al., 2010; Feng and Feng, 2011). 
The expression of these miRNAs appears to be critical, since they regulate 
differentiation of NSCs into neuronal or glial lineages. 
 In the present study, although increased expression of cell lineage 
specific miRNAs, miR-124, miR-219 and miR-26a in NSCs from diabetic 
pregnancy was observed, neurogenesis was increased while gliogenesis was 
decreased in these cells.  Although the expression of miR-26a is specific to 
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astrocytes, this miRNA has also been shown to be enriched in mouse neuronal 
dendrites (Smirnova et al., 2005; Kye et al., 2007; Fiore et al., 2009). The cell 
type specific miRNA patterns of NSCs/ differentiating cells have not yet been 
elucidated in detail. Further, among the expression of cell lineage specific 
miRNAs, the expression of miR-124 that regulates neurogenesis was the 
highest, thus supporting the observed increase in neurogenesis.  In addition, 
the expression of Ezh2, a known target of miR-26a and miR-101a was found 
to be downregulated in NSCs from diabetic pregnancy. Ezh2 is a member of 
the polycomb group of proteins that are highly expressed by undifferentiated 
NSCs. The expression of Ezh2 protein is reported to be downregulated during 
differentiation of NSCs into neurons and astrocytes, and not oligodendrocytes 
(Sher et al., 2008). Therefore, the decreased expression of Ezh2 correlates with 
increased neurogenesis in this study. Overall, the present findings suggest that 
loss of stemness of NSCs and their precocious differentiation could be 
mediated by miRNAs in NSCs from diabetic mice. 
4.3. Maternal diabetes alters the expression of miRNAs that regulate 
signalling pathways critical for neural tube development 
Maternal diabetes induced NTD have long been attributed to be caused by 
deregulation of several metabolic pathways although the exact mechanism 
behind this remains unknown. Given that gene expression profiling in cranial 
neural tubes of embryos from diabetic pregnancy has revealed altered gene 
expression in developing brains exposed to maternal diabetes (Jiang et al., 
2008), and that miRNAs fine tune gene expression, we hypothesized that 
maternal diabetes alters expression of miRNAs that regulate genes critical for 
neural tube closure and patterning. In order to address this, miRNA expression 
profiling was performed using mouse embryonic NSCs isolated from forebrain 
of embryos from control and streptozotocin-induced diabetic pregnancy. Since 
maternal diabetes has been suggested to cause fetal hyperglycemia or 
hypoglycemia [Pedersen’s hypothesis 1952(Pedersen, 1952)], or hypoxia (due 
to hyperglycemia), the present author exposed the NSCs to low glucose or 
high glucose or hypoxic environment and compared the miRNA expression 
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profiles among the different groups to identify miRNA signatures of maternal 
diabetes induced NTD. 
NSCs exposed to LG showed lowest numbers of deregulated miRNAs 
targeting several pathways among which only two pathways (GnRH signalling 
pathway and ErbB signalling) were common when compared to the other 
groups.  In addition, NSCs exposed to hyperglycemia or hypoxia share more 
common pathways with NSCs from diabetic pregnancy. This clearly indicates 
that miRNA signatures in response to insults (high glucose or hypoxia) are 
unique. Diabetic embryopathy has been attributed to maternal hyperglycemia 
induced oxidative stress and hypoxia in the developing fetus (Li et al., 2012). 
Therefore, it is suggested that maternal diabetes-induced NTD and altered 
brain functions could be due to hyperglycemia and hypoxia-induced 
deregulation of miRNAs that control critical signalling pathways.  
4.3.1. The pathways identified in each group and their relevance to neural 
tube closure and brain function 
In NSCs exposed to LG, GnRH and ErbB pathways were shown to be 
deregulated by miRNAs. GnRH cells have been shown to arise from neural 
crest cells (Whitlock, 2005) and migrate from the nasal placode into the 
forebrain during development (Wray, 2010) while ErbB signalling is critical 
for migration of neurons, axonal pathfinding, myelination and synaptic 
function during CNS development (Flames et al., 2004; Lopez-Bendito et al., 
2006; Mei and Xiong, 2008). In humans, hypoglycemia has been shown to be 
teratogenic, resulting in growth retardation and neuropsychological defects, 
minimal brain dysfunction in attention, motor control, and perception in fetus 
(Stenninger et al., 1998; ter Braak et al., 2002) which may be attributed to the 
defective signalling pathways caused by altered miRNA expression.  
In NSCs exposed to HG or hypoxia, the oxidative stress responsive 
MAPK pathway was predicted to be deregulated by miRNAs. The MAPK 
pathway has already been shown to mediate diabetic embryopathy (Li et al., 
2012).The phosphatidylinositol (PI) signalling pathway was identified as the 
key pathway targeted by six miRNAs that were deregulated in diabetic 
97 
 
pregnancy compared to the other groups (LG/HG and hypoxia). PI signalling 
has been shown to regulate cell proliferation, survival, differentiation and 
chemotaxis (Katso et al., 2001) and to mediate insulin/IGF-1 hormone 
signalling. In adults, the development of type 2 diabetes has been attributed to 
impaired PI signalling (Jones and Varela-Nieto, 1999). In the brain, insulin 
signalling has been shown to be critical for learning and memory (Dou et al., 
2005; Chiu et al., 2008) and therefore the deregulation of PI signalling by 
these miRNAs can be attributed to altered brain function observed in 
offsprings of diabetic mothers.  
4.3.1.1. Mitogen- activated protein kinase (MAPK) signalling 
Diabetic embryopathy is attributed to maternal hyperglycemia induced 
oxidative stress in developing fetus (Yang et al., 1995, 1997; Yang et al., 
2010). Hyperglycemia-induced oxidative stress has been shown to increase 
apoptosis of the neuroepithelial cells resulting in NTD (Sun et al., 2005). 
Highest numbers of differentially expressed miRNAs in NSCs from diabetic 
pregnancy were predicted to target the MAPK signalling pathway which 
regulates cell growth, proliferation, differentiation and cell death (Pearson et 
al., 2001) and are known to be altered by oxidative stress. Members of the 
MAPK signalling pathway such as stress–activated c-Jun N terminal kinase 
(JNK) have been shown to increase apoptosis of the neuroepithelium causing 
NTD (Sabapathy et al., 1999) and also increase apoptosis of other cell types 
causing diabetic embryopathy (Yang et al., 2007). MAPKs are negatively 
regulated by MKP-1, the expression of which was found to be downregulated 
in NSCs from diabetic pregnancy suggesting activation of MAPK pathway.   
4.3.1.2. Focal adhesion 
Focal adhesions are specialised structures at the plasma membrane that link 
the extra cellular matrix to the actin cytoskeleton (Burridge and Chrzanowska-
Wodnicka, 1996; Petit and Thiery, 2000). Cell-adhesion molecules are 
essential in cell proliferation, motility, differentiation and survival. Cell-cell 
adhesion is deemed to be critical for initiating fusion at the tips of the neural 
folds in various animal species (Chen and Hales, 1995; Rashid et al., 2006).  
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Mutation in adhesion molecules has been shown to result in NTD in mice 
signifying their roles in neural tube closure (Holmberg et al., 2000). 
 
4.3.1.3. Regulation of actin cytoskeleton 
The role of actin cytoskeleton in neural fold formation has long been explored 
(Sadler et al., 1982; Schoenwolf et al., 1988). The distribution of actin 
filaments and actin related proteins in neuroepithelium is asymmetric which 
was suggested to facilitate bending and neural fold closure. Disruption of actin 
filaments (using pharmacological agents such as cytochalasin D or genetic 
mutations) results in NTD signifying the importance of actin filaments in 
neural tube closure (Lee and Kalmus, 1976; Xu et al., 1998; Copp et al., 2003; 
Luo et al., 2005). Our group has previously shown the altered expression of 
microtubule-associated protein Doublecortin (Dcx), in cranial neural tube of 
malformed embryos from diabetic pregnancy (Jiang et al., 2008). It is clear 
that maternal diabetes alters cytoskeletal proteins and signalling molecules 
resulting in defective neuronal migration that may form the basis for 
neurological impairments in offspring of diabetic mothers. 
4.3.1.4. Wnt signalling 
During neural tube formation, the neural plate undergoes narrowing and 
lengthening simultaneous with neural fold formation. Among the several 
processes that contribute to this phenomenon is the convergent extension cell 
movement involving non-canonical Wnt signalling (Keller, 2002; Ueno and 
Greene, 2003; Zohn et al., 2003). The Planar cell polarity pathway (PCP) is a 
non-canonical Wnt/frizzled/dishevelled signalling pathway that is responsible 
for cell polarity in epithelial and non-epithelial cells in vertebrates (Strutt, 
2003). The absence or mutation of PCP pathway has been shown to result in 
neural tube closure defects (Wallingford and Harland, 2002). In addition, more 
than 100 genes that belong to PCP pathway and that affect neural tube closure 






4.3.1.5. Axon guidance and Neurotrophin signalling 
Neuronal migration and axon guidance are required for proper wiring in the 
brain. These events require molecules that are involved in cytoskeleton 
rearrangement and secondly those that act as guidance cues (Uher and Golden, 
2000). Neurotrophic factors are known to be positive or negative regulators of 
axon guidance. In addition they positively regulate neuronal growth and 
survival (Gillespie, 2003; Lykissas et al., 2007). These neurotrophin molecules 
bind to receptor tyrosine kinases resulting in activation of major signalling 
pathways such as PI3K and PKC. Neurotrophins regulate neurite growth and 
axon guidance (Gillespie, 2003) and have been shown to be involved in neural 
tube development and differentiation (Bernd, 2008).  
Overall, maternal diabetes alters expression of miRNAs that regulate 
metabolic pathways and signalling molecules that are critical for neural tube 
closure and brain development and function. The present findings reveal novel 
insights into the mechanisms by which maternal diabetes induced NTD and 
neuropsychological deficits in infants of diabetic mothers. Since epigenetic 
mechanisms are reversible, exploring their therapeutic potential will be useful 






















Diabetes during pregnancy is known to be teratogenic causing congenital 
anomalies. Over the last 2-3 decades, the focus on this field of research has 
shifted from morphological and molecular characterisation of the etiology of 
maternal diabetes-induced malformations to, understanding the molecular 
mechanisms by which maternal diabetes perturbs fetal development. While 
several theories such as oxidative stress, hypoxia, and apoptosis triggered due 
to hyperglycemic conditions have been proposed and proven for being the 
causes for these defects, the exact mechanism or the link between how high 
glucose can alter gene expression/ transcriptome and activate epigenetic 
mechanisms is largely unknown. In recent years, the focus has gradually 
shifted to looking at pre-programmed changes and activation of epigenetic 
mechanisms that cause altered gene expression.  
 The present study provides some novel insights into the epigenetic 
mechanism of maternal diabetes-induced NTD. This study demonstrates for 
the first time that hyperglycemia alters epigenetic mechanisms in NSCs which 
may form the basis for NTD observed in diabetic pregnancy (illustration 3). 
Furthermore, it will be interesting to elucidate how epigenetic 
mechanisms such as DNA methylation, chromatin/ histone modifications and 
miRNA are activated in embryonic tissue by maternal diabetes. Identifying 
specific histone/DNA modifying enzymes involved in response to glucose 
prove as significant therapeutic targets, since epigenetic changes are 
reversible. Modulating fetal epigenetic programming in such metabolic 
syndromes may prove valuable to improve fetal outcomes or prevent onset of 
diabetes in offspring of diabetic mothers. 
This author concludes that the present study is preliminary in nature 
and just the ‘tip of the iceberg’ in understanding the epigenetic mechanisms by 
which maternal diabetes induces NTD and functional impairment in the brain. 
However, the present study opens up new vistas for epigenetic research to 
understand the maternal diabetes-induced NTD as well as potential therapies 








Illustration 3: Mechanism of maternal diabetes induced neural tube defects. 
Scope for future study 
The present study provides novel insights into the mechanism of maternal 
diabetes induced NTD. The results of the present study have shown that 
maternal diabetes alters epigenetic mechanisms in embryonic NSCs leading to 
altered gene expression and NTD observed in embryos of diabetic pregnancy. 
The chromatin contains genomic DNA that can be methylated and histone 
proteins that can undergo several post-translational modifications, some which 
appear to be influenced by high glucose. Based on the present findings, it is 
clear that maternal hyperglycemia alters DNA methylation and histone 
modifications genome wide. Therefore, high throughput techniques such as 
chromatin or methylated DNA immunoprecipitation (ChIP, MeDIP) combined 
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with massive parallel sequencing (ChIP-seq, CpG-seq) are necessary to 
identify genome-wide changes in specific histone modifications or CpG 
methylation. This high throughput analysis will be useful in identifying 
numerous genes whose expression may be modified by high glucose via 
altering specific histone marks and/or DNA methylation.  
Furthermore, the present study demonstrates that NSC fate is 
controlled by epigenetic mechanisms. Therefore, the expression of miRNAs, 
CpG methylation status and histone modification marks in NSCs and in 
differentiated cells (neurons and glial cells) needs to be examined in detailed 
under normoglycemia and hyperglycemia. This analysis would provide further 
novel insights on how maternal diabetes influences NSC fate via alteration of 
epigenetic status. 
The present study also demonstrates that maternal diabetes alters the 
expression of miRNAs that regulate genes/biological pathways that are critical 
for neural tube development and closure.  Since a single miRNA may target 
multiple genes, the miRNA profiling data needs to be correlated with gene 
expression/ protein expression profiling of NSCs obtained from non-
malformed embryos of diabetic pregnancy in order to validate the pathways 
targeted by miRNAs.  In addition, knockdown and over expression of specific 
miRNA (that is differentially expressed with high fold change and low p-
values) in NSCs will provide novel insights on its functional significance since 
the roles of a majority of miRNAs in brain development and function remain 
unknown. 
MicroRNAs prove to be excellent therapeutic candidates since each 
miRNA regulates numerous genes of a single or multiple pathways. Currently, 
several approaches have been developed to inhibit (2’ O-methyl group, 
chemical modifications of oligonucleotides, miR-sponges, miR-mask, target 
protectors) or restore (miRNA mimetics or mimics) miRNA function in cancer 
cells. The use of miRNAs as pharamacological targets (by restoring or 
inhibiting function of miRNAs) needs to be explored and offer great promise 
in alleviating disease outcomes. 
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At present, there are no epigenetic drugs developed for metabolic 
syndromes such as diabetes, and extensive studies are required to first 
establish and identify epigenetic signatures. The fact that epigenetic 
mechanisms are reversible offers great promise in reversing disease status to 
that of a healthy one. Furthermore, establishing epigenetic signatures may 
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Figure 1: Mouse embryos obtained from normal and diabetic pregnancy. 
 
Mouse embryos (Embryonic day 13.5) isolated from normal pregnancy (a) and 
diabetic pregnancy (b-d).  The embryos from diabetic mouse exhibited neural 























Figure 2: Isolation and culture of neural stem cells 
Neural stem cells (NSCs) isolated from telencephalon of E13.5 mouse 
embryos were cultured in serum-free conditions in the presence of EGF 
(Epidermal growth factor). NSCs grow as free floating clusters of cells called 
neurospheres in the medium. Phase contrast images of neurospheres at 10X 















Figure 3: Nestin staining of NSCs 
Neurosphere was stained with Nestin (a-d), an intermediate filamentous 
protein marker for NSCs in red and the nucleus was counterstained with DAPI 
in blue. (a,b) All neurospheres derived from embryos of control (a) and 
diabetic (b) pregnancy expressed Nestin. (c,d) All cells within a neurosphere 
derived from embryos of control (c) and diabetic (d) pregnancy showed 
















Figure 4: Differentiation of NSCs 
 
NSCs were allowed to differentiate in the presence of serum. Phase contrast 
images of differentiated cells at 48h (a) and 72h (b) following differentiation. 
Scale bar 100µm. NSCs gave rise to neurons (c), astrocytes (d) and 
oligodendrocytes (e) as indicated by immunostaining with Map2, Gfap and 
Ng2 antibodies respectively (in red). The nucleus was counterstained with 













Figure 5: Chromatin reorganization in NSCs. 
Representative transmission electron microscopy images of NSCs from 
normal pregnancy cultured in physiological glucose (a, control), or exposed to 
high glucose (b, HG) for 48h and NSCs from diabetic pregnancy cultured in 
physiological glucose (c, dia). Increased heterochromatin structure at the 
nuclear periphery was observed in NSCs exposed to HG in vitro and that from 
diabetic pregnancy (white arrows). The nucleolus is indicated by red arrows. 













Figure 6: Estimation of global DNA methylation levels in NSCs 
Global DNA methylation levels were examined in NSCs. Bars represent the 
percentage of global DNA methylation in NSCs from normal pregnancy (con, 
open bar), or exposed to high glucose (HG, black bar ) in vitro and NSCs from 
diabetic pregnancy (dia, grey bar).The percentage of DNA methylation was 
increased in NSCs exposed to HG or dia when compared to the control. Data 












Figure 7: Estimation of histone H3 lysine 9 trimethylation in NSCs 
Global trimethylated histone H3 lysine9 (H3K9me3), a transcriptional 
silencing mark was examined in NSCs (a-d). The percentage of global 
H3K9me3 in NSCs exposed to HG in vitro (black bar) and from diabetic 
pregnancy (grey bar) was increased when compared to the control (open bar) 
by ELISA based approach(a). Data are represented as mean ± SD from 4 
independent experiments, *p<0.05. Immunostaining with anti-H3K9me3 
antibody (in red) revealed increased dark dense spots in NSCs exposed to HG 
(c) and from diabetic pregnancy (d) when compared to the control (b) as 













Figure 8: Estimation of histone H3 lysine 9 acetylation in NSCs 
 
Global acetylated histone H3 lysine9 (H3K9ac), a transcriptional activating 
mark was examined in NSCs (a-d). The percentage of global H3K9ac in NSCs 
exposed to HG in vitro(black bar) and that from diabetic pregnancy (grey bar) 
was decreased when compared to the control (open bar) (a). Data are 
represented as mean ± SD from 4 independent experiments, *p<0.05. 
Immunostaining with anti-H3K9ac antibody (in red) revealed decreased 
immunoreactivity in NSCs exposed to HG (c) and from diabetic pregnancy (d) 












Figure 9: Analysis of gene expression in NSCs 
mRNA expression of genes involved in neurogenesis, neuronal migration and 
gliogenesis was analysed in NSCs by qRT-CR. The mRNA expression of Igf1, 
Neurog1, Dcx, Pafah1b1, Neurod4, Dcamkl2, Sema6a, Gmfb were increased 
significantly, while the expression of Reln was decreased significantly in 
NSCs from diabetic pregnancy (filled bars) when compared to the control 
(open bars) (a). The specificity of amplification was confirmed by agarose gel 
electrophoresis and the PCR amplicons were visualized as a single band on the 
gel (b) at the respective amplicon size. Bar represents the mean ± SD from at 














Figure 10: Estimation of percentages of Map2, Ng2 and Gfap positive cells 
Neurospheres derived from embryos of control and diabetic pregnancy were 
allowed to differentiate for 3 days (a-h) or 6 days (i-p) in vitro and the 
expression of neuronal (Map2), glial (Gfap, Ng2), and Nestin positive cell 
populations were determined by immunocytochemistry. The percentage of 
Map2 positive cells was significantly increased, while the percentages of Gfap 
and Ng2 positive cells were significantly reduced at3 days and 6 days in NSCs 
from diabetic pregnancy (filled bars) on both 3 days or 6 days post 
differentiation when compared to the control (open bars) (q). Data are 
















Figure 11: Estimation of CpG methylation at Pafah1b1 promoter in NSCs 
Pafah1b1 mRNA expression and promoter DNA methylation levels in NSCs 
exposed to HG (a-e). The expression of Pafah1b1 mRNA was significantly 
increased in NSCs exposed to HG in vitro when compared to the control (a). 
Data are represented as mean ± SD from at least four independent 
experiments, *p<0.05.A 1000bp region upstream and downstream of the 
transcription start site (TSS) of Pafah1b1 was analysed to identify CpG islands 
in the promoter (b). Pafah1b1 promoter contains a 620bp long CpG island 
(shaded in blue) that is located across the transcription start site (TSS) where 
primers for DNA methylation analysis were designed. (c,d) The methylation 
pattern is represented as lollipop grid where open circles represent 
unmethylated CpG sites and shaded circles represent methylated CpG sites. 
Each row represents the sequencing information received from a single clone 
across 27 CpG sites (-310 to -46 relative to TSS).There was no change in CpG 
methylation of Pafah1b1 promoter of NSCs from HG (d), or that from diabetic 















Figure 12: Estimation of CpG methylation at Neurod1 promoter in NSCs 
 
Neurod1 mRNA expression and promoter DNA methylation levels in NSCs 
exposed to HG (a-e). The expression of Neurod1 mRNA was significantly 
increased in NSCs exposed to HG in vitro when compared to the control (a). 
Data are represented as mean ± SD from at least four independent 
experiments, *p<0.05.A 1000bp region upstream and downstream of the 
transcription start site (TSS) of Neurod1 was analysed to identify CpG islands 
in the promoter (b). The Neurod1 promoter contains a 439bp long CpG island 
(shaded in blue) that is mainly located upstream of the transcription start site 
(TSS) where primers for DNA methylation analysis were designed. (c-e)The 
methylation pattern is represented as lollipop grid where open circles represent 
unmethylated CpG sites and shaded circles represent methylated CpG sites. 
Data from five clones are represented here where each row represents the 
sequencing information received from a single clone across 13 CpG sites (-383 
to -84 relative to TSS). Increased methylation of CpG sites was found in 
Neurod1 promoter of NSCs exposed to HG (d) when compared to the control 
(c). CpG methylation in Neurod1 promoter of NSCs from diabetic pregnancy 
could not be determined except at CpG site -383 which is methylated (e) when 



















Figure 13: Analysis of miRNA expression in NSCs by in situ hybridization 
in situ hybridization (ISH) reveals the expression and localization of miRNA 
mmu-miR-200b (a) and mmu-miR-466d-3p (b) in NSCs (green). The nucleus 
















Figure 14: Analysis of miRNA expression in NSCs by qRT-PCR. 
Expression of miRNAs were analysed in NSCs by qRT-PCR (a,b). The 
expression of miRNAs mmu-miR-200a, mmu-miR-200b, mmu-miR-466a-3p 
and mmu-miR-466d-3p were decreased significantly in NSCs from diabetic 
pregnancy (filled bars) when compared to the control (open bars) (a). The bars 
represent the mean ± SD (n=4), *p<0.05, **p<0.01. The specificity of 
amplification was confirmed by polyacrylamide gel electrophoresis and the 














Figure 15: Expression of miR-124 in NSCs 
Expression of miRNA miR-124 that regulates neurogenesis was examined in 
NSCs. The expression of mmu-miR-124 was significantly increased in NSCs 
from diabetic pregnancy (filled bar) when compared to the control (open bar). 















Figure 16: Expression of Dcx protein in NSCs 
Expression of Dcx protein in NSCs was estimated by Western blot (a,b). 
Representative blot showing the expression of Dcx protein in NSCs (a). The 
quantity of Dcx protein was found to be increased significantly in NSCs from 
diabetic pregnancy (filled bar) compared to the control (open bar). Beta actin 
was used as the control. Data are represented as mean ± SD from four 















Figure 17: Pafah1b1 protein expression in NSCs 
Expression of Pafah1b1 protein in NSCs was estimated by Western blot (a,b). 
Representative blot showing the expression of Pafah1b1 protein in NSCs (a). 
The quantity of Pafah1b1 protein was found to be increased significantly in 
NSCs from diabetic pregnancy (filled bar) compared to the control (open bar). 
Beta actin was used as the control. Data are represented as mean ± SD from 













Figure 18: Gmfb protein expression in NSCs 
Expression of Gmfb protein in NSCs was determined by Western blot (a,b). 
Representative blot showing the expression of Gmfb protein in NSCs (a). The 
quantity of Gmfb protein was found to be increased significantly in NSCs 
from diabetic pregnancy (filled bars) compared to the control (open bars). Beta 
actin was used as the control. Data are represented as mean ± SD from four 













Figure 19: miRNA transfection in NSCs 
Transfection of miRNAs in NSCs (a-c). Confocal images of NSCs transfected 
with 5’ fluorescein labeled Scr (a) or LNA-miR-466d-3p inhibitors (b) in 
green. Cells were counterstained with DAPI (blue). Scale bar: 50 µm. In 
NSCs, the knockdown efficiency following transfection with mmu-miR-466d-
3p was found to be 71% (c) when compared to scrambled (scr) transfected 
cells. The average from four independent experiments is represented as mean 















Figure 20: Analysis of Dcx protein expression after miRNA knockdown in 
NSCs 
Representative Western blot showing Dcx protein expression after knockdown 
of specific miRNAs in NSCs (a). The quantity of Dcx protein was found to 
increase significantly in NSCs following knockdown of mmu-miR-200a or 
mmu-miR-200b or mmu-miR-466a-3p or mmu-miR-466d-3p when compared 
to scrambled (scr) transfected cells (b). Data are represented as mean ± SD 














Figure 21: Analysis of Pafah1b1 protein expression after miRNA knockdown 
in NSCs 
Validation of miRNA target prediction in NSCs (a,b). Representative Western 
blot showing the expression of Pafah1b1 protein after knockdown of specific 
miRNAs in NSCs (a). The quantity of Pafh1b1 protein was found to increase 
significantly in NSCs following knockdown of mmu-miR-200a or mmu-miR-
200b or mmu-miR-466a-3p or mmu-miR-466d-3p when compared to 
scrambled (scr) transfected cells (b). Data are represented as mean ± SD from 















Figure 22: Analysis of Gmfb protein expression after miRNA knockdown in 
NSCs 
Validation of miRNA target prediction in NSCs (a,b). Representative Western 
blot showing the expression of Gmfb protein after knockdown of specific 
miRNAs in NSCs (a). The quantity of Gmfb protein decreased significantly in 
mmu-miR-200a knocked down cells whereas, knockdown of mmu-miR-466d-
3p in NSCs increased Gmfb protein expression significantly when compared 
to scrambled (scr) transfected cells (b). Data are represented as mean ± SD 













Figure 23: Effect of miRNA knockdown on NSC fate (astrogenesis) 
The effect of miRNA knockdown on NSC fate (astrogenesis) was assayed by 
immunocytochemistry. Specific miRNAs were knocked down in NSCs and 
the percentage of Gfap positive cells were quantitated in differentiated cells (a-
f). Confocal images showing the expression of Gfap positive differentiated 
cells (red) following knockdown of scrambled (scr) (a),or mmu-miR-200a (b) 
or mmu-miR-200b (c) or mmu-miR-466a-3p (d) or mmu-miR-466d-3p (e) in 
NSCs. The nuclei were counterstained with DAPI (blue). Scale bar: 100µm. 
Quantitative analysis shows the percentage of Gfap positive cells was 
significantly increased following knockdown of miRNA mmu-miR-200a or 
mmu-miR-200b or mmmu-miR0466a-3p transfected cells when compared to 
the scr transfected cells (f). Data are represented as mean ± SD from at least 














Figure 24: Effect of miRNA knockdown on NSC fate (oligodendrogenesis) 
The effect of miRNA knockdown on NSC fate (oligodendrogenesis) was 
assayed. Specific miRNAs were knocked down in NSCs and the percentage of 
Ng2 positive cells were quantitated in differentiated cells (a-f). Confocal 
images showing the expression of Ng2 positive differentiated cells (red) 
following knockdown of scrambled (scr) (a) or mmu-miR-200a (b) or mmu-
miR-200b (c) or mmu-miR-466a-3p (d) or mmu-miR-466d-3p (e) in NSCs. 
The nucleus is counterstained with DAPI (blue). Scale bar: 50µm. Quantitative 
analysis shows the percentage of Ng2 positive cells was significantly 
increased following knockdown of miRNA mmu-miR-200b or mmmu-miR-
466d-3p transfected cells when compared to the scr transfected cells (f). Data 













Figure 25: Effect of miRNA knockdown on NSC fate (neurogenesis) 
The effect of miRNA knockdown on NSC fate (neurogenesis) was assayed. 
Specific miRNAs were knocked down in NSCs and the percentage of Map2 
positive cells were quantitated in differentiated cells (a-f). Confocal images 
showing the expression of Map2 positive differentiated cells (red) following 
knockdown of scrambled (scr) (a), mmu-miR-200a (b) or mmu-miR-200b (c) 
or mmu-miR-466a-3p (d) or mmu-miR-466d-3p (e) in NSCs. The nucleus is 
counterstained with DAPI (blue). Scale bar: 100µm. Quantitative analysis 
shows the percentage of Map2 positive cells was significantly increased 
following knockdown of miRNA mmu-miR-200a or mmmu-miR-466a-3p 
transfected cells when compared to the scr transfected cells (f). Data are 













Figure 26: miRNA profiling in NSCs 
Heat map showing the top 50 miRNAs with highest standard deviation in 
NSCs derived from normal pregnancy and exposed to physiological glucose 
(Control, 5mmol/L D-glucose), low glucose (LG, 2mmol/L D-glucose), high 
glucose (HG, 40mmol/L D-glucose), hypoxia (Hypoxia, 5mmol/L D-glucose + 
1% oxygen) or that from diabetic pregnancy (Dia, 5mmol/L D-glucose). Red 
color represents expression levels above the mean and blue color represents 
expression levels below mean. Each row represents one miRNA and each 















Figure 27: PCA plot analysis 
Principal Component Analysis (PCA) plot shows the clustering of samples 
according to their biology. Each group consists of three biological replicates of 
NSCs from Control, low glucose (Low), high glucose (High), hypoxia (Ox), 
diabetic pregnancy (Dia). NSCs from diabetic pregnancy (right extreme) show 














Figure 28: Validation of microarray results by qRT-PCR. 
Six miRNAs were selected for validation from the top miRNAs that were 
differentially expressed between NSCs from control pregnancy (Control, 
5mmol/L D-glucose) and diabetic pregnancy (5mmol/L D-glucose). The 
expression of selected miRNAs was quantitated by qRT-PCR in NSCs from 
control (open bars) and diabetic pregnancy (filled bars) and the pattern of 
expression was found to be in agreement with the microarray results. Data are 
















Figure 29: Expression of known gene targets of differentially expressed 
miRNAs 
Known gene targets of differentially expressed miRNAs were quantitated in 
NSCs (a.b). Representative Western blot showing the expression of Ezh2, 
Mkp-1 and Hif1a proteins in NSCs from control and diabetic pregnancy (a). 
The quantities of Ezh2 and Mkp-1 proteins were significantly decreased while 
Hif1a was increased in NSCs from diabetic pregnancy (filled bars) compared 
to the control (open bars). Data are represented as mean ± SD from at least 
















Figure 30: Differentially expressed miRNAs in NSCs from various groups 
Differentially expressed miRNAs between NSCs from various groups were 
identified by t-test. The bar graph shows the number of upregulated (dark 












Figure 31: Differentially expressed miRNAs in NSCs exposed to LG vs 
control 
Low glucose (LG) alters the expression of miRNAs that regulate GnRH and 
ErbB signalling in NSCs (a-c). Heat map showing the differentially expressed 
miRNAs in NSCs exposed to LG compared to the control (a). Red color 
represents expression levels above the mean and blue color represents 
expression levels below mean. Each row represents one miRNA and each 
column represents one sample. The miRNA clustering is shown on the left. 
Bar graph shows the top ten pathways targeted by miRNAs altered by LG 
arranged in the order of p-value. Bars represent the number of differentially 
expressed miRNAs (grey bars) and the number of genes targeted (white bars) 
by these miRNA in each pathway (b). The miRNAs deregulated by LG were 
predicted to regulate GnRH and ErbB signalling in NSCs. IPA analysis shows 




















































Figure 32: Differentially expressed miRNAs in NSCs exposed to HG vs 
control 
High glucose alters the expression of miRNAs that regulate actin cytoskeleton 
and MAPK signalling in NSCs (a-c). Heat map showing the differentially 
expressed miRNAs in NSCs exposed to HG compared to the control (a). Red 
color represents expression levels above the mean and blue color represents 
expression levels below mean. Each row represents one miRNA and each 
column represents one sample. The miRNA clustering is shown on the left. 
Bar graph shows the top ten pathways targeted by miRNAs altered by HG 
arranged in the order of p-value. Bars represent the number of differentially 
expressed miRNAs (grey bars) and the number of genes targeted (white bars) 
by these miRNA in each pathway (b). The miRNAs deregulated by HG were 
predicted to regulate actin cytoskeleton and MAPK signalling in NSCs. IPA 























































Figure 33: Differentially expressed miRNAs in NSCs exposed to Hypoxia vs 
control 
Hypoxia alters the expression of miRNAs that regulate MAPK and calcium 
signalling in NSCs (a-c). Heat map showing the differentially expressed 
miRNAs in NSCs exposed to hypoxia compared to the control (a). Red color 
represents expression levels above the mean and blue color represents 
expression levels below mean. Each row represents one miRNA and each 
column represents one sample. The miRNA clustering is shown on the left. 
Bar graph shows the top ten pathways targeted by miRNAs altered by hypoxia 
arranged in the order of p-value. Bars represent the number of differentially 
expressed miRNAs (grey bars) and the number of genes targeted (white bars) 
by these miRNA in each pathway (b). The miRNAs deregulated by hypoxia 
were predicted to regulate MAPK and calcium signalling in NSCs. IPA 























































Figure 34: Differentially expressed miRNAs in NSCs from diabetic pregnancy 
vs control 
Maternal diabetes alters the expression of miRNAs that regulate MAPK and 
actin cytoskeleton in NSCs (a-c). Heat map showing the differentially 
expressed miRNAs in NSCs from diabetic pregnancy compared to the control 
(a). Red color represents expression levels above the mean and blue color 
represents expression levels below mean. Each row represents one miRNA 
and each column represents one sample. The miRNA clustering is shown on 
the left. Bar graph shows the top ten pathways targeted by miRNAs altered 
maternal diabetes arranged in the order of p-value. Bars represent the number 
of differentially expressed miRNAs (grey bars) and the number of genes 
targeted (white bars) by these miRNA in each pathway (b). The miRNAs 
deregulated by maternal diabetes were predicted to regulate MAPK and actin 
cytoskeleton in NSCs. IPA analysis shows the miRNA-gene interaction 































































Figure 35: Differentially expressed miRNAs in NSCs exposed to LG vs 
diabetic pregnancy 
Pathways targeted by differentially expressed miRNAs in NSCs exposed to 
LG when compared to diabetic pregnancy (a-c). Heat map showing the 
differentially expressed miRNAs in NSCs exposed to LG when compared to 
NSCs from diabetic pregnancy (a). Red color represents expression levels 
above the mean and blue color represents expression levels below mean. Each 
row represents one miRNA and each column represents one sample. The 
miRNA clustering is shown on the left. Bar graph shows the top ten pathways 
targeted by differentially expressed miRNAs arranged in the order of p-value. 
Bars represent the number of differentially expressed miRNAs (grey bars) and 
the number of genes targeted (white bars) by these miRNA in each pathway 
(b). The miRNAs deregulated by LG were predicted to regulate MAPK 
signalling, Insulin signalling, TGF-beta signalling in NSCs. IPA analysis 

















































Figure 36: Differentially expressed miRNAs in NSCs exposed to HG vs 
diabetic pregnancy 
Pathways targeted by differentially expressed miRNAs in NSCs exposed to 
HG when compared to diabetic pregnancy (a-c). Heat map showing the 
differentially expressed miRNAs in NSCs exposed to HG when compared to 
NSCs from diabetic pregnancy (a). Red color represents expression levels 
above the mean and blue color represents expression levels below mean. Each 
row represents one miRNA and each column represents one sample. The 
miRNA clustering is shown on the left. Bar graph shows the top ten pathways 
targeted by differentially expressed miRNAs arranged in the order of p-value. 
Bars represent the number of differentially expressed miRNAs (grey bars) and 
the number of genes targeted (white bars) by these miRNA in each pathway 
(b). The miRNAs deregulated by HG were predicted to regulate actin 
cytoskeleton, axon guidance and Wnt signalling in NSCs.  IPA analysis shows 




















































Figure 37: Differentially expressed miRNAs in NSCs exposed to hypoxia vs 
diabetic pregnancy 
Pathways targeted by differentially expressed miRNAs in NSCs exposed to 
hypoxia when compared to diabetic pregnancy (a-c). Heat map showing the 
differentially expressed miRNAs in NSCs exposed to hypoxia when compared 
to NSCs from diabetic pregnancy (a). Red color represents expression levels 
above the mean and blue color represents expression levels below mean. Each 
row represents one miRNA and each column represents one sample. The 
miRNA clustering is shown on the left. Bar graph shows the top ten pathways 
targeted by differentially expressed miRNAs arranged in the order of p-value. 
Bars represent the number of differentially expressed miRNAs (grey bars) and 
the number of genes targeted (white bars) by these miRNA in each pathway 
(b). The miRNAs deregulated by hypoxia were predicted to regulate MAPK 
signalling and actin cytoskeleton in NSCs.  IPA analysis shows the miRNA-































































































Figure 38: Pathways targeted by miRNAs differentially regulated in diabetic 
pregnancy vs LG/HG/hypoxia 
Bar graph shows the pathways targeted by miRNAs common to 
LG/HG/hypoxia vs dia arranged in the order of p-value. Bars represent the 
number of differentially expressed miRNAs (grey bars) and the number of 
genes targeted (white bars) by these miRNA in each pathway (a). The 
miRNAs were predicted to target the phosphatidylinositol pathway.  IPA 

























































Sheet1: Top 50 microRNAs with highest standard deviation 
 Annotation Count Stdev 
mmu-miR-210 15 1.116068 
mmu-miR-124 15 0.934708 
mmu-miR-1a 15 0.886978 
mmu-miR-219-5p 15 0.820122 
mmu-miR-138 15 0.718707 
mmu-miR-219-3p 15 0.66549 
mmu-miR-882 15 0.6072 
mmu-miR-25* 15 0.58339 
mmu-miR-710 15 0.555703 
mmu-miR-762 15 0.542564 
mmu-miR-185* 15 0.539079 
mmu-miR-135a 15 0.537415 
mmu-miR-592* 15 0.51364 
mmu-miR-204* 15 0.503336 
mmu-miR-338-3p 15 0.499685 
mmu-miR-711 15 0.487714 
mmu-miR-21 15 0.477586 
mmu-miR-21* 15 0.473828 
mmu-miR-1971 15 0.473751 
mmu-miR-34c 15 0.452319 
mmu-miR-29b 15 0.439415 
mmu-miR-3102* 15 0.433453 
mmu-miR-34b-5p 15 0.431208 
mmu-miR-346* 15 0.424621 
mmu-miR-5097 15 0.422695 
mmu-miR-470 15 0.411766 
mmu-miR-101a 15 0.400191 
mmu-miR-3068* 15 0.399843 
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mmu-miR-493* 15 0.388133 
mmu-miR-22 15 0.386176 
mmu-miR-365 15 0.385798 
mmu-miR-146b 15 0.38489 
mmu-miR-1894-3p 15 0.378694 
mmu-miR-2861 15 0.376601 
mmu-miR-667 15 0.362443 
mmu-miR-3090* 15 0.361189 
mmu-miR-224 15 0.358282 
mmu-miR-181a 15 0.356957 
mmu-miR-665 15 0.349929 
mmu-miR-130b 15 0.349844 
mmu-miR-15b 15 0.344727 
mmu-miR-487b 15 0.344428 
mmu-miR-3103* 15 0.342521 
mmu-miR-675-5p 15 0.335724 
mmu-miR-503 15 0.334091 
mmu-miR-3473 15 0.325719 
mmu-miR-140* 15 0.325448 
mmu-let-7f 15 0.324264 
mmu-miR-674 15 0.323366 


























































Sheet 3A: Differentially expressed miRNAs in NSCs exposed to LG vs 
Con 
 
Con vs LG     
Annotation Fold change T-test 
Upregulated miRNAs     
mmu-miR-290-5p 1.406013348 0.000724 
mmu-miR-17* 1.378166009 0.002062 
mmu-let-7d* 1.267611391 0.005121 
mmu-miR-291b-5p 1.138211204 0.007115 
mmu-miR-677* 1.211031384 0.007726 
mmu-miR-25* 1.743919502 0.009867 
      
Downregulated miRNAs     
mmu-miR-1186b 0.83357082 0.005795 
 
 
Sheet 3B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to LG 
 
KEGG pathway #miRNAs #genes p-value 
Adherens junction 4 10 0.000852 
GnRH signaling pathway 6 16 0.000859 
ErbB signaling pathway 6 13 0.007089 
Long-term potentiation 6 11 0.019016 
Apoptosis 5 9 0.030103 
Phosphatidylinositol signaling  6 11 0.030103 
Long-term depression 6 10 0.030103 
Circadian rhythm - mammal 2 2 0.034036 
Wnt signaling pathway 6 16 0.040511 
Ubiquitin mediated proteolysis 6 15 0.049573 
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Upregulated miRNAs     
mmu-let-7f-1* 1.250887 0.000349 
mmu-miR-378/mmu-miR-378b 1.220776 0.001578 
mmu-miR-3069-5p 1.171618 0.002764 
mmu-miR-320 1.272591 0.002773 
mmu-miR-1247 1.253317 0.00285 
mmu-miR-350 1.172639 0.003156 
mmu-miR-3098-3p 1.188163 0.0034 
mmu-miR-149 1.090253 0.004512 
Downregulated miRNAs     
mmu-miR-297a-5* 0.765665 0.000438 
mmu-miR-693-5p 0.775347 0.000538 
mmu-miR-1894-3p 0.822378 0.000897 
mmu-miR-30b 0.844811 0.004347 
mmu-miR-187* 0.779009 0.004474 






Sheet 4B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to HG 
 
KEGG pathway p-value #miRNAs #genes 
Neurotrophin signaling pathway 1.49E-07 10 44 
Axon guidance 7.75E-07 10 42 
Cell cycle 3.31E-06 9 36 
Circadian rhythm - mammal 1.32E-05 9 11 
TGF-beta signaling pathway 4.53E-05 8 27 
Lysine degradation 7.18E-05 8 12 
ErbB signaling pathway 0.000109 10 29 
Ubiquitin mediated proteolysis 0.000128 9 36 
Long-term potentiation 0.000296 10 23 
Focal adhesion 0.00034 10 49 
Gap junction 0.000632 7 20 
Long-term depression 0.000873 8 18 
mTOR signaling pathway 0.002107 9 18 
VEGF signaling pathway 0.00303 8 22 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 0.003944 7 15 
T cell receptor signaling pathway 0.004853 8 29 
Hedgehog signaling pathway 0.005109 8 16 
Insulin signaling pathway 0.011138 10 32 
Wnt signaling pathway 0.011645 9 36 
Bacterial invasion of epithelial cells 0.011645 10 18 
B cell receptor signaling pathway 0.012091 9 21 
Regulation of actin cytoskeleton 0.013898 12 46 
Type II diabetes mellitus 0.014324 9 14 
Endocrine and other factor-regulated calcium 
reabsorption 0.015295 6 9 
p53 signaling pathway 0.015295 9 18 
Fc gamma R-mediated phagocytosis 0.015295 10 23 
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Adherens junction 0.021879 7 19 
Aldosterone-regulated sodium reabsorption 0.021879 10 13 
SNARE interactions in vesicular transport 0.025989 7 10 
Dorso-ventral axis formation 0.027597 7 8 





Sheet 5A: Differentially expressed miRNAs in NSCs exposed to Hypoxia 
vs Con 
Annotation Fold change T-test 
Upregulated miRNAs     
mmu-miR-466a-5p/mmu-miR-466p-5p 1.24320872 0.000378 
mmu-miR-1247 1.173336362 0.000752 
mmu-miR-744 1.350280871 0.000777 
mmu-miR-191 1.217521816 0.000841 
mmu-miR-3098-3p 1.268982804 0.000854 
mmu-miR-361* 1.341903882 0.000922 
mmu-miR-151-5p 1.19978515 0.001612 
mmu-miR-466c-5p 1.184977361 0.001883 
mmu-miR-378/mmu-miR-378b 1.252009523 0.00189 
mmu-miR-467g 1.20200634 0.002254 
mmu-miR-210* 1.320910927 0.00234 
mmu-miR-425 1.121530565 0.0024 
mmu-miR-466f-3p 1.198167688 0.002443 
mmu-let-7f-1* 1.214271832 0.002491 
mmu-miR-149 1.070595189 0.002555 
mmu-miR-466e-5p 1.192542863 0.00258 
mmu-miR-185* 2.472295543 0.002748 
mmu-miR-320 1.221559448 0.00277 
mmu-miR-291b-5p 1.155916547 0.002908 
mmu-miR-664 1.124272296 0.002942 
mmu-miR-669d 1.196234904 0.003017 
mmu-miR-874* 1.139639932 0.003302 
mmu-miR-335-5p 1.157777953 0.003524 
mmu-miR-21* 1.44304163 0.003575 
mmu-miR-500 1.261298283 0.003926 
mmu-miR-27b 1.088159206 0.004008 
mmu-miR-674* 1.16630787 0.004283 
      
241 
 
Downregulated miRNAs     
mmu-miR-691 0.74142605 0.00025 
mmu-miR-297a-5* 0.764210083 0.000592 
mmu-miR-693-5p 0.802733617 0.000871 
mmu-miR-433* 0.80645156 0.001043 
mmu-miR-3103* 0.694055544 0.001351 
mmu-let-7e 0.739981413 0.001517 
mmu-miR-155* 0.801290311 0.002362 
mmu-miR-541* 0.81123393 0.00241 
mmu-miR-883b-5p 0.767971679 0.003459 
mmu-miR-668 0.763955286 0.003484 
mmu-miR-450a-1* 0.77862578 0.004079 
mmu-miR-712 0.890938702 0.004431 
mmu-miR-3068* 0.621597973 0.004449 
 
Sheet 5B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to Hypoxia 
 
KEGG pathway p-value #genes #miRNAs 
ErbB signaling pathway 1.05E-07 42 25 
TGF-beta signaling pathway 1.30E-07 40 26 
MAPK signaling pathway 2.06E-06 93 32 
Neurotrophin signaling pathway 9.26E-06 50 26 
T cell receptor signaling pathway 3.58E-05 45 24 
Axon guidance 9.84E-05 46 25 
mTOR signaling pathway 0.000452205 24 22 
Apoptosis 0.000500816 30 22 
Focal adhesion 0.000500816 66 26 
Lysine degradation 0.000592708 16 16 
Circadian rhythm - mammal 0.000599491 12 16 
Ubiquitin mediated proteolysis 0.001461643 46 23 
Endocytosis 0.001632281 68 30 
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Wnt signaling pathway 0.002157717 51 27 
Fc gamma R-mediated phagocytosis 0.002789394 34 23 
Insulin signaling pathway 0.006000185 45 28 
Endocrine and other factor-regulated calcium 
reabsorption 0.008198521 19 18 
Amoebiasis 0.01002693 38 26 
Progesterone-mediated oocyte maturation 0.01002693 31 27 
Dorso-ventral axis formation 0.01292014 11 16 
Long-term potentiation 0.01338186 25 24 
Adherens junction 0.01465999 26 19 
GnRH signaling pathway 0.01689189 32 26 
SNARE interactions in vesicular transport 0.02052085 13 15 
Toll-like receptor signaling pathway 0.0206405 32 21 
Calcium signaling pathway 0.03821092 49 31 





Sheet 6A: Differentially expressed miRNAs in NSCs exposed to Dia vs 
Con 
Annotation Fold change T-test 
Upregulated miRNAs     
mmu-miR-26a 1.660880554 6.77E-05 
mmu-miR-101a 1.879030893 0.000116 
mmu-miR-331-3p 1.41230617 0.000244 
mmu-miR-124 5.05829314 0.00028 
mmu-miR-3068 1.509409186 0.000303 
mmu-miR-219-3p 2.662200825 0.000345 
mmu-miR-204* 1.973940232 0.000437 
mmu-miR-744 1.569156004 0.00046 
mmu-miR-138 3.16434294 0.000548 
mmu-miR-135a 2.131256396 0.000559 
mmu-miR-361 1.182485661 0.000585 
mmu-miR-1895 1.582955536 0.000718 
mmu-miR-320 1.333776334 0.000719 
mmu-miR-21* 1.987861358 0.000749 
mmu-miR-140* 1.599479042 0.000911 
mmu-miR-675-5p 1.740983491 0.001038 
mmu-miR-365 1.817230525 0.00106 
mmu-miR-219-5p 3.238311623 0.00116 
mmu-miR-1897-5p 1.496480717 0.001165 
mmu-miR-346* 1.669682781 0.001265 
mmu-miR-1935 1.189668658 0.001323 
mmu-miR-335-5p 1.236846197 0.001352 
mmu-miR-2137 1.723003989 0.001406 
mmu-miR-26b 1.442859131 0.001438 
      
Downregulated miRNAs     
mmu-miR-210 0.183900427 3.5E-06 
mmu-miR-450a-1* 0.776140805 1.01E-05 
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mmu-miR-9* 0.848931507 0.000243 
mmu-miR-3096-5p 0.677591225 0.000475 
mmu-miR-1264-3p 0.768677599 0.000689 
mmu-miR-466j 0.839272199 0.000705 
mmu-miR-374/mmu-miR-374c 0.741215521 0.000725 
mmu-miR-191 0.874981339 0.000793 
mmu-miR-210* 0.804729001 0.000817 
mmu-miR-25* 0.579067579 0.000895 
mmu-miR-5097 0.539079298 0.000925 
mmu-miR-674 0.680450676 0.000994 
mmu-miR-297a-5* 0.822592429 0.001044 
mmu-miR-106b* 0.884406057 0.001104 
mmu-miR-130b 0.6649794 0.001113 
mmu-miR-3096-3p 0.640562448 0.001122 
mmu-miR-767 0.642887606 0.001199 
mmu-miR-3069-3p 0.814951166 0.00148 
Sheet 6B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to Dia 
KEGG pathway p-value #miRNAs #genes 
Biosynthesis of unsaturated fatty acids 1.46E-06 16 15 
Axon guidance 1.46E-06 31 57 
Neurotrophin signaling pathway 1.54E-06 30 58 
mTOR signaling pathway 6.49E-06 24 30 
TGF-beta signaling pathway 6.84E-06 28 40 
Cell adhesion molecules (CAMs) 9.69E-06 29 48 
ErbB signaling pathway 0.000835 28 40 
Adherens junction 0.000984 27 28 
Long-term potentiation 0.001032 25 31 
Phosphatidylinositol signaling system 0.001032 26 30 
Protein digestion and absorption 0.001329 25 34 
Focal adhesion 0.001422 31 71 
Ubiquitin mediated proteolysis 0.00163 27 52 
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MAPK signaling pathway 0.00163 32 92 
Carbohydrate digestion and absorption 0.003416 16 18 
Lysine degradation 0.003467 19 17 
Jak-STAT signaling pathway 0.003559 28 55 
Cell cycle 0.0039 27 44 
Protein processing in endoplasmic reticulum 0.004535 26 59 
Apoptosis 0.008666 27 34 
Toll-like receptor signaling pathway 0.010254 27 35 
Regulation of actin cytoskeleton 0.01394 32 72 
Cytokine-cytokine receptor interaction 0.014157 31 70 
Calcium signaling pathway 0.016769 29 56 
Circadian rhythm - mammal 0.016824 18 10 
Notch signaling pathway 0.0197 16 21 
Wnt signaling pathway 0.0197 31 51 
Chemokine signaling pathway 0.020204 28 61 
T cell receptor signaling pathway 0.022452 27 40 
Dorso-ventral axis formation 0.027848 16 11 
Insulin signaling pathway 0.029363 27 46 
VEGF signaling pathway 0.029382 25 28 
Tight junction 0.038516 31 44 





Sheet 7A: Differentially expressed miRNAs in NSCs exposed to LG vs Dia 
 
Annotation Fold change T-test 
Upregulated miRNAs     
mmu-miR-26a 1.794162146 3.4203E-05 
mmu-miR-181a 1.537079902 0.000181616 
mmu-miR-219-3p 3.243235496 0.000276878 
mmu-miR-1895 1.674421257 0.000326364 
mmu-miR-219-5p 3.662800382 0.00061798 
mmu-miR-124 5.175778862 0.000785236 
mmu-miR-224 1.853650856 0.000817624 
mmu-miR-138 3.301690262 0.000825127 
mmu-miR-365 1.955308002 0.001360628 
mmu-miR-30d 1.518492181 0.001453726 
      
Downregulated miRNAs     
mmu-miR-106a 0.794718923 0.000273746 
mmu-miR-17* 0.614402216 0.000427393 
mmu-miR-450a-1* 0.70104771 0.000541041 
mmu-miR-25* 0.332049489 0.00082513 
mmu-let-7d* 0.764379322 0.001361298 
mmu-miR-466j 0.87283777 0.001389397 
mmu-miR-467c* 0.839121113 0.00144148 





Sheet 7B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to LG 
 
 
KEGG pathway p-value #miRNAs #genes 
Axon guidance 2.49E-09 12 56 
Neurotrophin signaling pathway 1.78E-06 12 48 
Lysine degradation 1.74E-05 11 16 
T cell receptor signaling pathway 1.74E-05 12 41 
Gap junction 5.57E-05 13 24 
ErbB signaling pathway 0.00011 12 33 
mTOR signaling pathway 0.000224 11 23 
MAPK signaling pathway 0.000237 14 74 
Insulin signaling pathway 0.000237 14 44 
Apoptosis 0.000259 12 27 
TGF-beta signaling pathway 0.000447 14 31 
Wnt signaling pathway 0.00061 13 43 
Endocytosis 0.000912 14 61 
Adherens junction 0.001008 13 26 
Circadian rhythm - mammal 0.002106 8 8 
Focal adhesion 0.00258 13 54 
Phosphatidylinositol signaling system 0.003034 12 22 
Chemokine signaling pathway 0.00845 12 49 
Regulation of actin cytoskeleton 0.00845 13 57 
Type II diabetes mellitus 0.009933 10 16 
Long-term potentiation 0.01104 9 22 
Long-term depression 0.013407 10 18 
Small cell lung cancer 0.014435 11 26 
B cell receptor signaling pathway 0.016074 11 24 
Calcium signaling pathway 0.016548 12 43 
Protein processing in endoplasmic 
reticulum 0.018515 13 42 
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Ubiquitin mediated proteolysis 0.021284 11 37 
Jak-STAT signaling pathway 0.024952 11 39 
Hedgehog signaling pathway 0.034627 10 16 
Tight junction 0.035632 13 36 
Protein digestion and absorption 0.045145 13 22 




Upregulated miRNAs     
mmu-miR-101a 1.777167 3.97E-05 
mmu-miR-1897-5p 1.447968 5.08E-05 
mmu-miR-26a 1.636424 0.000124 
mmu-miR-124 3.609121 0.000149 
mmu-miR-219-3p 2.589241 0.000202 
mmu-miR-99a 1.610086 0.000227 
mmu-miR-331-3p 1.415253 0.000262 
mmu-miR-1895 1.550915 0.000282 
mmu-miR-26b 1.559679 0.000304 
mmu-miR-219-5p 3.834652 0.000405 
mmu-miR-204* 2.387889 0.000473 
mmu-miR-21* 2.033856 0.000513 
mmu-miR-15a 1.479202 0.000584 
mmu-miR-346* 1.965793 0.000617 
mmu-miR-125a-5p 1.30477 0.000728 
mmu-miR-710 2.269317 0.000742 
mmu-miR-181a 1.772023 0.000797 
mmu-miR-125b-5p 1.331251 0.000983 
mmu-miR-1935 1.248961 0.000992 
mmu-miR-138 3.149297 0.001001 
mmu-miR-224 1.804884 0.001087 
mmu-miR-92b 1.288357 0.001144 
mmu-miR-883a-5p 1.149094 0.001328 
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mmu-miR-30a 1.404541 0.001413 
      
Downregulated miRNAs     
mmu-miR-374/mmu-miR-374c 0.715509 1.8E-05 
mmu-miR-210 0.209892 5.47E-05 
mmu-miR-350 0.796576 5.59E-05 
mmu-miR-378/mmu-miR-378b 0.675917 7.79E-05 
mmu-let-7d* 0.85031 0.000134 
mmu-miR-1949 0.597566 0.000148 
mmu-miR-9* 0.867546 0.000164 
mmu-miR-3096-3p 0.612121 0.000183 
mmu-miR-467c* 0.839664 0.00024 
mmu-miR-3069-3p 0.763559 0.000359 
mmu-miR-3069-5p 0.768109 0.000411 
mmu-miR-130b 0.543674 0.000471 
mmu-miR-674* 0.726641 0.000619 
mmu-miR-15b 0.549088 0.000693 
mmu-miR-325 0.834943 0.000698 
mmu-miR-421 0.731901 0.000876 
mmu-miR-3072 0.722999 0.000948 
mmu-miR-374 0.731053 0.00096 
mmu-miR-466a-3p/mmu-miR-466e-3p 0.798882 0.001359 
mmu-miR-3084 0.767318 0.001443 
mmu-miR-3096-5p 0.738166 0.001453 
 
Sheet 8B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to HG 
 
KEGG pathway p-value #miRNAs #genes 
Axon guidance 5.32E-13 35 76 
Neurotrophin signaling pathway 3.14E-10 31 71 




Lysine degradation 2.19E-08 22 24 
TGF-beta signaling pathway 4.53E-08 30 45 
Glycosaminoglycan biosynthesis - heparan sulfate 1.30E-07 14 11 
mTOR signaling pathway 8.98E-07 26 33 
Wnt signaling pathway 2.45E-06 35 68 
MAPK signaling pathway 6.04E-06 34 110 
Endocrine and other factor-regulated calcium 
reabsorption 8.39E-06 29 26 
ErbB signaling pathway 9.59E-06 30 47 
T cell receptor signaling pathway 5.39E-05 29 52 
Adherens junction 0.000262 30 38 
B cell receptor signaling pathway 0.000384 30 37 
Protein processing in endoplasmic reticulum 0.001135 28 64 
Circadian rhythm - mammal 0.001215 20 11 
Phosphatidylinositol signaling system 0.001362 25 32 
Endocytosis 0.001528 34 84 
Insulin signaling pathway 0.001594 29 56 
Long-term potentiation 0.001968 26 32 
Gap junction 0.002145 25 34 
Mucin type O-Glycan biosynthesis 0.002282 14 10 
Long-term depression 0.00261 25 30 
VEGF signaling pathway 0.00261 29 34 
Focal adhesion 0.002626 33 75 
Ubiquitin mediated proteolysis 0.002856 30 58 
Regulation of actin cytoskeleton 0.002856 36 82 
Carbohydrate digestion and absorption 0.003642 20 19 
Chemokine signaling pathway 0.004473 31 70 
Type II diabetes mellitus 0.004976 20 23 
Apoptosis 0.008357 26 35 
Jak-STAT signaling pathway 0.010696 29 57 
Toll-like receptor signaling pathway 0.011561 30 38 
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Notch signaling pathway 0.01334 22 23 
Hedgehog signaling pathway 0.017897 21 23 
Dorso-ventral axis formation 0.018541 18 12 
Fc gamma R-mediated phagocytosis 0.025873 27 36 
Protein digestion and absorption 0.033985 27 31 










Upregulated miRNAs     
mmu-miR-882 2.712744 8.92E-05 
mmu-miR-219-3p 3.270493 0.000108 
mmu-let-7g 1.362677 0.000131 
mmu-miR-124 3.900043 0.000141 
mmu-miR-219-5p 4.42123 0.00027 
mmu-miR-26a 1.494085 0.000332 
mmu-miR-204* 2.211366 0.000392 
mmu-miR-138 3.376028 0.000426 
mmu-miR-331-3p 1.321772 0.000561 
mmu-miR-1897-5p 1.519161 0.000585 
mmu-miR-101a 1.691224 0.00067 
mmu-miR-26b 1.534801 0.000858 
mmu-miR-140* 1.507428 0.001105 
mmu-miR-338-3p 2.284281 0.00128 
mmu-miR-365 1.80112 0.001304 
mmu-miR-710 2.152889 0.001316 
mmu-miR-3068 1.365418 0.001457 
      
Downregulated miRNAs     
mmu-miR-362-3p 0.828099 4.97E-05 
mmu-miR-9* 0.827441 5.93E-05 
mmu-miR-210 0.122481 6.03E-05 
mmu-miR-674 0.57228 8.82E-05 
mmu-miR-191 0.718658 0.000106 
mmu-miR-378/mmu-miR-378b 0.659055 0.000133 
mmu-miR-3096-3p 0.600738 0.000166 
mmu-miR-1949 0.633546 0.000209 
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mmu-miR-3096-5p 0.680491 0.000212 
mmu-miR-421 0.68352 0.000214 
mmu-miR-500 0.782631 0.000229 
mmu-miR-874* 0.884271 0.000324 
mmu-miR-130b 0.558591 0.000351 
mmu-miR-210* 0.609223 0.000369 
mmu-miR-674* 0.710404 0.000383 
mmu-miR-296-3p 0.726476 0.000523 
mmu-miR-361* 0.72063 0.00066 
mmu-miR-15b 0.582255 0.000744 
mmu-miR-374 0.720296 0.000793 
mmu-miR-467c* 0.802954 0.000813 
mmu-miR-3084* 0.703289 0.001089 
mmu-miR-3069-5p 0.727043 0.001163 
mmu-miR-3084 0.772624 0.001292 
mmu-miR-1247 0.861767 0.001317 
mmu-miR-374/mmu-miR-374c 0.712812 0.001338 
mmu-miR-21 0.581535 0.001475 
 
Sheet 9B: Pathways targeted by differentially expressed miRNAs in NSCs 
exposed to Hypoxia 
KEGG pathway p-value #miRNAs #genes 
Glycosaminoglycan biosynthesis - heparan sulfate 1.75E-16 13 14 
Axon guidance 1.38E-11 27 63 
Glycosaminoglycan biosynthesis - chondroitin 
sulfate 1.71E-10 8 11 
Lysine degradation 1.32E-08 19 22 
Glycosphingolipid biosynthesis - lacto and neolacto 
series 3.74E-08 11 10 
Circadian rhythm - mammal 4.07E-08 16 14 
Neurotrophin signaling pathway 5.54E-06 30 54 
MAPK signaling pathway 8.13E-06 34 92 
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TGF-beta signaling pathway 1.10E-05 23 37 
Endocrine and other factor-regulated calcium 
reabsorption 6.91E-05 23 23 
Wnt signaling pathway 9.67E-05 30 58 
Focal adhesion 0.000138 32 71 
Long-term potentiation 0.000246 22 31 
ErbB signaling pathway 0.000253 29 38 
Endocytosis 0.000282 31 77 
Biotin metabolism 0.000417 1 1 
Cytokine-cytokine receptor interaction 0.000833 30 78 
p53 signaling pathway 0.00086 16 28 
Hedgehog signaling pathway 0.00086 17 24 
Chemokine signaling pathway 0.000976 28 64 
Apoptosis 0.0013 25 32 
Biosynthesis of unsaturated fatty acids 0.001951 12 11 
T cell receptor signaling pathway 0.002248 28 41 
Insulin signaling pathway 0.003058 27 48 
mTOR signaling pathway 0.005133 22 23 
Cell cycle 0.005237 23 45 
Protein digestion and absorption 0.005797 24 30 
Long-term depression 0.008252 17 24 
Jak-STAT signaling pathway 0.009199 26 50 
Protein processing in endoplasmic reticulum 0.009361 23 52 
Adherens junction 0.010828 24 27 
Non-small cell lung cancer 0.011631 23 22 
Gastric acid secretion 0.011664 19 28 
Calcium signaling pathway 0.01222 28 52 
Aldosterone-regulated sodium reabsorption 0.017286 22 18 
Notch signaling pathway 0.018735 23 20 
Regulation of actin cytoskeleton 0.020587 33 67 
Glycosaminoglycan biosynthesis - keratan sulfate 0.040711 5 5 
Ubiquitin mediated proteolysis 0.040711 24 46 
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Sheet 10A: miRNAs common to Dia vs LG/HG/hypoxia 




Upregulated miRNAs     
mmu-miR-124 5.175779 0.000785 
mmu-miR-219-5p 3.6628 0.000618 
mmu-miR-138 3.30169 0.000825 
mmu-miR-219-3p 3.243235 0.000277 
mmu-miR-26a 1.794162 3.42E-05 
      
Downregulated miRNA     
mmu-miR-467c* 0.839121 0.001441 
 





Upregulated miRNAs     
mmu-miR-124 3.609121 0.000149 
mmu-miR-219-3p 2.589241 0.000202 
mmu-miR-138 3.149297 0.001001 
mmu-miR-219-3p 2.589241 0.000202 
mmu-miR-26a 1.636424 0.000124 
      
Downregulated miRNA     
mmu-miR-467c* 0.839664 0.00024 
 





Upregulated miRNAs     
mmu-miR-124 3.900043 0.000141 
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mmu-miR-219-3p 3.270493 0.000108 
mmu-miR-138 3.376028 0.000426 
mmu-miR-219-3p 3.270493 0.000108 
mmu-miR-26a 1.494085 0.000332 
      
Downregulated miRNA     









s #genes p-value 
Glycosaminoglycan biosynthesis - 
heparan sulfate 2 2 1.08E-13 
Lysine degradation 4 11 8.45E-09 
Wnt signaling pathway 4 23 
0.00021999
4 
Phosphatidylinositol signaling system 5 12 0.00092887 
Cell cycle 4 19 0.02353163 
Axon guidance 4 19 0.0424589 





























Wnt signalling  √ √ √ √ √ √ √ 
Erbb signalling √ √ √ √ √ √ √ 
MAPK signalling  − √ √ √ √ √ √ 
Focal adhesion − √ √ √ √ √ √ 
Axon guidance − √ √ √ √ √ √ 
Neurotrophin 
signalling  − √ √ √ √ √ √ 
Regulation of actin 
cytoskeleton − √ − √ √ √ √ 
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